JP2008174555A - Compound for treating disease - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new β2 agonist having a proper pharmaceutical profile concerning effectiveness, selectivity, pharmacokinetics or duration of function. <P>SOLUTION: A compound represented by, for example, the following formula and a composition containing the compound are provided. The medicinal composition containing the compound is useful for inflammatory, allergic and respiratory diseases, troubles and the like. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention provides a general formula

(Wherein R ¹ , R ² , n, and Q ¹ have the meanings shown below), a method for producing the substance, a composition containing the substance, and a derivative thereof Regarding use.

Adrenergic receptors are members of a broad G protein-coupled receptor superfamily. The adrenergic receptor subfamily is itself divided into an α subfamily and a β subfamily, which comprises at least three receptor subtypes (β1,
β2 and β3). These receptors display unique expression patterns in tissues of various mammalian systems and organs. β2 adrenergic receptors appear primarily in smooth muscle cells (e.g., vascular smooth muscle, bronchial smooth muscle, uterine smooth muscle, or intestinal smooth muscle), whereas β3 adrenergic receptors appear primarily in adipose tissue (hence β3 agonists are Β1 adrenergic receptors, which appear to be useful for the treatment of obesity and diabetes, appear primarily in heart tissue (thus β1 agonists are mainly used as inotropic agents).

The pathophysiology and treatment of respiratory tract diseases are described in the literature (`` Barnes, PJChest, 1997, 111: 2, pp17S-26S '' and `` Bryan, SAet al, Expert Opinion on investigational drugs, 2000, 9: 1, pp25-42 ''. (See below). Therefore, only a brief summary is provided here to provide some background information.

Glucocorticosteroids, anti-leukotrienes, theophylline, chromones, anticholinergics, and β2 agonists treat allergic and non-allergic airway diseases (e.g., asthma and chronic obstructive airway disease (COPD)) Constitutes the currently used drug class. Treatment guidelines for these diseases include short-acting inhaled β2 agonists and long-acting inhaled β2 agonists. Short-acting rapid onset β2 agonists are used to “rescue” bronchodilation, while long-acting β2 agonists provide slow release and are used as maintenance therapy.

Bronchodilation is mediated by the agonism of β2 adrenergic receptors expressed on airway smooth muscle cells, which causes relaxation and therefore bronchodilation. Thus, β2 agonists including leukotriene D4 (LTD4), acetylcholine, bradykinin, prostaglandin, histamine, and endothelin can prevent and reverse the effects of any bronchoconstrictor substance. Since β2 receptors are fairly widely distributed in the respiratory tract, β2 agonists can further affect other types of cells that play a role in asthma. For example, it has been reported that β2 agonists may stabilize mast cells. Preventing the release of bronchoconstrictor substances is how β2 agonists block bronchoconstriction caused by allergens, exercise, and cold. β2 agonists further inhibit cholinergic neurotransmission in the human respiratory tract, resulting in a decrease in cholinergic-reflex bronchoconstriction.

β2 adrenergic receptors have been demonstrated to be expressed in other organs and tissues in addition to the respiratory tract, and thus β2 agonists (e.g. those described in the present invention) can be found in other diseases (e.g. Diseases of the nervous system, diseases of premature labor, congestive heart failure, depression, inflammatory and allergic skin diseases, psoriasis, proliferative skin diseases, glaucoma, and diseases that are beneficial by reducing gastric acidity (especially , Gastric ulcer and peptic ulcer), but not limited thereto.

However, many β2 agonists are unfavorable, mainly mediated through low side effects or undesirable side effects caused by high systemic exposure, and the action of β2 adrenoceptors expressed outside the airways Side effects (muscle tremor, tachycardia,
Limited use due to palpitation and emotional anxiety). Therefore, there is a need for improved drugs in this class.

Thus, there remains a need for new β2 agonists that have an appropriate pharmacological profile, for example with respect to potency, selectivity, pharmacokinetics, or duration of action. Under such circumstances, the present invention relates to a novel β2 agonist.

  The present invention relates to general formula (1)

[Where,
The (CH ₂ ) _n —C (═O) Q ¹ group is located at the meta or para position
R ¹ and R ² are independently selected from H and C ₁ -C ₄ alkyl;
n is 0, 1, or 2; and
Q ¹ is

A group selected from ^* -NR ⁸ -Q ² -A or ^* -NR ⁸ -Q ³
p is 1 or 2 and q is 1 or 2;
Q ² is a single bond or C ₁ -C ₄ alkylene optionally substituted with OH;
R ⁸ is H or C ₁ -C ₄ alkyl;
Q ³ is NR ⁹ R ¹⁰ , OR ⁹ , or C ₁ -C ₆ alkyl optionally substituted with phenoxy;
A is
C ₁ -C ₁₀ which may be bridged by one or more, preferably 1, 2, 3, or 4 carbon atoms and may be substituted by one hydroxy group Cycloalkyl,
One or two selected from O, N, or S, optionally substituted with one or two substituents selected from C ₁ -C ₄ alkyl, benzyl, and cyclopropylmethyl A 5- to 6-membered heterocyclic group which may be aromatic, containing a heteroatom, or quinolyl group, isoquinolyl group,

Or a group represented by

A group represented by
Selected from;
R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different and are H, C ₁ -C ₄ alkyl, OR ⁹ , SR ⁹ , SOR ⁹ , SO ₂ R ⁹ , halo, CN, Selected from CF ₃ , OCF ₃ , SO ₂ NR ⁹ R ¹⁰ , COOR ⁹ , CONR ⁹ R ¹⁰ , NR ⁹ R ¹⁰ , NHCOR ¹⁰ , and phenyl optionally substituted with OH;
R ⁹ and R ¹⁰ are the same or different and are selected from H or C ₁ -C ₄ alkyl;
R ¹¹ is selected from H or OH;
R ¹² and R ¹³ are identical or different, H, optionally substituted by OR ⁹ C ₁ -C ₄ ^{alkyl, OR 9, C (= O} ) NH 2, C (= O) CH 3, N (CH ₃ ) C (═O) CH ₃ , C (═O) OR ⁹ , phenyl optionally substituted with halogen, pyridyl optionally substituted with CN, and substituted with C ₁ -C ₄ alkyl Selected from optionally oxadiazolyl; and
^* Indicates a bonding site to a carbonyl group], or, where appropriate, a pharmaceutically acceptable salt of the compound, and / or an isomer or tautomer of the compound or the salt. , Solvates, or isotopic variations.

  The compounds of formula (1) are β2 receptor agonists and are particularly useful for the treatment of diseases and / or diseases mediated by β2, especially because they exhibit excellent efficacy when administered via the inhalation route. is there.

In the above general formula (1), C ₁ -C ₄ alkyl and C ₁ -C ₄ alkylene represent a straight-chain group or branched group having 1, 2, 3, or 4 carbon atoms. Yes.
C ₁ -C ₆ alkyl represents a straight or branched group having 1, 2, 3, 4, 5, or 6 carbon atoms. This is true even if it has a substituent or appears as a substituent of another group (for example, O- (C ₁ -C ₄ ) alkyl group or S- (C ₁ -C ₄ ) Alkyl group and the like]. Examples of suitable (C ₁ -C ₄ ) alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Examples of suitable O- (C ₁ -C ₄ ) alkyl groups include methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, and tert-butyloxy.

C ₃ -C ₁₀ cycloalkyl, in which two or more carbon atoms (2 carbon atoms or more) may be bridged by one or more carbon atoms (one or more carbon atoms), includes cyclopropyl, cyclobutyl, Examples include cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, bicyclo [3.1.1] heptane, bicyclo [2.2.1] heptane, and bicyclo [2.2.2] octane. Preferred cycloalkyl groups are cyclohexyl and adamantyl.

Examples of “optionally aromatic 5-6 membered heterocyclic group having 1 or 2 heteroatoms selected from O, N, or S” include morpholinyl, pyrrolidinyl, piperidyl, piperazinyl , Pyrazolyl, thienyl, furanyl, imidazolyl, isothiazolyl, thiazolyl, isoxazolyl, oxazolyl, pyridyl, and pyrimidyl, but are not limited thereto.

The heterocyclic group preferably has one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one oxygen atom.
Preferred 5- to 6-membered aromatic heterocyclic groups are pyrazolyl and pyridyl.

Preferred 5-6 membered non-aromatic heterocyclic groups are morpholinyl, pyrrolidinyl, piperidyl, and piperazinyl.
Finally, halo represents a halogen atom (especially fluoro or chloro) selected from the group consisting of fluoro, chloro, bromo and iodo.

  The following structural formula

The free bond on the phenyl group means that the phenyl group may be substituted at the meta position or may be substituted at the para position.
Formula (I)

Can be prepared using conventional methods (eg, by the methods described below), where Q ¹ , Q ² , R ¹ , R ² , A, unless otherwise specified. And n are as defined above for the compound of formula (1).

  The amide derivative of formula (1) is represented by formula (2)

The acid of the formula NHR ⁸ -Q ² -A, NHR ⁸ -Q ³ ,

Or

It can be produced by coupling with an amine.
Coupling reactions are generally carried out in excess of the amine (as acid receptor) using conventional coupling agents such as 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride or N, N ″ -dicyclohexylcarbodiimide. In the presence of a catalyst (e.g. 1-hydroxybenzotriazole hydrate or 1-hydroxy-7-azabenzotriazole) and optionally a tertiary amine base (e.g. The reaction is carried out in the presence of N-methylmorpholine, triethylamine or diisopropylethylamine) This reaction is carried out in a suitable solvent (eg pyridine, dimethylformamide, tetrahydrofuran, dimethyl sulfoxide, dichloromethane, N, N-dimethylacetamide or ethyl acetate). ) At a temperature of 10 ° C to 40 ° C (room temperature) for 1 to 24 hours. wear.

The amines are either commercially available or commercially available by conventional methods well known to those skilled in the art (e.g. reduction, alkylation, transition metal mediated coupling, protection treatment, and deprotection treatment). It can be manufactured from the following materials.

  The acid of formula (2) is represented by formula (4)

Where Ra is a suitable acid protecting group and is well known to those skilled in the art for preparing acids from esters without altering other parts of the molecule. Is preferably a (C ₁ -C ₄ ) alkyl group (including but not limited to methyl, ethyl, etc.). For example, the ester is an aqueous acid or base, optionally in the presence of a solvent or mixed solvent (e.g., 1,4-dioxane, tetrahydrofuran / water) at a temperature of 20 ° C to 100 ° C for 1-40 hours. It can be hydrolyzed by treatment with (eg hydrogen chloride, potassium hydroxide or lithium hydroxide).

  Esters of formula (4) are represented by formula (5)

Wherein PG is a suitable phenol protecting group and is generally an alkyl or alkoxy ether (eg, methyl, benzyl, methoxymethyl, etc., preferably benzyl), preferably a benzyl protecting group. It can be manufactured by removing.

Reagents suitable for achieving this deprotection treatment are described in the text book “TWGREENE, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981”. In a typical procedure, when PG is benzyl, an appropriate catalyst (e.g., activated carbon supported palladium hydroxide or activated carbon supported palladium) is used under a hydrogen atmosphere in an appropriate solvent (e.g., ethanol or methanol). Thus, deprotection can be achieved by hydrogenation at room temperature to 60 ° C. for 8-24 hours at high pressure (eg, 60 psi) if necessary.

  Alternatively, transfer hydrogenation using a suitable catalyst (e.g. palladium hydroxide) and ammonium formate as a hydrogen source in a suitable solvent (e.g. ethanol) at a temperature between room temperature and 60 ° C. ) Can also be used.

  Esters of formula (5) are represented by formula (6)

(Wherein Ra and n are as defined above) and a formula (7)

Can be prepared by reacting with bromide.
In a typical procedure, an amine of formula (6) and a bromide of formula (7) are optionally combined with a solvent or mixed solvent (e.g., dimethyl sulfoxide, toluene, N, N-dimethylformamide, acetonitrile, or THF). ) In the presence of a suitable base (e.g., triethylamine, diisopropylethylamine, or calcium carbonate) as needed.
The reaction is allowed to proceed for 12 to 120 hours at a temperature of from ° C to 120 ° C. The aminoketone intermediate thus obtained can then be reduced using a suitable reducing agent (eg sodium borohydride or diisobutylaluminum hydride).

  The bromide of formula (7) is represented by formula (19)

Can be prepared by bromination with a suitable bromine source. In a typical procedure, a ketone is treated with a brominating agent (eg, Et ₄ NBr ₃ ) in a suitable solvent (eg, THF or methanol) at room temperature for about 24 hours.

Ketones of formula (19) are commercially available.
The amine of formula (6) when R ¹ is Me and R ² is H is the formula (8)

Wherein Ra and n are as defined above, Rb and Rc are suitable substituents such that NHRbRc is a chiral amine (e.g. Rb may be hydrogen and Rc is α Can be prepared as the (R) enantiomer or (S) enantiomer from the corresponding protected amine. However, the bond between N and Rb and the bond between N and Rc are standard methods for cleaving nitrogen protecting groups (e.g., textbooks `` TWGREENE, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, (Method described in 1981)
Can be easily cleaved to obtain the free amine of formula (5).

  The amine of formula (8) is an amine of formula HNRbRc and the formula (9)

It can be produced as a single diastereomer by reacting with a ketone (wherein Ra, Rb, Rc and n are as defined above).
In a typical procedure, a chiral intermediate is obtained by reaction of a ketone of formula (9) with an amine of formula HNRbRc, which is then optionally combined with a desiccant (e.g., molecular sieves or magnesium sulfate). in the presence, and an acid catalyst (e.g. acetic acid) suitable reducing agent (e.g., sodium triacetoxyborohydride sodium cyanoborohydride or expression Na (OAc) ₃ BH of formula NaCNBH ₃ in the presence of optionally To give the amine of formula (8) as a mixture of diastereomers. This reaction is generally carried out in a solvent such as tetrahydrofuran or dichloromethane at a temperature of 20 ° C. to 80 ° C. for 3 to 72 hours. The product thus obtained is then converted to the hydrochloride salt and selectively crystallized from a suitable solvent or mixed solvent (e.g. isopropanol, ethanol, methanol, diisopropyl ether, or diisopropyl ether / methanol) to give the formula (8 Is obtained as a single diastereomer.

  The ketone of formula (9) when n is 1 is the formula (10)

(Wherein Ra is as defined above, Hal is a halogen atom, including but not limited to bromo and iodo) and an enolate or enolate equivalent Can be prepared by palladium-mediated coupling with.

In a typical procedure, an aryl halide of formula (10) and a tin enolate generated in situ by treatment of isopropenyl acetate with tri-n-butyltin methoxide of formula Bu ₃ SnOMe are suitably used. In a non-polar solvent (for example, toluene, benzene, hexane, etc.) in the presence of a palladium catalyst (palladium acetate / tri-ortho-tolylphosphine of formula Pd (OAc) ₂ / P (o-Tol) ₃ ) React. This reaction is preferably carried out at a temperature of 80 ° C. to 110 ° C. for 6 to 16 hours.

The aryl halide of formula (10) is
Formula (11)

(Wherein Hal is as defined above) according to methods well known to those skilled in the art for preparing esters from acids without altering other parts of the molecule. It can be obtained by esterification.

In a typical procedure, an acid of formula (11) and an alcohol solvent of formula RaOH (where Ra is as defined above) are heated at 10 ° C. in the presence of an acid (e.g. hydrogen chloride). The reaction is carried out at a temperature of -40 ° C (room temperature) for 8-16 hours.

The acid of formula (11) is a commercial product.
The amine of formula (6) when R ¹ and R ₂ are both C ₁ -C ₄ alkyl is the following scheme:

Wherein R ¹ , R ² , and Ra are as defined above.
In a typical procedure, the above method is used to react an ester of formula (12) with an “activated” alkyl (an organometallic alkyl such as R ² MgBr, R ² MgCl, or R ² Li). To obtain the corresponding tertiary alcohol of formula (13).

The tertiary alcohol of formula (13) and an alkyl nitrile (e.g. acetonitrile or chloroacetonitrile) are then treated in the presence of an acid (e.g. sulfuric acid or acetic acid) to obtain a protected intermediate, which is then Standard methods for cleaving nitrogen protecting groups (e.g.,
Cleavage using the method described in the textbook. The amino acid thus obtained is esterified using the methods described herein to give an amine of formula (6).

Apart from this, the amine of formula (6) when R ¹ and R ² are both C ₁ -C ₄ alkyl and n is 0 is

Wherein R ¹ , R ² , and Ra are as defined above.
In a typical procedure, the above method is used to react an ester of formula (14) with an “activated” alkyl (an organometallic alkyl such as R ² MgBr, R ² MgCl, or R ² Li). To obtain the corresponding tertiary alcohol of formula (15).

The tertiary alcohol of formula (15) and an alkyl nitrile (e.g. acetonitrile or chloroacetonitrile) are then treated in the presence of an acid (e.g. sulfuric acid or acetic acid) to obtain a protected intermediate, which is then intermediate Standard methods for cleaving nitrogen protecting groups (e.g.,
Cleavage using the method described in the textbook to give bromoamine (16).

The bromoamine (16) thus obtained can be transformed into a suitable palladium catalyst (for example, at elevated temperature (100 ° C.), high pressure (100 psi) using RaOH as a solvent (for example MeOH or EtOH) under an atmosphere of carbon monoxide. , [1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II)].

  The ketone of formula (9) when n is 2 is the formula (17)

This can be produced by reducing the alkene.
In a typical procedure, the olefin of formula (17) is combined with a suitable solvent (e.g. methanol,
A solution obtained by dissolving in ethanol or ethyl acetate) is treated with a palladium catalyst (e.g., 10% palladium on activated carbon) and optionally under high pressure (e.g., 60 psi) under a hydrogen atmosphere.
The mixture is stirred at room temperature to 60 ° C. for 8 to 24 hours.

  The alkene of formula (17) is composed of an activated olefin and a formula (18)

Can be prepared by palladium-mediated coupling with an aryl halide.
In a typical procedure, an aryl halide (18) and a vinyl ester (such as methyl acrylate) are combined with a suitable palladium in a suitable solvent (such as acetonitrile, N, N-dimethylformamide, or toluene). Catalysts [e.g., tetrakis (triphenylphosphine) palladium (0) represented by the formula Pd (PPh ₃ ) ₄ , palladium acetate / tri-ortho-tolyl represented by the formula Pd (OAc) ₂ / P (o-tol) ₃ phosphines, or in the presence of chloride of formula DppfPdCl ₂ (diphenylphosphino) ferrocenyl palladium], at a temperature of 40 ° C. to 110 ° C. in the presence of optionally a base (e.g. triethylamine) 8-24 Allow time coupling reaction.

The ketone of formula (18) is a commercial product.
Apart from this, the compound of formula (1) is a bromide of formula (7) and a compound of formula (20)

Wherein R ¹ , R ² , Q ¹ , and n are as defined above for compounds of formula (1) unless otherwise specified, may be prepared by reacting with an amine of it can.
In a typical procedure, an amine of formula (20) and a bromide of formula (7) are optionally combined in a solvent or mixed solvent (e.g., dimethyl sulfoxide, toluene, N, N-dimethylformamide, or acetonitrile). In the presence, the reaction is carried out at a temperature of 60 ° C. to 120 ° C. for 12 to 48 hours in the presence of a suitable base (for example, triethylamine, diisopropylethylamine, or potassium carbonate) as necessary. The aminoketone intermediate thus obtained is converted into a suitable reducing agent (
Sodium borohydride, diisobutylaluminum hydride, etc.) can be used for the reduction.

Amides of formula (20) are those of formula (21) into which a suitable amine protecting group P ₁ has been introduced.

The acid of the formula

Or

It can be produced by coupling with an amine.
Coupling reactions are generally carried out in excess of the amine (as acid receptor) using conventional coupling agents such as 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride or N, N′-dicyclohexylcarbodiimide. In the presence of a catalyst (e.g. 1-hydroxybenzotriazole hydrate or 1-hydroxy-7-azabenzotriazole) and optionally a tertiary amine base (e.g. N-methylmorpholine, triethylamine, or diisopropylethylamine). This reaction is carried out in a suitable solvent (eg, pyridine, dimethylformamide, tetrahydrofuran, dimethyl sulfoxide, dichloromethane, or ethyl acetate) at a temperature of 10 ° C. to 40 ° C. (room temperature) for 1 to 24 hours.

The amines are either commercially available or commercially available by conventional methods well known to those skilled in the art (e.g. reduction, oxidation, alkylation, transition metal mediated coupling, protection or deprotection). Can be manufactured from.

The acid of formula (21) when R ¹ and R ² are both C ₁ -C ₄ alkyl is an ester (6) introduced with an appropriate protecting group P ₁ before or after acid formation.

Where Ra is a suitable acid protecting group and according to methods well known to those skilled in the art for preparing acids from esters without altering other parts of the molecule, A (C ₁ -C ₄ ) alkyl group (including, but not limited to, methyl and ethyl) is preferred. For example, the ester is an aqueous acid or base, optionally in the presence of a solvent or mixed solvent (e.g., 1,4-dioxane, tetrahydrofuran / water) at a temperature of 20 ° C to 100 ° C for 1-40 hours. It can be hydrolyzed by treatment with (eg hydrogen chloride, potassium hydroxide, sodium hydroxide or lithium hydroxide).

The amine of formula (6) when R ¹ and R ² are both H is the following scheme

Wherein R ¹ , R ² , and Ra are as defined above.
In a typical procedure, the acid of formula (22) is selectively reduced to the corresponding alcohol (23) in the presence of an ester. This reaction can be carried out by forming an acyl imidazole or mixed anhydride followed by reduction with sodium borohydride or other suitable reducing agent.

The primary alcohol of formula (23) is then converted to a leaving group such as mesylate, tosylate, bromide, or iodide, which is replaced with a suitable amine nucleophilic reagent. A preferred nucleophilic agent is an azide ion, which can be reduced to a primary amine by hydrogenation or triphenylphosphine.

For some of the steps in the above process for the preparation of the compound of formula (1), functional groups that do not want to react but may react are required to be protected and the resulting protecting groups are cleaved. It is necessary to let In such cases, any compatible protecting group can be used. In particular, protection and deprotection methods such as those described by TWGREENE (Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981) and PJ Kocienski (Protecting Groups, Georg Thieme Verlag, 1994) can be used. .

  For example, in the above method, the bromide of formula (7) is

Can be replaced with protected bromide.
This bromide can be prepared in a manner that forms a racemate using a reducing agent such as sodium borohydride in a suitable solvent such as ethanol. Alternatively, alcohols can be produced as (R) enantiomers or (S) enantiomers according to the methods described in the literature (Tetrahedron Letters 1994, 35 (50), 9375).

  The compound of formula (1) has the formula

Wherein PG is a suitable alcohol protecting group and is generally a silyl group such as TBDMS or TMS, preferably TBDMS, and can be obtained by deprotection of the compound.
Deprotection is done using standard textbooks (eg “Protective Groups by TWGreene”).
in Organic Synthesis ”A. Wiley-Interscience Publication, 1981). In a typical procedure, when PG is TBDMS, 10-18 equivalents of compound of formula (24) Is treated with ammonium fluoride in aqueous methanol for about 18-42 hours at about 45 ° C. Another agent for deprotection is 1 equivalent of triethylamine trihydrofluoride in tetrahydrofuran or in a suitable solvent, This is used for 12 hours at room temperature.

  The above reactions and the production of new starting materials used in the above processes are all based on what is known in the art, and the appropriate reagents and reaction conditions for their implementation or production, as well as the desired products are simply described. The procedures for releasing are well known to those skilled in the art with respect to the prior literature, various examples, and their manufacture.

  Furthermore, the compound of the formula (1) and the intermediate for producing the compound of the formula (1) can be purified according to various well-known methods (for example, recrystallization and chromatography).

In a preferred embodiment of the invention, Q ² is a single bond.
In a preferred embodiment of the invention, A is selected from morpholinyl, pyrrolidinyl, piperidyl, piperazinyl or pyrazolyl and may be substituted with a methyl group.

In a preferred embodiment of the invention, A is selected from pyrazolyl optionally substituted with ₁ or 2 C ₁ -C ₄ alkyl groups.
In a preferred embodiment of the invention, Q ¹ is ^* —NR ⁸ —Q ³ .

In a preferred embodiment of the invention, Q ¹ is

Selected from.
In a preferred embodiment, Q ¹ is

Or

(Wherein R ¹¹ and R ¹³ are H and R ¹² is pyridyl or oxadiazolyl optionally substituted with C ₁ -C ₄ alkyl).
More preferred is the following group of formula (1):

[Where,
The (CH ₂ ) _n —C (═O) Q ¹ group is located at the meta or para position
R ¹ and R ² are independently selected from H and C ₁ -C ₄ alkyl;
n is 0, 1, or 2; and
Q ¹ is

And a group selected from the group ^* -NR ⁸ -Q ² -A, this time p is 1 or 2; Q ² is a C ₁ -C ₄ alkylene; R ⁸ is H or C ₁ - be a C ₄ alkyl; A is pyridyl, C ₃ -C ₁₀ cycloalkyl (1
, 2, 3, or 4 carbon atoms, preferably bridged by 1 or 2 carbon atoms), tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl,

Or

R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different and are H, C ₁ -C ₄ alkyl, OR ⁹ , SR ⁹ , SOR ⁹ , SO ₂ R ⁹ , halo, CN, CF ₃ , OCF ₃ , SO ₂ NR ⁹ R ¹⁰ , COOR ⁹ , CONR ⁹ R ¹⁰ , NR
^{9 selected from} R ¹⁰ , NHCOR ¹⁰ , and phenyl optionally substituted with OH; R ⁹ and R ¹⁰ are the same or different and selected from H or C ₁ -C ₄ alkyl; and ^* is carbonyl Or a pharmaceutically acceptable salt of the compound, and / or an isomer, tautomer, or solvate of the compound or the salt, as appropriate. Or isotope variation.

Compounds of formula (1) having the following substituents are preferred.
Q ¹ is preferably a ^* —NH—Q ² —A group when A is cyclopropenyl, cyclohexyl, cycloheptyl, or adamantyl.

Q ¹ is preferably a ^* —NH—Q ² —A group when A is cyclohexyl or adamantyl.
A is preferably naphthyl optionally substituted with OR ⁹ .

R ⁸ is preferably H or CH ₃ . More preferably, R ⁸ is H.
Q ¹ is

(Wherein R ³ , R ⁴ , R ⁵ and R ⁶ are H).
Q ¹ is A ¹

(Wherein R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different, and H, C ₁ -C ₄ alkyl, OR ⁹ , SR ⁹ , halo, CN, CF ₃ , OCF ₃ , SO ₂ NR ⁹ R ¹⁰ , COOR ⁹ , CONR ⁹ R ¹⁰ , NR ⁹ R ¹⁰ , NHCOR ¹⁰ , and phenyl optionally substituted with OH; provided that at least two of R ^{3 to} R ⁷ are H R ⁹ and R ¹⁰ are preferably the same as or different from each other and are selected from H or C ₁ -C ₄ alkyl) ^* -NH-Q ² -A groups.

Q ¹ is A

(Wherein R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different and are selected from H, CH ₃ , OCH ₃ , OCH ₂ —CH ₃ , SCH ₃ , halo, and CF _3. ^* —NH—Q ² —A group in the case of a group represented by the following formula is selected, provided that at least two of R ^{3 to} R ⁷ are H:

In the above group of compounds, the following substituents are particularly preferred.
Q ² is -CH ₂ -,-(CH ₂ ) ₂ -,-(CH ₂ ) _3- , -CH (CH ₃ )-, -CH ₂ CH (CH ₃ )-, or (CH (CH ₃ ) ₂₎ -, and preferably it is -CH ₂ -.

R ¹ is H or C ₁ -C ₄ alkyl and R ² is C ₁ -C ₄ alkyl. More preferably, R ¹ is H or CH ₃ and R ² is CH ₃ .
n is 1.

R ¹ is H, R ² is CH ₃ and n is 1.
R ¹ is CH ₃ , R ² is CH ₃ , and n is 1.
The following compounds that can be prepared according to the methods disclosed herein are preferred.

N-benzyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
N-cyclopropyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] a
Mino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1R, 2S) -2- (hydroxy Methyl) cyclohexyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-morpholin-4-ylpropyl) acetamide ;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (pyridin-2-ylmethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-morpholin-4-ylethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-isopropylacetamide;
N- (4-chlorobenzyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [2- (dimethylamino) ethyl] acetamide;
N- [2- (diethylamino) ethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3- (dimethylamino) propyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-pentylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpro
Pyr) phenyl] -N- (2-pyrrolidin-1-ylethyl) acetamide;
N- (2,4-dichlorobenzyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
N- (3,4-dichlorobenzyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-methoxybenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-hydroxyethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-propylacetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-methoxypropyl) acetamide;
N-cyclobutyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino
No} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1R) -1- (1-naphthyl) ) Ethyl] acetamide;
N-2,3-dihydro-1H-inden-1-yl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-
Droxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [2- (1-methylpyrrolidine-2- Yl) ethyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-fluorobenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-phenylbutyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-methoxybenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-ethoxypropyl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3,4,5-trimethoxybenzyl) Acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [4- (trifluoromethyl) benzyl] acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [2- (trifluoromethyl) benzyl] acetamide ;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3,5-dimethoxybenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-phenoxyethyl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -2-hydroxy-1- Methylethyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1- (hydroxymethyl) -2-methylpropyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S, 2S) -1- (hydroxy Methyl) -2-methylbutyl] acetamide;
N-[(1R) -benzyl-2-hydroxyethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl ] Acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1R) -1- (hydroxymethyl) Propyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpro
Pyr) phenyl] -N-[(1S) -1- (hydroxymethyl) -2,2-dimethylpropyl] acetamide;
N-[(1S) -2-cyclohexyl-1- (hydroxymethyl) ethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2 -Methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S, 2R) -2-hydroxy- 2,3-Dihydro-1H-inden-1-yl] acetoa
Mid;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-propoxyethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-hydroxycyclohexyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-propoxypropyl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-ethyl-N- (2-hydroxyethyl) acetamide ;
1-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl
(Ropyl) phenyl] acetyl} piperidine-4-carboxamide;
5- {2-[(2- {3- [2- (4-acetylpiperazin-1-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino] -1-hydroxyethyl} benzene- 1,3-diol;
5- {2-[(2- {3- [2- (3,4-Dihydroisoquinolin-2 (1H) -yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
N-benzyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-methylacetamide;
5- (1-hydroxy-2-{[2- (3- {2- [4- (2-hydroxyethyl) piperazin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino } Ethyl) benzene-1,3-diol;
5- (2-{[2- (3- {2- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino} -1-hydroxyethyl) benzene-1,3-diol;
5- {2-[(1,1-dimethyl-2- {3- [2- (4-methylpiperazin-1-yl) -2-oxoethyl] pheny
L} ethyl) amino] -1-hydroxyethyl} benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-methyl-N- (2-phenylethyl) acetamide ;
5- {2-[(1,1-dimethyl-2- {3- [2-oxo-2- (4-pyridin-2-ylpiperazin-1-yl) ethyl
Ru] phenyl} ethyl) amino] -1-hydroxyethyl} benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3- (dimethylamino) propyl] -N -Methylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-hydroxyethyl) -N-propylacetamide ;
N- [2- (diethylamino) ethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- Methylacetamide;
5- {2-[(1,1-dimethyl-2- {3- [2- (4-methyl-1,4-diazepan-1-yl) -2-oxoethyl] phenyl} ethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
5- [2-({1,1-dimethyl-2- [3- (2-morpholin-4-yl-2-oxoethyl) phenyl] ethyl}
Amino) -1-hydroxyethyl] benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-methyl-N-[(1S) -1- Phenylethyl] acetamide;
5- [2-({1,1-dimethyl-2- [3- (2-oxo-2-piperidin-1-ylethyl) phenyl] ethyl}
Amino) -1-hydroxyethyl] benzene-1,3-diol;
5- (1-hydroxy-2-{[2- (3- {2-[(3R) -3-hydroxypyrrolidin-1-yl] -2-oxoethyl
L} phenyl) -1,1-dimethylethyl] amino} ethyl) benzene-1,3-diol;
5- (1-hydroxy-2-{[2- (3- {2-[(3R) -3-hydroxypiperidin-1-yl] -2-oxoethyl
L} phenyl) -1,1-dimethylethyl] amino} ethyl) benzene-1,3-diol;
5- {2-[(2- {3- [2- (4-acetyl-1,4-diazepin-1-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
5- (1-hydroxy-2-{[2- (3- {2- [4- (hydroxymethyl) piperidin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino} ethyl ) Benzene-1,3-diol;
N- (1-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetyl} pyrrolidin-3-yl) -N -Methylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-methoxyethyl) -N-propylmethyl Acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-ethyl-N- (2-methoxyethyl) acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3- (dimethylamino) -2,2 -Dimethylpropyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3-fluoro-5- (trifluoromethyl ) Benzyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1- (hydroxymethyl) -3-methylbutyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -2-hydroxy-1- Phenylethyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N, N-diethylacetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-1H-pyrazol-5-ylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (5-methyl-1H-pyrazole-3- Yl) acetamide;
N- (cyclohexylmethyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
4-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methyl group
(Lopyl) phenyl] acetyl} piperazine-1-carboxylate;
N- (5-chloropyridin-2-yl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxy
Cyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (6-methylpyridin-2-yl) acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-methylpyridin-2-yl) acetamide ;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-isoquinolin-1-ylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4,6-dimethylpyridin-2-yl Acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-methoxybenzyl) acetamide;
N-[(1S) -1-benzyl-2-hydroxyethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl ) Phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (1-ethyl-1H-pyrazole-5- Yl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (1,3-dimethyl-1H-pyrazole- 5-yl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-fluorobenzyl) acetamide;
1-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl
(Lopyl) phenyl] acetyl} -L-prolinamide;
5- {2-[(2- {3- [2- (5-Amino-3-tert-butyl-1H-pyrazol-1-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino ] -1-hydroxyethyl} benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1-phenylethyl] acetamide ;
5- {2-[(2- {3- [2- (1,4-Dioxa-8-azaspiro [4.5] dec-8-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino ] -1-hydroxyethyl} benzene-1,3-diol;
N- [2- (4-Chloro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydro
Xoxy-ethylamino] -2-methyl-propyl} -benzamide;
N-adamantan-1-yl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (3-fluoro-phenyl) -ethyl] -benzamide ;
N- [2- (2-Chloro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydro
Xoxy-ethylamino] -2-methyl-propyl} -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (2,3-dimethyl-phenyl) -ethyl] -Benzamide;
N- [2- (2-Chloro-4-fluoro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl- Propyl} -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (4-methoxy-2,3-dimethyl-phenyl) ) -Ethyl] -benzamide;
N- (3,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (3,4-dichloro-benzyl) -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Tilamino] -2-methyl-propyl} -benzamide;
N- (4-Chloro-benzyl) -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Amino] -2-methyl-propyl} -benzamide;
N-adamantan-1-yl-3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Amino] -2-methyl-propyl} -benzamide;
N- (4-Chloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide ;
N- (4-trifluoromethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl)- Acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N-pyridin-2-ylmethyl-acetamide;
N- (3,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N-cyclohexylmethyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Tilamino] -propyl} -phenyl) -acetamide;
1- (3,4-Dihydro-1H-isoquinolin-2-yl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl}- Phenyl) -ethanone;
N-benzyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino]-
Propyl} -phenyl) -N-methyl-acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-hydroxy-benzyl) -acetamide;
N- (4-Cyano-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide ;
N- (2,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (2-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Ruamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (3-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tilamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (cyclohexylmethyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N-phenethyl-acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (4-chlorophenethyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (4-phenylphenethyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (4′-hydroxy-biphenyl-3-ylmethyl) -acetamide;
N-cycloheptyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyla
Mino] -2-methyl-propyl} -phenyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-phenethyl-acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-methylsulfanyl-benzyl) -acetamide;
N- (2,6-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-indan-2-yl-acetamide;
N- (2-Chloro-6-fluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydride
Roxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (4-Chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Ruamino] -propyl} -phenyl) -acetamide;
N- (2,5-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (3,5-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (2,6-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N-biphenyl-2-ylmethyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (2-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Ruamino] -propyl} -phenyl) -acetamide;
N- (3-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tilamino] -propyl} -phenyl) -acetamide;
N- (3-trifluoromethylbenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (3,4-difluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (2-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tilamino] -propyl} -phenyl) -acetamide;
N- (3,4-dimethylbenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -propyl} -phenyl) -acetamide;
N- (3,4-dimethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetylamino] -methyl} -benzamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-indan-1-yl-acetamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (3-fluoro-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-chloro-phenyl) -ethyl] -benzamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-naphthalen-1-ylmethyl-acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-fluoro-5-trifluoromethyl-benzyl) -Acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (3-chlorobenzyl) -acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (4-fluoro-3-trifluoromethyl-benzyl) -Acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (2-methylsulfanyl-benzyl) -acetamide;
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetylamino] -methyl}- Benzamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (4-sulfamoyl-benzyl) -acetamide;
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetylamino] -methyl}- Benzoic acid methyl ester;
N- (1-Benzyl-piperidin-4-yl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl}- Phenyl) -acetamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2-phenethyl] -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (5-fluoro-2-methyl-phenyl) -ethyl] -benzamide ;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-trifluoromethyl-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- (2-naphthalen-1-yl-ethyl) -benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2,4,5-trimethyl-phenyl) -ethyl] benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2,3-dimethyl-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-hydroxy-3-chloro-phenyl) -ethyl] -benzamide ;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (4-chloro-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-hydroxy-5-chloro-phenyl) -ethyl] -benzamide ;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-chloro-4-fluoro-phenyl) -ethyl] -benzamide ;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (2-methyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (3-methyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (4-methyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (2-methoxy-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (4-methoxy-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (2,3-dimethyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (3,4-dimethyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (2-chloro-6-methyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- (3-chloro-4-methyl-benzyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
Ropyl} -phenyl) -N- [2- (6-methoxy-naphthalen-2-yl) -ethyl] -acetamide;
N- (2-chlorobenzyl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethyl
Amino] propyl} phenyl) propionamide;
N- (2,6-dichlorobenzyl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxy ester
Tilamino] propyl} phenyl) propionamide;
1- (3,4-Dihydro-1H-isoquinolin-2-yl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) propane- 1-on;
N- (2-chloro-4-fluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) acetamide;
N- (4-Bromobenzyl) -2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethyl
Amino] -2-methylpropyl} phenyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- (3,4-dimethylphenyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -N- (2,3-dimethylbenzyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -N- (4-fluorobenzyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -1- (4-pyridin-2-ylpiperazin-1-yl) ethanone; and
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- (2-phenylpropyl) acetamide.

According to one aspect of the present invention, compounds of formula (1) are generally preferred when the (CH ₂ ) _n —C (═O) Q ¹ group is located in the meta position.
Pharmaceutically acceptable salts of the compound of formula (1) include acid addition salts and base addition salts of the compound of formula (1).

Suitable acid addition salts are acid addition salts formed from acids that form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camsylate salt, citric acid Salt, cyclamate, edicylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate,
Hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, hydrogen phosphate, isethionate, D-lactate, L-lactate, malate, Maleate, malonate, methanesulfonate, methyl sulfate, 2-napsylate salt, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphorus Acid salt / hydrogen,
Phosphate / dihydrogen phosphate, pyroglutamate, saccharinate, stearate, succinate, tannate, D-tartrate, L-tartrate, 1-hydroxy-2-naphthoate tosylate Salt, and xinafoate salt.

  Suitable base salts are those formed from bases that form non-toxic salts. Examples include aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, and There are zinc salts. Hemisalts of acids and bases (eg, hemisulfate and hemicalcium salts) can also be formed.

  For a review on suitable salts, see “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

Pharmaceutically acceptable salts of the compound of formula (1) can be prepared by one or more of the following three methods:
(i) by reacting the compound of formula (1) with the desired acid or base;
(ii) using the desired acid or base to remove the acid or base labile protecting group from a suitable precursor of the compound of formula (1), or a suitable cyclic precursor (e.g. lactone Or a lactam); or
(iii) by converting one salt of a compound of formula (1) to another salt by reacting with a suitable acid or base or using a suitable ion exchange column.

  Both of these reactions are generally performed in solution. The salt thus obtained can be precipitated and collected by filtration or can be recovered by evaporating off the solvent. The degree of ionization in the resulting salt may vary from a fully ionized state to a hardly ionized state.

The compounds of the invention may exist in both unsolvated and solvated forms. The term 'solvate' refers herein to a molecular complex comprising a compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules (eg, ethanol). Is used. The term 'hydrate' is used when the solvent is water.

Complexes such as inclusion compounds (i.e., complexes that include a drug-host) are also included within the scope of the present invention, in which case the drug and host are in contrast to the solvate. It exists in stoichiometric or non-stoichiometric amounts. Furthermore, a complex of a drug containing two or more organic components and / or inorganic components (which may be a stoichiometric amount or a non-stoichiometric amount) is also included in the present invention. The complex thus obtained may be ionized, ionized to some extent or not ionized. For a review on such complexes, see J Pharm Sci. 64 (8), 1269-1288 by Haleblian (August 1975).

Hereinafter, all references to compounds of formula (1) include references to salts, solvates and complexes of compounds of formula (1), and references to solvates and complexes of salts of said compounds. Including.
The compounds of the present invention include compounds of formula (1) as defined above, including all polymorphs and crystal habits of compounds of formula (1), of compounds of formula (1) as defined above. Prodrugs and isomers (optical isomers,
And includes isotopically labeled compounds of the compound of formula (1).

As mentioned above, so-called 'prodrugs' of the compound of formula (1) are also included within the scope of the present invention. Thus, certain derivatives of the compound of formula (1), which have little or no pharmacological activity per se, are administered in or on the body, for example by cleavage by hydrolysis. Can be converted to compounds of formula (1) having the desired activity. Such derivatives are called 'prodrugs'. Further information on the use of prodrugs can be found in 'Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella)' and 'Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (EB Roche Ed., American Pharmacy Association) '.

Prodrugs according to the present invention may be prepared, for example, by converting the appropriate functionality present in the compound of formula (1) to 'pro-moieties' [eg “Design of Prodrugs” by H. Bundgaad (Elsevier, 1985) '' as known to those skilled in the art.
Can be obtained by replacing with

Some examples of prodrugs according to the present invention include:
(i) when the compound of formula (1) contains a carboxylic acid functionality (-COOH), an ester of the compound of formula (1), for example, hydrogen of the carboxylic acid functionality of the compound of formula (1) When is replaced by (C ₁ -C ₈ ) alkyl;
(ii) when the compound of formula (1) contains an alcohol functionality (-OH), the ether of the compound of formula (1), for example the hydrogen of the alcohol functionality of the compound of formula (1) is ( C ₁ -C ₆ ) a compound when replaced by alkanoyloxymethyl; and
(iii) if the compound of formula (1) contains a primary or secondary amino functionality [-NH ₂ or NHR (where R is not H), the compound of formula (1) An amide of, for example, a compound where one or two hydrogens of the amino functionality of the compound of formula (1) are replaced by (C ₁ -C ₁₀ ) alkanoyl;
and so on.

Further examples of substitution groups according to the above examples, and further examples of substitution groups according to examples of other prodrug types are described in the aforementioned literature.
Furthermore, certain compounds of formula (1) may themselves act as prodrugs of other compounds of formula (1).

Also included within the scope of the invention are metabolites of compounds of formula (1) (ie, compounds formed in vivo upon administration of a drug). Some examples of metabolites according to the present invention include:
(i) when the compound of formula (1) contains a methyl group, a hydroxylmethyl derivative of the compound of formula (1) (-CH ₃ → -CH ₂ OH);
(ii) when the compound of formula (1) contains an alkoxy group, a hydroxy derivative (-OR → -OH) of the compound of formula (1);
(iii) when the compound of formula (1) contains a tertiary amino group, a secondary amino derivative of the compound of formula (1) (-NR ¹ R ² → -NHR ¹ or NHR ² );
(iv) when the compound of formula (1) contains a secondary amino group, a primary amino derivative of the compound of formula (1) (-NHR ¹ → -NH ₂ );
(v) when the compound of formula (1) contains a phenyl moiety, a phenol derivative of the compound of formula (1) (-Ph → -PhOH); and
(vi) when the compound of formula (1) contains an amide group, a carboxylic acid derivative of the compound of formula (1) (-CONH ₂ → -COOH);
and so on.

Compounds of formula (1) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where the compound of formula (1) contains an alkenyl or alkenylene group, cis / trans (or Z / E) geometric isomers are possible. Tautomeric isomerism ('tautomerism') can occur when structural isomers are interconvertible due to low energy barriers. Tautomerization may take the form of, for example, proton tautomerism in a compound of formula (1) containing an imino group, keto group, or oxime group, or valence tautomerism in a compound containing an aromatic moiety. There is. Thus, a single compound may exhibit more than one type of isomerism.

All stereoisomers, all geometric isomers, and all tautomers of the compounds of formula (1), including compounds exhibiting two or more isomerisms, and mixtures of one or more of these compounds, It is included within the scope of the present invention. Acid addition salts or base salts when the counter ion is optically active (for example, d-lactase or l-lysine, or racemic compounds such as dl-tartrate or dl-arginine)
Are also included within the scope of the present invention.

Cis / trans isomers can be separated by conventional methods well known to those skilled in the art (eg, chromatography or fractional distillation).
Conventional methods for preparing / isolating individual enantiomers include chiral synthesis from appropriate optically pure precursors, or racemates (or salts and derivatives using, for example, chiral high performance liquid chromatography (HPLC)). A racemate).

Separately, a racemate (or a racemic precursor), an optically active compound (for example, an alcohol), or a compound of the formula (1) is an acidic moiety or a basic moiety (a basic moiety)
In the case of containing a moiety), it can be reacted with an acid or a base (for example, tartaric acid or 1-phenylethylamine). The diastereomeric mixtures thus obtained can be separated by chromatography and / or fractional crystallization, or one or both of the diastereomers can be separated by the methods known to those skilled in the art by the corresponding pure enantiomers. Can also be converted.

The chiral compounds (and chiral precursors) of the present invention consist of hydrocarbons (generally heptane or hexane) by chromatography (generally HPLC) and are 0-50% by volume (generally 2%
In a highly enantiomeric form on an asymmetric resin using a mobile phase containing ~ 20%) isopropanol and 0-5% by volume alkylamine (generally 0.1% diethylamine). Obtainable. By concentrating the eluent, a mixture with a high content of enantiomers is obtained.

Stereoisomeric aggregates can be separated by conventional methods known to those skilled in the art (see, for example, “Stereochemistry of Organic Compounds” by ELEliel (Wiley, New York, 1994)).

  According to one aspect of the present invention, the following formula

(R, R) -stereo form of the formula wherein R ¹ is hydrogen, R ² is C ₁ -C ₄ alkyl (preferably methyl) and n and Q ¹ are as defined above. Isomers are generally preferred.
In the present invention, one or more atoms are replaced by atoms having the same atomic number, but the atomic weight or mass number is different from the atomic mass or mass number that is predominantly present in nature. All pharmaceutically acceptable isotope-labeled compounds of formula (1).

Examples of isotopes suitable for incorporation into the compounds of the present invention include hydrogen isotopes (eg, ² H and ³ H), carbon isotopes (eg, ¹¹ C, ¹³ C, and ¹⁴ C), Chlorine isotopes (eg ³⁶ Cl), fluorine isotopes (eg ¹⁸ F), iodine isotopes (eg ¹²³ I and ¹²⁵ I), nitrogen isotopes (eg ¹³ N and ¹⁵ N), oxygen isotopes Isotopes (eg, ¹⁵ O, ¹⁷ O, and ¹⁸ O), phosphorus isotopes (eg, ³² P), sulfur isotopes (eg, ³⁵ S), and the like.

Certain isotopically-labelled compounds of formula (1) (eg, those incorporating a radioactive isotope) are useful in drug and / or substrate tissue distribution experiments. The radioactive isotopes tritium (ie, ³ H) and carbon-14 (ie, ¹⁴ C) are particularly useful for this purpose because of their ease of incorporation and ready means of detection.

Replacing with a heavier isotope such as deuterium (i.e. ² H) gives higher metabolic stability (
For example, increased in vivo half-life or reduced dosage requirements) may provide certain therapeutic benefits and may therefore be preferred in some circumstances.

Replacing with positron emitting isotopes (eg, ¹¹ C, ¹⁸ F, ¹⁵ O, and ¹³ N) is useful in positron emission topography (PET) experiments to examine substrate receptor occupancy.

The isotope-labeled compounds of formula (1) are generally described below using conventional methods known to those skilled in the art or using appropriate isotope-labeled reagents instead of conventionally used unlabeled reagents. It can be produced by a method similar to the method described in Examples and Production Examples.

Solvates that are acceptable as pharmaceutical according to the invention replaces the solvent of crystallization isotopically - a solvate when (e.g., D ² O, d ⁶ acetone, or d ^6-DMSO) can Including.
The compounds of formula (1), pharmaceutically acceptable salts and / or derivatives of said compounds are pharmaceutically active useful compounds. These compounds are useful for the treatment and prevention of many disorders involving the β2 receptor, or many disorders where agonism of this receptor may have benefits (particularly allergic and non-allergic airway diseases). Suitable for other diseases (e.g. nervous system diseases, premature labor diseases, congestive heart failure, depression, inflammatory and allergic skin diseases, psoriasis, proliferative skin diseases, glaucoma, and gastric acidity It is also suitable for the treatment of diseases (especially including, but not limited to, gastric ulcers and peptic ulcers) that can be beneficially reduced.

The compounds of the present invention intended for pharmaceutical use can be administered as crystalline or amorphous articles. The compounds of the present invention can be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporation drying. Microwave drying and high frequency drying can also be used for this purpose.

The compounds of the present invention can be administered alone, in combination with one or more other compounds of the present invention, or in combination with one or more other drugs (or these (As any combination). Generally, the compounds of this invention are administered as a formulation in combination with one or more pharmaceutically acceptable excipients. “
The term “excipient” is used herein to denote any ingredient other than the compound of the invention. The choice of excipient depends on the particular mode of administration, solubility and stability of the excipient. Depends to a large extent on factors such as impact and dosage form characteristics.

  Pharmaceutical compositions suitable for supplying the compounds of the present invention and methods for making them will be readily apparent to those skilled in the art. Such compositions and methods for their preparation are described, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).

  The compounds of the present invention can be administered orally. Oral administration may be by swallowing the compound into the gastrointestinal tract, or buccal or sublingual administration, where the compound enters the bloodstream directly from the mouth.

Formulations suitable for oral administration include solid formulations such as tablets; capsules containing granules, liquids, or powders; troches (including liquid-filled troches); chew; multiparticulates and nanoparticles; gels Solid solutions; liposomes; films; vaginal suppositories; sprays; and liquid formulations;

Liquid formulations include suspensions, solutions, syrups, and elixirs. Such formulations can be used as fillers in soft capsules or hard capsules, generally a carrier (eg, water, ethanol, polyethylene glycol, propylene glycol, methyl cellulose, or a suitable oil), and one or more Emulsifiers, and / or
Or it contains a suspending agent. Liquid formulations can also be prepared, for example, by reconstitution of a solid from a sachet.

The compound of the present invention further comprises a rapidly dissolving and rapidly disintegrating dosage form (for example, the dosage form described in "Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001)"). Can also be used.

For tablet dosage forms, depending on dose, the drug may make up from 1% to 80% by weight of the dosage form (more typically from 5% to 60% by weight of the dosage form). Tablets generally contain a disintegrant in addition to the drug. Examples of disintegrants include sodium starch glycolate, sodium carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methylcellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropylcellulose, starch, pregelatinized There are starch and sodium alginate. Disintegrants are generally 1% to 25% by weight of the dosage form (preferably 5%
% To 20% by weight).

Binders are commonly used to impart cohesiveness to tablet formulations. Suitable binders include microcrystalline cellulose, gelatin, sugar, polyethylene glycol, natural gum, synthetic gum, polyvinylpyrrolidone, pregelatinized starch, hydroxypropylcellulose, and hydroxypropylmethylcellulose. Tablets can further include lactose (monohydrate, spray dried monohydrate, and anhydride), mannitol, xylitol, glucose,
Diluents such as sucrose, sorbitol, microcrystalline cellulose, starch, or dibasic calcium phosphate dihydrate may be included.

  The tablet may further contain a surfactant such as sodium lauryl sulfate or polysorbate 80, and a glidant such as silicon dioxide or talc, if necessary. When present in the surfactant and glidant, the surfactant may comprise 0.2% to 5% by weight of the tablet and the glidant may comprise 0.2% to 1% by weight of the tablet.

Tablets generally further contain a lubricant, such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and a mixture of magnesium stearate and sodium lauryl sulfate. Lubricants are generally from 0.25% to 10% by weight of the tablet
% By weight (preferably 0.5% to 3% by weight).

Other components that can be incorporated include antioxidants, colorants, flavors, preservatives, and taste blockers.
Exemplary tablets are up to about 80% drug, about 10% to about 90% binder, about 0% to about 85% diluent, about 2% to about 10% by weight. Contains a disintegrant and about 0.25 wt% to about 10 wt% lubricant.

Tablet blends can be compressed directly or by roller to make tablets. Alternatively, the tablet blend or part of the blend can be tableted after wet granulation, dry granulation, melt granulation, melt coagulation, or extrusion. The final product is 1
One or more layers may be included and may or may not be coated. The final preparation may be encapsulated.

Tablet formulations are described in “Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980)”.
Consumable oral films for use in humans or animals are usually water-soluble or water-swellable flexible thin film dosage forms that dissolve rapidly or are mucoadhesive. In general, it comprises a compound of formula (1), a film-forming polymer, a binder, a solvent, a humectant, a plasticizer, a stabilizer or emulsifier, a viscosity modifier, and a solvent. Some components of the formulation may perform more than one function.

The compound of formula (1) may be water-soluble or water-insoluble. In general, the water-soluble compound constitutes 1% to 80% by weight (more typically 20% to 50% by weight) of the solute. Less soluble compounds may make up a greater percentage of the composition (typically up to 88% by weight of the solute). Alternatively, the compound of formula (1) may be in the form of multiparticulate beads.

  The film-forming polymer can be selected from natural polysaccharides, proteins, or synthetic hydrocolloids, generally in the range of 0.01 wt% to 99 wt% (more typically 30 wt% to 80 wt%). Exists.

  Other ingredients that can be incorporated include antioxidants, colorants, flavors and seasonings, preservatives, saliva stimulants, cooling agents, co-solvents (including oils), emollients, bulking agents, antifoaming agents. , Surfactants, and taste blockers.

  The films of the present invention are generally made by evaporating and drying a thin aqueous film coated on a peelable backing or backing paper. This operation can be performed in a drying furnace or a tunnel dryer (generally a combination of a coater and a dryer), or by freeze drying or vacuum drying.

Solid formulations for oral administration can be formulated to allow immediate release and / or modified release. Modified release formulations include delayed release formulations, sustained release formulations, pulsatile release formulations, controlled release formulations, target release formulations, and programmed release formulations.

Suitable modified release formulations suitable for the purposes of the present invention are described in US Pat. No. 6,106,964.
For details on other suitable release technologies (eg, high energy dispersion, and osmotic and coated particles), see “Pharmaceutical Technology On-line, 25 (2), 1-14, by Verma et al (2001)”.
It is described in. The use of chewing gum to achieve controlled release is described in WO00 / 35298.

The compounds of the invention can further be administered directly into the bloodstream, into muscles, or into organs. Suitable methods for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, and subcutaneous There is administration. Suitable devices for parenteral administration include needle (including microneedle) injectors, needleless injectors, and injection methods.

Parenteral formulations are generally aqueous solutions and may contain excipients such as salts, carbohydrates, and buffering agents (preferably adjusted to a pH of 3-9). However, for some applications, parenteral formulations can be more appropriately formulated as a sterile non-aqueous solution or as a dry form for use in combination with a suitable vehicle (eg, sterile pyrogen-free water). .

Preparation of parenteral formulations under aseptic conditions (eg, by lyophilization) can be readily accomplished using standard pharmaceutical procedures well known to those skilled in the art.
The solubility of the compound of formula (1) used in the preparation of parenteral solutions can be increased by using appropriate formulation techniques (eg, incorporation of solubility enhancers).

Formulations for parenteral administration can be formulated to allow immediate release and / or modified release. Modified release formulations include delayed release formulations, sustained release formulations, pulsatile release formulations, controlled release formulations, target release formulations, and programmed release formulations. Thus, the compounds of the present invention can be formulated as solids, semisolids, or thixotropic liquids for administration as an implanted depot that provides controlled release of the active compound. Examples of such formulations include drug-coated stents and poly (dl-lactic-co-glycolic acid) (PGLA) microspheres.

  The compounds of the present invention can also be administered topically (ie, dermally or transdermally) to the skin or mucosa. Typical formulations suitable for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, dressings, and microemulsions. There is. Liposomes can also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol, and propylene glycol. Penetration enhancers can also be incorporated (see, for example, “J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 199)”).

Other means of topical administration include delivery by electroporation, ionphoresis, phonophoresis, sonophoresis, and microneedle, or needleless injection (e.g., Powderject (TM), bioject (Bioject) (trademark)
] Delivery.

Formulations for topical administration can be formulated to allow immediate release and / or modified release. Modified release formulations include delayed release formulations, sustained release formulations, pulsatile release formulations, controlled release formulations, target release formulations, and programmed release formulations.

The compounds of the present invention can further be obtained in the form of a dry powder from a dry powder inhaler [alone, as a mixture (eg, in a dry blend with lactose), or as mixed component particles (eg, phospholipids such as phosphatidylcholine). Or a pressurized container, pump, nebulizer, atomizer (preferably an atomizer that uses electrohydrodynamics to obtain a fine mist), or an aerosol spray from a nebulizer (1,1,1,2-tetra Appropriate propellants such as fluoroethane and 1,1,1,2,3,3,3-heptafluoropropanone may or may not be used) and can be administered by inhalation into the nasal cavity. For intranasal use, the powder may comprise a bioadhesive agent (eg, chitosan or cyclodextrin).

A pressurized container, pump, nebulizer, atomizer or nebulizer contains a solution or suspension of a compound of the invention, for example, ethanol; aqueous ethanol; for dispersing or solubilizing the active ingredient, or of the active ingredient A suitable alternative agent to enhance release; a propellant as solvent; and an optional surfactant (eg, sorbitan trioleate, oleic acid, or oligolactic acid).

Prior to use in a dry powder or suspension formulation, the drug is micronized to a size suitable for delivery by inhalation (generally less than 5 microns). This treatment can be done by any suitable comminuting method (e.g., spiral jet comminution, fluid bed jet comminution, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying). Can fulfill.

  Cartridges for use in capsules (eg manufactured from gelatin or hydroxypropylmethylcellulose), blisters, and inhalers or aerators are powder mixtures of the compounds of the invention, suitable powder bases (eg lactose or starch) And a performance modifier (eg, l-leucine, mannitol, or magnesium stearate). Lactose may be in the form of an anhydride or in the form of a monohydrate (preferably the latter). Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.

A suitable solution formulation for use in an atomizer that uses electrohydrodynamics to generate a fine mist may contain from 1 μg to 20 mg of a compound of the invention per actuation and a working volume of 1 μl to 100 μl. It may be changed within the range. A typical solution formulation is a compound of formula (1),
May include propylene glycol, sterile water, ethanol, and sodium chloride. Other solvents that can be used in place of propylene glycol include glycerol and polyethylene glycol.

Appropriate flavors (eg, menthol and levomenthol) or sweeteners (eg, saccharin and sodium saccharin) can be added to formulations of the invention intended for inhalation / intranasal administration.

  Formulations for inhalation / intranasal administration can be formulated to allow immediate release and / or modified release using, for example, PGLA. Modified release formulations include delayed release formulations, sustained release formulations, pulsatile release formulations, controlled release formulations, target release formulations, and programmed release formulations.

In the case of powder inhalers and aerosols, the unit dose is determined by a valve that supplies a metered amount. Unit doses according to the present invention are generally arranged such that a metered dose or “puff” containing 0.001 mg to 10 mg of the compound of formula (1) is administered. The total daily dose is generally in the range of 0.001 mg to 40 mg, and these doses can be administered in a single dose or, more generally, as divided doses throughout the day. it can.

The compounds of formula (1) are particularly suitable for administration by inhalation.
The compounds of the present invention can be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives can be used if desired.

  Formulations for rectal / vaginal administration can be formulated to allow immediate and / or modified release. Modified release formulations include delayed release formulations, sustained release formulations, pulsatile release formulations, controlled release formulations, target release formulations, and programmed release formulations.

The compounds of the present invention can also be administered directly to the eye or ear, generally in the form of a fine powder suspension or a solution droplet obtained by dissolving in sterile pH-adjusted saline. . Other formulations suitable for ophthalmic and otic administration include ointments, biodegradable implants (e.g., absorbable gels, sponges or collagen) and non-biodegradable implants (e.g., silicone), There are wafers, lenses, and granular or vesicular systems (eg, nlosomes and liposomes). A polymer such as crosslinked polyacrylic acid, crosslinked polyvinyl alcohol, or crosslinked hyaluronic acid, a cellulosic polymer (e.g., hydroxypropylmethylcellulose, hydroxyethylcellulose, or methylcellulose), or a heteropolysaccharide polymer (e.g., gellan gum) is used as a preservative (e.g., benzamide chloride). (Luconium). Such formulations can also be supplied by iontophoresis.

  Formulations for ocular / ear administration can be formulated to allow immediate release and / or modified release. Modified release formulations include delayed release formulations, sustained release formulations, pulsatile release formulations, controlled release formulations, target release formulations, and programmed release formulations.

The compounds of the present invention may be soluble macromolecule entities to improve solubility, dissolution rate, taste blocking, bioavailability, and / or stability for use in any of the above modes of administration. ) (E.g. cyclodextrin and its appropriate derivatives,
Or a polyethylene glycol-containing polymer).

For example, drug-cyclodextrin complexes have been found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes can be used. As an alternative to direct complexation with the drug, cyclodextrin can also be used as an auxiliary additive (ie, as a carrier, diluent, or solubilizer). The most commonly used for these purposes are α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin, examples of which are described in international patent applications WO91 / 11172, WO94 / 02518, And in WO98 / 55148.

For example, to treat a particular disease or condition, it is preferable to administer a combination of active compounds, so that two or more pharmaceutical compositions (of which at least one contains a compound according to the invention) It is also within the scope of the present invention that it can be suitably combined in the form of a kit suitable for simultaneous administration of the composition.

Thus, the kit of the present invention comprises two or more separate pharmaceutical compositions (of which at least one contains a compound of formula (1) according to the present invention) and a separate pharmaceutical composition for holding said pharmaceutical composition Means (e.g. containers, split bottles or split foil packets). One example of such a kit is the well-known blister pack used for packaging tablets and capsules.

The kits of the invention can be used to administer different dosage forms (eg, parenteral administration), to administer separate compositions at different dosing intervals, or to titrate separate compositions against each other. Especially suitable for. In order to make it easier to comply with the medication, the kit is generally accompanied by instructions for administration and is equipped with a so-called memory aid.

For administration to human patients, the total daily dose of the compounds of the invention is of course in the range of 0.001 mg to 5000 mg depending on the mode of administration. For example, a daily dose of intravenous injection only requires 0.001 mg to 40 mg. The total daily dose can be administered in a single dose or in divided doses,
It may deviate from the typical scope described herein at the discretion of the physician.

  These dosages are based on an average human patient having a weight of about 65 kg to 70 kg. The physician can easily determine the dose for patients whose weight falls outside this range (eg, infants and the elderly).

In order to avoid ambiguity, “treatment” as used herein refers to therapeutic treatment,
It should include palliative and preventive measures.
According to another embodiment of the present invention, the compound of formula (1), or a pharmaceutically acceptable salt, derivative or composition of said compound, may have a certain desired therapeutic outcome [eg (i) bronchoconstriction. (Ii) treatment of pathophysiologically related disease processes including (but not limited to) signs and symptoms such as inflammation, (iii) allergies, (iv) tissue destruction, and (v) shortness of breath and cough). To obtain, it can also be used in combination with one or more additional therapeutic agents that are co-administered to the patient. The second therapeutic agent and the additional additional therapeutic agent can be a compound of formula (1), or a pharmaceutically acceptable salt, derivative, or composition of said compound, or one known in the art. The above β2 agonist may be used. More generally, the second therapeutic agent and the additional additional therapeutic agent are selected from different types of therapeutic agents.

“Co-administration”, “co-administered” as used herein in reference to the compound of formula (1) and one or more other therapeutic agents And the term “in combination with” is intended to mean the following content, refers to the following content, and includes:
To a patient in need of treatment when the compound of formula (1) and the therapeutic agent are formulated together in a single dosage form that releases the ingredients to the patient at substantially the same time Simultaneous administration of a combination of a compound of formula (1) and a therapeutic agent;
The compound of formula (1) and the therapeutic agent are formulated in separate dosage forms separately from each other and these dosage forms are taken by the patient at substantially the same time so that the ingredients are substantially the same Substantially simultaneous administration of a combination of a compound of formula (1) and a therapeutic agent to a patient in need of treatment when released to the patient over time;
The compound of formula (1) and the therapeutic agent are formulated separately from each other in separate dosage forms, these dosage forms
To patients in need of treatment when ingested by the patient at a continuous time with a significant amount of time between each administration, whereby the ingredients are released to the patient at substantially different times Sequential administration of a combination of a compound of formula (1) and a therapeutic agent; and-a compound and a therapeutic agent of formula (1) together in a single dosage form that releases the ingredients in a controlled manner. To a patient in need of treatment when the ingredients are administered simultaneously, continuously, and / or overlappingly to the patient at the same time and / or different times Sequential administration of a combination of a compound of formula (1) and a therapeutic agent;
In this case, each part can be administered by the same route or by different routes.

Suitable examples of compounds of formula (1), or other therapeutic agents that can be used in combination with pharmaceutically acceptable salts, derivatives, or compositions of said compounds include:
(a) a 5-lipoxygenase (5-LO) inhibitor, or a protein (FLAP) antagonist that activates 5-lipoxygenase,
_{(b) LTB 4, LTC 4} , LTD 4, and leukotriene antagonists, including antagonists of LTE ₄ (LTRA),
(c) histamine receptor antagonists including H1 and H3 antagonists,
(d) α ₁ -adrenergic receptor agonist and α ₂ -adrenergic receptor agonist, which are vasoconstrictive sympathomimetic agents for use as a decongestant,
(e) a muscarinic M3 receptor antagonist or anticholinergic agent,
(f) PDE inhibitors, such as PDE3 inhibitors, PDE4 inhibitors, and PDE5 inhibitors,
(g) Theophylline,
(h) sodium cromoglycate,
(i) COX inhibitors (NSAIDs), including non-selective COX-1 inhibitors, non-selective COX-2 inhibitors, selective COX-1 inhibitors, and selective COX-2 inhibitors,
(j) oral glucocorticosteroids and inhaled glucocorticosteroids such as DAGR (dissociated agonist of the corticoid receptor),
(k) a monoclonal antibody active against endogenous inflammatory entities,
(l) an anti-tumor necrosis factor (anti-TNF-α) drug,
(m) adhesion molecule inhibitors including VLA-4 antagonists,
(n) a kinin B ₁ receptor antagonist and a kinin B ₂ receptor antagonist,
(o) immunosuppressants,
(p) an inhibitor of matrix metalloprotease (MMP),
(q) tachykinin NK ₁ receptor antagonist, tachykinin NK ₂ receptor antagonist, and tachykinin NK ₃ receptor antagonist,
(r) an elastase inhibitor,
(s) an adenosine A2a receptor agonist,
(t) an inhibitor of urokinase,
(u) a compound acting on a dopamine receptor, such as a D2 agonist,
(v) a modulator of the NFκβ pathway, such as an IKK inhibitor,
(w) a modulator of a cytokine signaling pathway, such as a p38 MAP kinase inhibitor, a syk kinase inhibitor, or a JAK kinase inhibitor,
(x) a drug that can be classified as a mucolytic or antitussive,
(y) antibiotics,
(z) an HDAC inhibitor, and
(aa) There are PI3 kinase inhibitors, but it is not limited to these.

According to the present invention, a compound of formula (1)
-H3 antagonist,
-Muscarinic M3 receptor antagonist,
-PDE4 inhibitors,
-Glucocorticosteroids,
-Adenosine A2a receptor agonist,
-Modulators of cytokine signaling pathways, such as p38 MAP kinase inhibitors or syk kinase inhibitors, or
_{- LTB 4, LTC 4, LTD} 4, and leukotriene antagonists, including antagonists of LTE ₄ (LTRA),
A combination with is preferred.

According to the present invention, a compound of formula (1)
-Glucocorticosteroids with low systemic side effects, including prednisone, prednisolone, flunisolide, triamcinolone, beclomethasone, dipropionate, budesonide, fluticasone propionate, ciclesonide, and mometasone furoate (especially
Inhaled glucocorticosteroids), or
-In particular, ipratropium salt (ie bromide), tiotropium salt (ie bromide),
More preferred are combinations with muscarinic M3 receptor antagonists or anticholinergic agents including oxitropium salts (bromide), perenzepine, and telenzepine.

It will be appreciated that any “treatment” referred to herein includes therapeutic treatment, palliative treatment, and prophylactic treatment. The description below relates to therapeutic applications in which compounds of formula (1) can be utilized.

The compound of formula (1) has the ability to interact with the β2 receptor, and therefore, considering the essential role that the β2 receptor plays in all mammalian physiological functions, a broad range is described below. Has therapeutic application.

Accordingly, a further aspect of the present invention provides a compound of formula (1), or a pharmaceutically acceptable salt, derivative of said compound, for use in the treatment of diseases, disorders and diseases involving β2 receptors. Or a composition. More particularly, the present invention provides:
Asthma of any type, of any etiology, or of any pathogen, especially atopic asthma, non-atopic asthma, allergic asthma, IgE-mediated atopic bronchial asthma, bronchial asthma, essential asthma, true asthma, pathophysiology Intrinsic asthma caused by mechanical disorders, extrinsic asthma caused by environmental factors, asthma of unknown cause, non-atopic asthma, bronchial asthma, emphysema asthma, exercise-induced asthma, allergen-induced asthma, cold-induced asthma, Asthma selected from the group consisting of occupational asthma, bacterial infection, fungal infection, protozoal infection, or infectious asthma caused by viral infection, non-allergic asthma, early asthma, childhood wheezing syndrome, and bronchiolytis ;
Chronic or acute bronchoconstriction, chronic bronchitis, peripheral airway obstruction, and emphysema;
• Obstructive or inflammatory airway disease of any type, of any etiology, or of any pathogen, especially chronic eosinophilic pneumonia; chronic obstructive pulmonary disease (COPD); associated with chronic bronchitis, emphysema, or COPD COPD including unrelated dyspnea; COPD characterized by irreversible and progressive airway obstruction; adult respiratory distress syndrome (ARDS); worsening airway hyperresponsiveness as a result of other medications; and pulmonary hypertension Airway disease associated with; obstructive or inflammatory airway disease selected from the group consisting of;
Bronchitis of any type, of any etiology, or of any pathogen, in particular acute bronchitis, acute laryngotracheobronchitis, arachidic bronchitis, catarrhal bronchitis, croup bronchitis, dry bronchitis, infectious asthma Bronchitis selected from the group consisting of traumatic bronchitis, wet cough bronchitis, staphylococcal or streptococcal bronchitis, and alveolar bronchitis;
Acute lung injury;
Bronchiectasis of any type, of any etiology or of any pathogenicity, in particular columnar bronchiectasis, microcystic bronchiectasis, spindle bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, Bronchiectasis selected from the group consisting of dry bronchiectasis and follicular bronchiectasis;
Formula (1) for use in the treatment of diseases, disorders, and diseases selected from the group consisting of
Or a pharmaceutically acceptable salt, derivative or composition of said compound.

Yet another aspect of the present invention relates to the use of a compound of formula (1), or a pharmaceutically acceptable salt, derivative or composition of said compound in the manufacture of a drug having β2 agonist activity. The present invention particularly relates to the manufacture of a medicament for the treatment of β2-mediated diseases and / or diseases (especially the diseases and / or diseases described above), or a pharmaceutically acceptable compound of formula (1) It relates to the use of salts, derivatives or compositions that can be made.

As a result, the present invention provides a very interesting method of treating mammals, including humans, with an effective amount of a compound of formula (1), or a pharmaceutically acceptable salt, derivative or composition of said compound. . More precisely, the invention relates to a mammal comprising administering an effective amount of a compound of formula (1), a pharmaceutically acceptable salt and / or derivative of said compound to a mammal, including a human. A very interesting method for treating β2-mediated diseases and / or illnesses (particularly the diseases and / or illnesses mentioned above) is provided. Production examples of the compound of formula (1) are shown below.

(Production Example 1)
Diethyl 2,2 '-(1,3-phenylene) diacetate

2,2 ′-(1,3-phenylene) diacetic acid (10.0 g, 51 mmol) was dissolved in ethanol (100 ml),
This solution was treated dropwise with acetyl chloride (2.5 ml) as a catalyst. The reaction mixture was stirred at reflux temperature for 18 hours, then naturally cooled and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (100 ml) and washed with sodium bicarbonate solution (3 × 50 ml) and brine (3 × 50 ml). The organic phase was dried over magnesium sulfate and concentrated under reduced pressure. The residue was triturated with pentane to give the title product (11.8g).
¹ HNMR (CDCl _3, 400MHz) δ 1.31 (6H, t), 3.65 (4H, s), 4.20 (4H, q), 7.24-7.36 (4H, m).
LRMS: m / z ES ⁺ 251 [MH] ⁺ .

(Production Example 2)
[3- (2-Ethoxy-2-oxoethyl) phenyl] acetic acid

Diester (44.3 g, 177 mmol) and 2,2 '-(1,3-phenylene) diacetic acid (59.2 g, 308 mmol) from Preparation Example 1 were dissolved in ethanol (24 ml) and dioxane (290 ml). The resulting solution was treated dropwise with 12M hydrochloric acid (4.9 ml, 58.8 mmol). The reaction mixture was stirred and heated to reflux for 18 hours, then allowed to cool naturally and concentrated to reduce volume. The reaction mixture was diluted with toluene (125 ml) and the resulting slurry was filtered. The filtrate was concentrated under reduced pressure and the residue was dissolved in water and neutralized with sodium bicarbonate. The mixture was diluted with ethyl acetate (200 ml) and the organic layer was separated and washed with sodium bicarbonate solution (5 × 30 ml) and brine (50 ml). The aqueous extracts were combined, acidified with 6M hydrochloric acid to pH 3, and extracted with ether (3 × 30 ml). The organic extracts were combined, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was triturated with pentane to give the title compound as a colorless solid (10.8 g).
¹ HNMR (CD ₃ OD, 400MHz) δ 1.25 (3H, t), 3.60 (2H, m), 3.63 (2H, m), 4.15 (2H, q),
7.18-7.32 (4H, m)
LRMS: m / z ES ⁺ 245 [MNa] ⁺ .

(Production Example 3)
[3- (2-Hydroxy-2-methyl-propyl) -phenyl] -acetic acid

A solution obtained by dissolving the acid of Production Example 2 (6.85 g, 32 mmol) in diethyl ether (100 ml)
Cool to 0 ° C. and treat with a 3M solution of methylmagnesium bromide in ether (23.5 ml, 70.0 mmol). The reaction mixture was gradually warmed to room temperature. After 2 hours, the reaction mixture was quenched by adding saturated aqueous ammonium chloride (200 ml). The organic phase was separated, washed with brine (100 ml), dried over magnesium sulfate and concentrated under reduced pressure. Purification by column chromatography on silica gel eluting with pentane: dichloromethane (60:40 to 0: 100) gave the title compound as a colorless oil (6.23 g).
¹ H NMR (CDCl ₃ , 400 MHz) δ 1.22 (6H, s), 2.75 (2H, s), 3.63 (2H, s), 7.12-7.30 (4H, m).
LRMS: m / z ES ⁺ 209 [MH] ⁺ .

(Production Example 4)
{3- [2- (2-Chloro-acetylamino) -2-methyl-propyl] -phenyl} -acetic acid

To a solution obtained by dissolving the alcohol (16.0 g, 70 mmol) from Preparation Example 3 in acetic acid (33 ml), 2-
Chloroacetonitrile (8.8 ml, 140 mmol) was added. The resulting solution was cooled to 0 ° C., treated with concentrated sulfuric acid (33 ml) and the reaction mixture was gradually warmed to room temperature. After 4 hours, the reaction mixture was poured onto ice and basified with solid sodium carbonate. This solution was extracted with ethyl acetate (2 × 500 ml), the organic extracts were combined, dried over magnesium sulfate, and concentrated under reduced pressure to give the title compound as a colorless solid (19.0 g).
¹ H NMR (CDCl ₃ , 400MHz) δ 1.36 (6H, s), 3.02 (2H, s), 3.62 (2H, s) 3.95 (2H, s),
6.19 (1H, br s), 7.06-7.31 (4H, m)
LRMS: m / z ES ^- 282, 284 [MH] ^- .

(Production Example 5)
Methyl [3- (2-amino-2-methylpropyl) phenyl] acetate

A solution obtained by dissolving the amide from Preparation Example 4 (5.1 g, 18 mmol), thiourea (1.6 g, 21 mmol), and acetic acid (18 ml) in methanol (80 ml) was obtained under a nitrogen atmosphere for 16 hours. Heated to reflux. The reaction mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and the residue was dissolved in methanol (150 ml). The solution was saturated with hydrogen chloride gas and heated to reflux for 16 hours. The solvent was removed by evaporation under reduced pressure, and the residue was partitioned between ethyl acetate (200 ml) and 5% aqueous sodium carbonate (200 ml). The organic extract was washed with a saturated aqueous sodium chloride solution (100 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by strong cation exchange resin (eluting with methanol then 2N ammonia in methanol) to elute the product. Concentrate the eluent under reduced pressure,
The title compound was obtained as a yellow oil (2.68 g).
¹ H NMR (CDCl ₃ , 400 MHz) δ 1.14 (6H, s), 2.68 (2H, s), 3.62 (2H, s), 3.69 (3H, s), 7.08-7.16 (3H, m), 7.23-7.27 (1H, m).
LRMS: m / z ES ⁺ 236 [MH] ⁺ .

(Production Example 6)
1- [3,5-Bis (benzyloxy) phenyl] -2-bromoethanone

To a solution of 1- [3,5-bis (benzyloxy) phenyl] ethanone (5 g, 15.04 mmol) dissolved in tetrahydrofuran (60 ml) and methanol (35 ml) was added tetrabutylammonium tribromide (7.25 g , 15.04 mmol) in tetrahydrofuran (20 ml) was added at room temperature with stirring. The reaction mixture was stirred for 24 hours and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (100 ml) and washed with water (2 × 50 ml). The combined organic extracts were dried over magnesium sulfate and concentrated to give the desired compound quantitatively as a yellow oil.
¹ H NMR (400 MHz, CDCl ₃ ) δ 4.38 (2H, s), 5.05 (4H, s), 6.81 (1H, s), 7.10-7.25 (2H, m), 7.30-7.42 (10H, m).
LRMS: m / z APCI ⁺ 413 [MH ⁺ ].

(Production Example 7)
Methyl {3- [2-({2- [3,5-bis (benzyloxy) phenyl] -2-hydroxyethyl} amino) -2-methylpropyl] phenyl} acetate

Obtained by dissolving the compound of Production Example 6 (4.7 g, 11.4 mmol), the compound of Production Example 5 (2.53 g, 11.4 mmol), and N-ethyldiisopropylamine (2 ml, 11.4 mmol) in tetrahydrofuran (140 ml). The solution was heated to reflux with stirring for 24 hours. The reaction mixture was cooled to room temperature, sodium borohydride (647 mg, 17.10 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was quenched by adding methanol (5 ml) and the solvent was evaporated off under reduced pressure. The remaining orange oil was partitioned between dichloromethane (60 ml) and saturated sodium bicarbonate solution (40 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (3 × 40 ml). The organic extracts were combined and concentrated under reduced pressure. Purification by column chromatography on silica gel using dichloromethane and then dichloromethane: methanol: 0.88 ammonia (95: 5: 0.5) as eluent gave the desired product (4.50 g, 70% yield). .
¹ H NMR (400 MHz, CD ₃ OD) δ 1.01 (6H, d), 2.61 (4H, m), 3.58 (2H, s), 3.62 (3H, s), 4.61-4.64 (1H, dd), 5.03 (4H, s), 6.54-6.55 (1H, t), 6.63-6.64 (2H, d), 7.00-7.01 (1H, d), 7.08-7.10 (2H, d), 7.16-7.20 (1H, t) , 7.25-7.28 (2H, m), 7.31-7.34
(4H, t), 7.38-7.40 (4H, d).
LRMS: m / z APCI ⁺ 554 [MH ⁺ ].

(Production Example 8)
Methyl [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetate

Compound of Production Example 7 (4.50 g, 8.13 mmol), ammonium formate (3.59 g, 113.86 mmol),
And a mixture of palladium hydroxide on carbon (900 mg) in ethanol (80 ml) was heated to reflux for 24 hours. The reaction mixture was cooled to room temperature, filtered through Arbocel® and washed with methanol (3 × 20 ml). The filtrate was concentrated under reduced pressure to give an orange oil as the desired product (2.64 g, 87% yield).
¹ H NMR (400 MHz, CD ₃ OD) δ 1.06 (3H, s), 1.07 (3H, s), 2.67-287 (4H, m), 3.62 (2H, s), 3.66 (3H, s), 4.56 -4.59 (1H, q), 6.18-6.19 (1H, t), 6.34 (2H, d), 7.03-7.23 (4H, m).
LRMS: m / z APCI ⁺ 374 [MH ⁺ ].

(Production Example 9)
[3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetic acid

To a solution obtained by dissolving the compound of Production Example 8 (2.64 g, 7.07 mmol) in tetrahydrofuran (30 ml), 1M lithium hydroxide solution (21.2 ml, 21.2 mmol) was added dropwise, and the reaction mixture was stirred for 24 hours. . 1M hydrochloric acid (21.2 ml, 21.2 mmol) was added and the solvent was removed under reduced pressure. The resulting crude residue was azeotropically distilled with methanol and the product was subsequently used without further purification.
¹ H NMR (400 MHz, DMSO-d ₆ ) δ 1.07 (6H, s), 2.74-2.87 (4H, m), 3.39 (2H, s), 4.63-4.61 (1H, d), 6.14-6.15 (1H , t), 6.24-6.25 (2H, d), 6.96-7.22 (4H, m).
LRMS: m / z APCI ⁺ 357 [MH ⁺ ].

(Production Example 10)
1- (3,5-bis-benzyloxy-phenyl) -2-bromo-ethanol

A solution of trimethylboroxine (0.58 ml, 4.20 mmol) in toluene (15 ml) was added to (R) -2- (diphenylhydroxymethylpyrrolidine) (1.48 g, 5.80 mmol) and the reaction mixture was stirred for 15 minutes under a nitrogen atmosphere. . The solution was brought to a volume of 5 ml by distillation at 1 atm and additional toluene (10 ml) was added. Perform 3 distillation / redilution cycles to obtain an orange solution (10 ml of toluene).
Obtained). This orange solution was added to a solution obtained by dissolving the compound of Preparation Example 6 (5.00 g, 12.2 mmol) in tetrahydrofuran (72 ml) at a time at −8 ° C. under nitrogen atmosphere with stirring. . To this mixture, a solution obtained by dissolving borane dimethyl sulfide complex (1.60 ml, 16.8 mmol) in tetrahydrofuran (16 ml) was added by syringe pump in 90 minutes while maintaining the temperature at −8 ° C. Once the addition was complete, methanol (16 ml) was added via syringe pump in 45 minutes while maintaining the temperature at 0 ° C. and the reaction mixture was allowed to warm to room temperature over 12 hours. The solvent was removed under reduced pressure to give a yellow oil. Methanol (80 ml) was added and removed under reduced pressure. Methanol (80 ml) was added and removed under reduced pressure.The resulting yellow oil was dissolved in dichloromethane (500 ml), washed with 1M hydrochloric acid (96 ml) and water (2 × 120 ml), and dried over magnesium sulfate. The solvent was removed under reduced pressure to give the title compound as a cream solid (4.73 g).
¹ H NMR (400MHz, CD ₃ OD) δ 3.52 (1H, m), 3.62 (1H, m), 4.82 (1H, dd), 5.09 (4H, s), 6.60 (1H, m), 6.69 (1H, s), 6.70 (1H, s), 7.33 (2H, m), 7.40 (4H, m), 7.45 (5H, m).
LRMS: m / z electrospray 413, 415 [M + H ⁺ ].

(Production Example 11)
[1- (3,5-Bis-benzyloxy-phenyl) -2-bromo-ethoxy] -tert-butyl-dimethyl-silane

To a solution obtained by dissolving the compound of Production Example 10 (3.08 g, 7.45 mmol) and 2,6-lutidine (1.75 ml, 15.0 mmol) in dichloromethane (74 ml), tert-butyldimethylsilane triflate (3.40 ml, 7.45 mmol) was added dropwise at 0 ° C. under a nitrogen atmosphere. The reaction mixture was warmed to room temperature over 12 hours, washed with 1M hydrochloric acid (2 × 24 ml) and water (2 × 32 ml), dried over magnesium sulfate and the solvent removed under reduced pressure to give a yellow oil. . The oil was purified by column chromatography on silica gel eluting with dichloromethane to give the title compound as a colorless oil (3.51g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.07 (3H, s), 0.13 (3H, s), 0.93 (9H, s), 3.52 (2H, m), 4.86 (1H, dd), 5.10 (4H , s), 6.60 (1H, m), 6.65 (1H, s), 6.66 (1H, s), 7.33 (2H, m), 7.40 (4H, m), 7.45 (4H, m).
LRMS: m / z electrospray 549 [M + Na ⁺ ].

(Production Example 12)
3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy
Xyl) -ethylamino] -2-methyl-propyl} -benzoic acid methyl ester

A solution obtained by dissolving the compound of Preparation Example 11 (2.54 g, 4.80 mmol) and the compound of Preparation Example 21 (2.00 g, 9.60 mmol) in dichloromethane (40 ml) was heated to 75 ° C., and the solvent was removed by evaporation. . The resulting melt was heated at 75 ° C. for 4 days and then cooled to room temperature. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (100: 0: 0 then 95: 5: 0.5) to give the title compound as a yellow oil (2.00 g). .
¹ H NMR (400MHz, CD ₃ OD) δ -0.18 (3H, s), -0.04 (3H, s), 0.78 (9H, s), 1.11 (3H, s), 1.13 (3H, s), 2.70 ( 4H, m), 3.92 (3H, s), 4.70 (1H, dd), 5.12 (4H, s), 6.60 (1H, m), 6.62 (1H, s), 6.63 (1H, s), 7.32 (2H , m), 7.38 (6H, m), 7.45 (4H, m), 7.92 (2H, m).
LRMS: m / z electrospray 654 [M + H ⁺ ].

(Production Example 13)
3- {2- [2- (tert-Butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -2-methyl-propyl} -benzoic acid methyl ester

To a solution obtained by dissolving the compound of Production Example 12 (1.97 g, 3.00 mmol) and ammonium formate (2.17 g, 47.1 mmol) in ethanol (31 ml), palladium hydroxide (340 mg) was added once at room temperature while expanding sales. Added to. The reaction mixture was heated at reflux for 2 hours and then cooled to room temperature. The reaction mixture was filtered through arbocel and the filtrate was concentrated under reduced pressure to give the title compound as a white foam (1.41 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.11 (3H, s), -0.00 (3H, s), 0.81 (9H, s), 1.13 (3H, s), 1.15 (3H, s), 2.70 ( 4H, m), 3.96 (3H, s), 4.63 (1H, dd), 6.22 (1H, m), 6.33 (1H, s), 6.34 (1H, s), 7.42 (2H, m), 7.92 (2H , m).
LRMS: m / z electrospray 474 [M + H ⁺ ], 496 [MNa ⁺ ], 472 [MH ⁻ ].

(Production Example 14)
3- {2- [2- (tert-Butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -2-methyl-propyl} -benzoic acid

To a solution obtained by dissolving the compound of Production Example 13 (1.39 g, 2.93 mmol) in tetrahydrofuran (30 ml), 1M aqueous lithium hydroxide solution (9.00 ml, 9.00 mmol) was added at a time at room temperature with stirring. It was. The reaction mixture was stirred at room temperature for 24 hours and 1M hydrochloric acid (9.00 ml) was added in one portion. The solvent was removed under reduced pressure to give the title compound as a brown foam (2.06 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.05 (3H, s), 0.07 (3H, s), 0.83 (9H, s), 1.35 (3H, s), 1.37 (3H, s), 3.08 (2H , m), 3.25 (2H, m), 4.93 (1H, m), 6.29 (1H, m), 6.38 (1H, s), 6.39 (1H, s), 7.42 (2H, m), 7.92 (1H, m), 8.00 (1H, m).
LRMS: m / z electrospray 460 [M + H ⁺ ].

(Production Example 15)
3- {2- [2- (tert-Butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -2-methyl-propyl} -N- [2- (4-chloro -Phenyl) -ethyl] -benzamide

In a container obtained by dissolving the compound of Production Example 14 (2.06 g, 3.50 mmol) in N, N-dimethylformamide (35 ml), 4-chlorophenethylamine (967 mg, 6.20 mmol), triethylamine (1.00 ml, 7.20 mmol) were added. ), Hydroxybenzotriazole (567 mg, 4.20 mmol), and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (910 mg, 4.70 mmol) were added at room temperature under a nitrogen atmosphere with stirring. The reaction mixture is stirred for 12 hours, the solvent is removed under reduced pressure, the residue is azeotropically distilled with toluene (20 ml), dichloromethane: methanol: 880 ammonia (100: 0: 0, then 95: 5: 0.5, then Purified by column chromatography on silica gel eluting with 90: 10: 1) and eluted again with ethyl acetate: pentane: 880 ammonia (0: 100: 0, changing to 80: 20: 5 in 10% increments). Column chromatography gave the title compound as cream foam (773 mg).
¹ H NMR (400MHz, CD ₃ OD) δ -0.10 (3H, s), 0.01 (3H, s), 0.84 (9H, s), 1.12 (3H, s), 1.14 (3H, s), 2.74 (4H , m), 3.94 (2H, m), 3.62 (2H, m), 4.66 (1H, dd), 6.22 (1H, m), 6.34 (1H, s), 6.35 (1H, s), 7.42 (6H, m), 7.67 (2H, m).
LRMS: m / z electrospray 597 [M + H ⁺ ].

(Production Example 16)
1- (3-Bromophenyl) -2-methylpropan-2-ol

To a solution of 1- (3-bromo-phenyl) propan-2-one (15.0 g, 70 mmol) dissolved in dry diethyl ether (200 ml) was added methylmagnesium bromide (3M solution in diethyl ether, 51.6 ml, 155 mmol) was slowly added at 0 ° C. The reaction mixture was left for 3 hours, then cooled to 0 ° C. and saturated aqueous ammonium chloride was added to quench the reaction mixture. The organic phase was washed with brine and dried over sodium sulfate. The yellow oil was purified by column chromatography on silica gel eluting with dichloromethane: pentane: methanol (90: 5: 5, volume ratio) to give a pale yellow oil (13.26 g).
¹ H NMR (400 MHz, CDCl ₃ ) δ = 7.40 (2H, m), 7.15 (2H, m), 2.74 (2H, s), 1.42 (1H, bs), 1.22 (6H, s).

(Production Example 17)
N- [2- (3-Bromophenyl) -1,1-dimethylethyl] -2-chloroacetamide

To a solution obtained by dissolving 1- (3-bromophenyl) -2-methylpropan-2-ol (Preparation Example 16) (12.0 g, 52.0 mmol) in acetic acid (25 ml), chloroacetonitrile ( 6.63 ml, 105 mmol) was added at room temperature. The resulting solution was cooled to 0 ° C. and concentrated sulfuric acid (25 ml) was added while keeping the temperature below 10 ° C. The resulting solution was stirred for 1 hour, then poured onto ice and made basic by adding solid potassium carbonate. The product was extracted with ethyl acetate (2 × 500 ml), the organic extracts were combined, washed with water (5 ml), dried over sodium sulfate and the solvent removed in vacuo to give the title compound in orange Obtained as a solid (16.08 g).
¹ H NMR (400MHz, CDCl ₃ ) δ = 7.39-7.32 (1H, d), 7.26 (1H, s), 7.1-7.13 (1H, t), 7.08-7.03 (1H, d), 6.17 (1H, bs ), 3.94 (2H, s), 3.02 (2H, s), 1.37 (6H, s).
CHN for C ₁₂ H ₁₅ BrClNO calculated. (Measured): C 47.32 (47.26), H 4.96 (4.87), N 4.60 (4.65).
LRMS (electrospray) m / z 306 [M + H] ⁺ .

(Production Example 18)
2- (3-Bromophenyl) -1,1-dimethylethylamine

N- [2- (3-Bromophenyl) -1,1-dimethylethyl] -2-chloroacetamide (Preparation Example 17) (32.0 g, 105 mmol), thiourea (9.60 g, 126 mmol), and acetic acid ( 50 ml) ethanol (250 ml)
The solution obtained by dissolving in was heated to reflux overnight. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure and basified using aqueous sodium hydroxide (1M, 450 ml). The product was extracted with dichloromethane (2 × 500 ml) and the combined organic extracts were washed with brine (50 ml), dried over sodium sulfate, the solvent was removed under reduced pressure and the title compound was recovered as a black oil (23 g ).
¹ H NMR (400MHz, CDCl ₃ ) d = 7.36-7.32 (2H, m), 7.16-7.08 (2H, m), 2.62 (2H, s), 1.84 (2H, bs), 1.12 (6H, s).
LRMS (electrospray) m / z 228 [M + H] ⁺ .

(Production Example 19)
2- (3-Bromophenyl) -1,1-dimethylethyl] carbamic acid tert-butyl ester

Treatment of 2- (3-bromophenyl) -1,1-dimethylethylamine (Preparation Example 18) (5.0 g, 22 mmol) with a solution of di-tert-butyl dicarbonate (5.26 g, 24 mmol) in dichloromethane (50 ml) And stirred for 20 hours. The reaction mixture was washed with water (50 ml), the organic extracts were combined and dried over sodium sulfate, and the solvent was removed under reduced pressure. The resulting crude material is purified using a cation exchange column (with methanol and then with 2M ammonia in methanol) and then by flash column chromatography on silica gel eluting with dichloromethane to give the title compound as a brown oil Obtained as a product (7.23 g).
¹ H NMR (400MHz, CDCl ₃ ) δ = 7.35 (1H, d), 7.30 (1H, s), 7.15-7.11 (1H, t), 7.05 (1H, d), 4.24 (1H, bs), 2.97 ( 2H, s), 1.50 (9H, s), 1.27 (6H, s).
LRMS (electrospray) m / z 350 [M + NH ₄ ] ⁺ .

(Production Example 20)
3- (2-tert-Butoxycarbonylamino-2-methylpropyl) benzoic acid methyl ester

2- (3-Bromophenyl) -1,1-dimethylethyl] carbamic acid tert-butyl ester (Production Example
19) (7.0 g, 21 mmol), [1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (1.74 g, 2.1 mmol), and triethylamine (5.94 ml, 43 mmol) in methanol (250 ml The resulting solution was heated at 100 ° C. for 12 hours under 100 psi carbon monoxide atmosphere. The reaction mixture is filtered through arbocel and the filtrate is concentrated under reduced pressure, dichloromethane:
Purification by flash chromatography on silica gel eluting with pentane (50:50, volume ratio) gave the title compound as a yellow solid (3.76 g).
¹ H NMR (400MHz, CDCl ₃ ) δ = 7.92-7.90 (1H, m), 7.82 (1H, s), 7.35-7.34 (2H, m), 4.24 (1H, bs), 3.90 (3H, s), 3.05 (2H, s), 1.48 (9H, s), 1.26 (6H, s).
LRMS (electrospray) m / z 208 [M + H-BOC] ⁺ .

(Production Example 21)
3- (2-Amino-2-methylpropyl) benzoic acid methyl ester

A solution obtained by dissolving 3- (2-tert-butoxycarbonylamino-2-methylpropyl) benzoic acid methyl ester (Production Example 20) (1.6 g, 5.2 mmol) in dichloromethane (160 ml) was heated to 0 ° C. Treated with trifluoroacetic acid (13.6 ml) and warmed to room temperature over 2 hours. The solvent was removed under reduced pressure and the product was purified by cation exchange chromatography (with methanol followed by 2M ammonia in methanol) to give the title compound as an amber oil (1.06 g).
¹ H NMR (400MHz, CDCl ₃ ) δ = 7.90-7.88 (1H, m), 7.84 (1H, s), 7.36-7.35 (2H, m), 3.90 (3H, s), 2.71 (2H, s), 1.67 (2H, bs), 1.12 (6H, s).
LRMS (electrospray) m / z 208 [M + H] ⁺ .

(Production Example 22)
Methyl {3-[(2R) -2-aminopropyl] phenyl} acetate

[3-((2R) -2-{[(1R) -1-Phenyl-ethyl] -amino} -propyl) -phenyl] -acetate hydrochloride (Preparation Example 23) (7.69 g, 22 mmol) and ammonium formate A solution with (6.94 g, 110 mmol) was heated to 75 ° C. in the presence of 20% palladium hydroxide on activated carbon (Pd (OH) ₂ / C, 2.00 g). After 90 minutes, the reaction mixture was cooled to room temperature, filtered through arbocel, and the filtrate was concentrated under reduced pressure. The residue was partitioned between dichloromethane (100ml) and 880 ammonia (100ml) and the organic phase separated.
The aqueous phase was extracted with dichloromethane (100 ml), the combined organic extracts were dried over magnesium sulfate and the solvent was evaporated off under reduced pressure to give the title compound as a colorless oil (4.78 g).
¹ H NMR (400MHz, CD ₃ OD): δ = 7.27-7.23 (1H, t), 7.13-7.09 (3H, m), 3.67 (3H, s), 3.63 (2H, s), 3.12-3.05 (1H , m), 2.67-2.57 (2H, m), 1.06 (3H, d) ppm.
LRMS (electrospray): m / z [M + H] ⁺ 208, [M + Na] ⁺ 230.

(Production Example 23)
Methyl [3-((2R) -2-{[(1R) -1-phenyl-ethyl] -amino} -propyl) -phenyl] -acete
Salt

Methyl [3- (2-oxopropyl) phenyl] acetate (Production Example 24) (8.50 g, 41.2 mmol), (R) -α-methylbenzylamine (4.8 ml, 37.2 mmol), sodium triacetoxyborohydride ( A solution obtained by dissolving 11.6 g, 56 mmol) and acetic acid (2.2 ml, 38 mmol) in dichloromethane (400 ml) was stirred at room temperature for 48 hours. The reaction mixture was quenched by adding saturated aqueous sodium bicarbonate and stirring was continued until bubbling ceased. The organic phase was separated and the aqueous phase was extracted with dichloromethane (100 ml). The organic extracts were combined and dried over magnesium sulfate, and the solvent was removed by evaporation under reduced pressure. Purify by flash column chromatography eluting with dichloromethane: methanol: ammonia (99: 1: 0.1 to 95: 5: 0.5, volume ratio) to obtain a 4: 1 mixture of diastereomers (R, R predominant) lightly. Obtained as a yellow oil (8.71 g). Treatment with hydrogen chloride (40 ml of a 1M solution in methanol, 40 mmol) followed by three successive recrystallizations (diisopropyl ether / methanol) gave the title compound as a white crystalline solid (5.68 g).
¹ H NMR (400MHz, CD ₃ OD): δ = 7.52-7.48 (5H, m), 7.28-7.25 (1H, m), 7.18-7.16 (1H,
m), 7.02-6.99 (2H, m), 4.59 (1H, q), 3.62 (2H, s), 3.30 (3H, s), 3.30-3.25 (1H,
m), 3.26-3.15 (1H, m), 2.66-2.60 (1H, m), 1.68 (3H, d), 1.18, (3H, d) ppm.
LRMS (electrospray): m / z [M + H] ⁺ 312, [M + Na] ⁺ 334.

(Production Example 24)
Methyl [3- (2-oxopropyl) phenyl] acetate

Tributyltin methoxide (28.3 ml, 98 mmol), compound of Production Example 25 (15.0 g, 65 mmol)
, Isopropenyl acetate (10.8 ml, 98 mmol), palladium (II) acetate (750 mg, 3.30 mmol)
A mixture obtained by mixing tri-ortho-tolylphosphine (2.0 g, 6.5 mmol) in toluene (75 ml) was stirred at 100 ° C. for 5 hours under a nitrogen atmosphere. After cooling, the reaction mixture was diluted with ethyl acetate (150 ml) and 4M aqueous potassium fluoride solution (90 ml) and stirred for 15 minutes. The mixture was filtered through arbocel, the organic phase was separated and the solvent was evaporated off under reduced pressure. The residue was purified by flash column chromatography eluting with a solvent gradient changing from diethyl ether: pentane (0: 100 to 25:75, volume ratio) to dichloromethane to give the title compound lightly. Obtained as a yellow oil (12.6 g).
¹ H NMR (400MHz, CDCl ₃ ): δ = 7.30 (1H, t), 7.19 (1H, d), 7.13-7.10 (2H, m), 3.69 (5H, s), 3.61 (2H, s), 2.15 (3H, s) ppm.
LRMS (electrospray): m / z [M + NH ₄ ] ⁺ 224, [M + Na] ⁺ 229.

(Production Example 25)
Methyl (3-bromophenyl) acetate

To a solution obtained by dissolving (3-bromo-phenyl) acetic acid (20.0 g, 93 mmol) in methanol (500 ml), acetyl chloride (0.7 ml, 9.3 mmol) was gradually added at 0 ° C. under a nitrogen atmosphere. In addition, the reaction mixture was gradually warmed to room temperature over 5 hours. The solvent was removed under reduced pressure and the residual oil was redissolved in dichloromethane, dried over magnesium sulfate and concentrated under reduced pressure to give the title compound as a colorless oil (20.6 g).
¹ H NMR (400MHz, CDCl ₃ ): δ = 7.37-7.45 (2H, m), 7.24-7.17 (2H, m), 3.70 (3H, s), 3.59 (2H, s) ppm.
LRMS (electrospray): m / z [M + Na] ⁺ 253.

(Production Example 26)
[3-((2R) -2-{[(1R) -1-phenyl-ethyl] -amino} -propyl) -phenyl] -acetic acid

To a solution obtained by dissolving the compound of Production Example 23 (13.5 g, 43.5 mmol) in methanol (2000 ml), 1M aqueous lithium hydroxide solution (90 ml, 90 mmol) was added at once at room temperature with stirring. The reaction mixture was stirred at room temperature for 24 hours and 1M aqueous hydrochloric acid (90 ml, 90 mmol) was added in one portion. The solvent was removed under reduced pressure to a volume of 80 ml, the white precipitate was removed by filtration, washed with water (20 ml) and 20% ethanol in water (100 ml) and dried to give the title compound as a white solid (11.8 g) Got as.
¹ H NMR (400MHz, CD ₃ OD) δ 1.16 (3H, d), 1.62 (3H, d), 2.64 (1H, m), 3.20 (2H, m), 3.46 (2H, s), 4.42 (1H, q), 6.91 (1H, d), 7.08 (1H, s), 7.19 (1H, s), 7.20 (1H, m), 7.48 (5H, m).
LRMS: m / z electrospray ^{298 [M + H +],} 296 [MH -].

(Production Example 27)
N-adamantan-1-yl-2- {3- [2- (1-phenyl-ethylamino) -propyl] -phenyl} -acetamide

To the suspension obtained by mixing the compound of Production Example 26 (297 mg, 1.00 mmol) in dichloromethane (4 ml), 1-adamantylamine (151 mg, 1.00 mmol) was added at room temperature with stirring, and the suspension Was stirred for 15 minutes. 2-Chloro-1,3-dimethylimidazolinium hexafluorophosphate (278 mg, 1.00 mmol) was added in one portion and the reaction mixture was stirred for 2 hours (reaction mixture became homogeneous). The reaction mixture was washed with water (5 ml), dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (98: 2: 0.2 then 95: 5: 0.5) to give the title compound as a pale yellow foam (325 mg). It was.
¹ H NMR (400MHz, CD ₃ OD) δ 0.89 (3H, d), 1.36 (3H, d), 1.75 (6H, m), 1.98 (6H, s), 2.04 (6H, s), 2.40 (1H, dd), 2.74 (1H, m), 3.00 (1H, dd), 3.36 (2H, s), 4.00 (1H, q), 6.90 (1H, d), 6.98 (1H, s), 7.08 (1H, d ), 7.19 (1H, t), 7.22 (1H, m), 7.38 (4H, m).
LRMS: m / z electrospray 431 [M + H ⁺ ].

(Production Example 28)
N-adamantan-1-yl-2- [3- (2-amino-propyl) -phenyl] -acetamide

A solution of the compound of Production Example 27 (17.6 g, 36 mmol) and ammonium formate (22.7 g, 360 mmol) in the presence of activated carbon-supported 20% palladium hydroxide (Pd (OH) _{2 /} C, 2.00 g) Heated to 70 ° C. After 60 minutes, additional catalyst (500 mg) was added and the reaction mixture was heated for an additional 4 hours. The reaction mixture was cooled to room temperature, filtered through arbocel, and the filtrate was concentrated under reduced pressure. The residue was partitioned between dichloromethane (300 ml) and 10% 880 ammonia (150 ml) in water, the organic phase was separated, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (95: 5: 0.5 then 90: 10: 1) to give the title compound as a white solid (10.8 g). .
¹ H NMR (400MHz, CD ₃ OD): δ 1.09 (3H, d), 1.68 (6H, m), 2.00 (6H, s), 2.03 (3H, s), 2.64 (2H, m), 3.14 (1H , q), 3.40 (2H, s), 7.14 (4H, m).
LRMS (electrospray): m / z [M + H] ⁺ 327.

(Production Example 29)
N-adamantan-1-yl-2- (3- {2- [2- (3,5-bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -propyl} -Phenyl) -acetamide

A solution obtained by dissolving the compound of Production Example 11 (263 mg, 0.50 mmol) and the compound of Production Example 28 (326 mg, 1.00 mmol) in dichloromethane (1 ml) was heated to 90 ° C., and the solvent was removed by evaporation. The resulting melt was heated at 90 ° C. for 1 day and then cooled to room temperature. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (98: 2: 0.2) to give the title compound as a clear oil (168 mg).
¹ H NMR (400MHz, CD ₃ OD) δ -0.09 (3H, s), -0.02 (3H, s), 0.82 (9H, s), 1.03 (3H, d), 1.66 (6H, s), 1.99 ( 6H, s), 2.02 (3H, s), 2.59 (1H, m), 2.65 (2H, m), 2.85 (2H, m), 3.37 (2H, s), 4.86 (1H, m), 5.06 (4H , m), 6.54 (3H, m), 7.00 (14H, m).
LRMS: m / z electrospray 773 [M + H ⁺ ].

(Production Example 30)
N-adamantan-1-yl-2- (3- {2- [2- (tert-butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -propyl} -phenyl) -Acetamide

A solution of the compound of Preparation Example 29 (160 mg, 0.21 mmol) and ammonium formate (150 mg, 2.10 mmol) was heated to 70 ° C. in the presence of activated carbon-supported 20% palladium hydroxide (Pd (OH) ₂ / C, 20 mg). Heated. After 3 hours, the reaction mixture was cooled to room temperature, filtered through arbocel, and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (10 ml) and 10% 880 ammonia in water (10 ml) and the organic phase was separated and dried. The aqueous phase was extracted with dichloromethane (2 × 50 ml) and the combined organic phases were dried over sodium sulfate and concentrated under reduced pressure to give the title compound as a yellow foam (160 mg).
¹ H NMR (400MHz, CD ₃ OD) δ -0.16 (3H, s), 0.01 (3H, s), 0.84 (9H, s), 1.03 (3H, d), 1.69 (6H, m), 2.01 (9H , m), 2.60 (3H, m), 2.91 (2H, m), 3.39 (2H, s), 4.60 (1H, m), 6.13 (1H, m), 6.20 (2H, m), 6.98 (1H, d), 7.05 (1H, s), 7.07 (1H, d), 7.18 (1H, t).
LRMS: m / z Electrospray 593 [M + H ⁺ ], 591 [MH] ^- .

(Production Example 31)
(3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -2-methyl-propyl} -phenyl) -methyl acetate ester

A solution of the compound of Preparation Example 11 (5.30 g, 10.0 mmol) and the compound of Preparation Example 5 (4.42 g, 20.0 mmol) was combined and heated to 92 ° C. under a nitrogen atmosphere. The resulting melt was heated at 92 ° C. for 24 hours and then cooled to room temperature. The residue was dissolved in dichloromethane: methanol: 880 ammonia (98: 2: 0.2).
Purification by column chromatography on silica gel eluting with gave the title compound as a golden oil (5.38 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.20 (3H, s), -0.03 (3H, s), 0.79 (9H, s), 1.01-1.03 (6H, d), 2.58-2.82 (4H, m ), 3.59 (2H, s), 3.63 (3H, s), 4.62-4.66 (1H, m), 4.84
(4H, s), 6.76 (3H, s), 7.15-7.65 (14H, m).
LRMS: m / z electrospray 668 [M + H ⁺ ].

(Production Example 32)
(3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -2-methyl-propyl} -phenyl) -acetic acid

A solution obtained by dissolving the compound of Production Example 31 (5.30 g, 7.95 mmol) in tetrahydrofuran (150 ml) was stirred at room temperature under a nitrogen atmosphere at room temperature with 1M lithium hydroxide aqueous solution (8.80 ml, 8.80 mmol). ) Was added at once. The reaction mixture was stirred at room temperature for 24 hours and 1M aqueous hydrochloric acid (8.80 ml, 8.80 mmol) was added in one portion. Most of the solvent was removed under reduced pressure, and the resulting mixture was partitioned between dichloromethane (200 ml) and water (200 ml). The organic layer was washed with brine (50 ml), dried over sodium sulfate and the solvent removed under reduced pressure to give the title compound as a colorless foam (5.16 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.17 (3H, s), 0.02 (3H, s), 0.82 (9H, s), 1.26 (6H, s), 2.84-2.96 (2H, q), 3.18 -3.19 (2H, d), 3.53 (2H, s), 4.87-4.92 (1H, t), 5.10 (4H, s), 6.60-6.63 (3H, m), 7.03-7.43 (14H, m)
LRMS: m / z electrospray 654 [M + H ⁺ ].

(Production Example 33)
(3- {2- [2- (tert-butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl)-
Ethylamino] -2-methyl-propyl} -phenyl) -acetic acid

To a solution obtained by dissolving the compound of Production Example 32 (5.10 g, 7.81 mmol) and ammonium formate (5.00 g, 74.6 mmol) in ethanol (250 ml), palladium hydroxide (500 mg) was added once at room temperature with stirring. Added to. The reaction mixture was heated at 70 ° C. for 3 hours. Additional palladium hydroxide (250 mg) was added and the reaction mixture was heated at 70 ° C. for an additional 1.5 hours and cooled to room temperature overnight under a nitrogen atmosphere. The reaction mixture was filtered through arbocel and the filtrate was concentrated under reduced pressure. The residue was triturated with water (50 ml) and filtered to give the title compound as a white solid (3.61 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.07 (3H, s), 0.03 (3H, s), 0.83 (9H, s), 1.34 (6H, s), 2.90-2.97 (2H, q), 3.18 -3.19 (2H, s), 3.50-3.58 (2H, q), 4.85-4.95 (1H, m), 6.12 (1H, s), 6.35 (2H, s), 7.03-7.35 (4H, m).
LRMS: m / z electrospray 474 [M + H ⁺ ].

(Production Example 34)
2- (3- {2- [2- (tert-butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -2-methyl-propyl} -phenyl) -N- ( 3,4-Dichloro-benzyl) -acetamide

To a solution obtained by dissolving the compound of Preparation Example 33 (142 mg, 0.300 mmol) in N, N-dimethylformamide (2 ml), while stirring, 3,4-dichlorobenzylamine (53 mg, 0.301 mmol), hydroxy Benzotriazole (39 mg, 0.289 mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (57 mg, 0.297 mmol) were added at room temperature under a nitrogen atmosphere.
The reaction mixture was stirred for 18 hours, the solvent was removed under reduced pressure, and the residue was partitioned between dichloromethane (50 ml) and saturated aqueous sodium bicarbonate (50 ml). The organic layer was dried over sodium sulfate, the solvent was removed under reduced pressure, and the residue was dichloromethane: methanol: 880 ammonia (95: 5: 0.5)
Purification by column chromatography on silica gel eluting with gave the title compound as a creamy foam (125 mg).
¹ H NMR (400MHz, CD ₃ OD) δ -0.16 (3H, s), 0.00 (3H, s), 0.82 (9H, s), 1.01-1.03 (6H, d), 2.60-2.86 (4H, m) , 3.52 (2H, s), 4.31 (2H, s), 4.78-4.81 (1H, m), 6.18 (1H, s), 6.29 (2H, s), 7.02-7.24 (5H, m), 7.36-7.42 (2H, m).
LRMS: m / z electrospray 631 [M + H ⁺ ].

(Production Example 35)
(3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -propyl} -phenyl) -acetic acid methyl ester

A solution obtained by dissolving the compound of Preparation Example 11 (5.00 g, 9.45 mmol) and the compound of Preparation Example 22 (3.92 g, 18.9 mmol) in dichloromethane (50 ml) was heated to 95 ° C., and the solvent was removed by evaporation. . The resulting melt was heated at 95 ° C. for 24 hours and then cooled to room temperature. Diethyl ether (50 ml) was added and the mixture was stirred for 5 minutes. The ether layer was separated from the gum and the gum was extracted twice more with diethyl ether (2 × 50 ml). The ether extracts were combined and the solvent was removed under reduced pressure. The residue
Purification by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (100: 0: 0 to 95: 5: 0.5) gave the title compound as a pale yellow gum (4.50 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.20 (3H, s), -0.05 (3H, s), 0.81 (9H, s), 1.01-1.03 (3H, d), 2.60 (3H, m), 2.86 (2H, m), 3.55 (2H, s), 3.63 (3H, s), 4.66 (1H, m), 4.85 (4H, m), 6.70 (3H, m), 6.73 (1H, m), 6.98 (2H, m), 7.06 (1H, m), 7.17 (1H, m), 7.10 (2H, m), 7.11-7.22 (7H, m).
LRMS: m / z electrospray 654 [M + H ⁺ ].

(Production Example 36)
3- {2- [2- (tert-butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -2-methyl-propyl} -N- [2- (3-fluoro -Phenyl) -ethyl] -benzamide

A solution obtained by dissolving the compound of Production Example 14 (151 mg, 0.330 mmol) in N, N-dimethylformamide (1 ml) was added to 2-fluorophenylethylamine (95 mg, 0.680 mmol), hydroxybenzotriazole (100 mg, 0.740 mmol). Mmol), triethylamine (0.10 ml, 0.720 mmol), and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (79 mg, 0.410 mmol)
Was added at room temperature under a nitrogen atmosphere with stirring. The reaction mixture is stirred for 18 hours, the solvent is removed under reduced pressure, and the residue is purified on silica gel eluting with dichloromethane: methanol: 880 ammonia (100: 0: 0 to 95: 5: 0.5 to 90: 10: 1). Was purified by column chromatography to give the title compound as a creamy foam (132 mg).
¹ H NMR (400MHz, CD ₃ OD) δ -0.16 (3H, s), -0.02 (3H, s), 0.78 (9H, s), 1.12 (6H, d), 2.65-2.95 (6H, m), 3.61 (2H, s), 4.64 (1H, s), 6.18 (1H, s), 6.29 (2H, s), 6.93 (1H, m), 7.02 (1H, m), 7.06 (1H, m), 7.20 -7.39 (3H, m), 7.64 (2H, m).
LRMS: m / z electrospray 581 [M + H ⁺ ].

  Preparative Examples 37-43 were prepared from the compound of Preparative Example 14 and the appropriate amine using the method disclosed for Preparative Example 36.

(Production Example 44)
(3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -propyl} -phenyl) -acetic acid

To a solution obtained by dissolving the compound of Production Example 35 (4.75 g, 7.26 mmol) in tetrahydrofuran (20 ml), 1M aqueous lithium hydroxide solution (16.0 ml, 16.0 mmol) was added at room temperature with stirring. The reaction mixture was stirred at room temperature for 24 hours and 1M aqueous hydrochloric acid was added until the pH was 1-2. Extract with dichloromethane (1 x 200 ml, then 2 x 50 ml) and combine the organic layers with brine (20 ml)
And dried over magnesium sulfate and the solvent removed under reduced pressure to give the hydrochloride salt of the title compound as an off-white foam (4.80 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.12 (3H, s), 0.06 (3H, s), 0.86 (9H, s), 1.23 (3H, d), 2.77 (1H, m), 3.03 (1H , m), 3.23 (1H, m), 3.45-3.60 (3H, m), 5.01 (1H, m), 5.10 (4H, s), 6.64 (2H, m), 6.68 (1H, m), 7.10 ( 1H, m), 7.15 (1H, s), 7.23 (1H, m), 7.27-7.43 (11H, m).
LRMS: m / z APCI 640 [M + H ⁺ ].

(Production Example 45)
(3- {2- [2- (tert-butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl)-
Ethylamino] -propyl} -phenyl) -acetic acid

To a solution obtained by dissolving the compound of Preparation Example 44 (3.50 g, 5.48 mmol) and ammonium formate (1.80 g, 39.1 mmol) in ethanol (250 ml), palladium hydroxide (350 mg) was added once at room temperature. Added to. The reaction mixture was heated to reflux for 45 minutes and cooled to room temperature. The reaction mixture was filtered through arbocel and the filtrate was concentrated under reduced pressure to give the title compound as a pale yellow solid (2.30 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.06 (3H, s), 0.06 (3H, s), 0.86 (9H, s), 1.25 (3H, d), 2.81 (1H, m), 2.96 (1H , m), 3.15 (1H, m), 3.25 (1H, m), 3.43-3.55 (3H, m), 4.89 (1H, m), 6.24 (1H, m), 6.33 (2H, m), 7.06 ( 1H, m), 7.17 (1H, s), 7.19-7.28 (2H, m).
LRMS: m / z APCI 460 [M + H ⁺ ].

  Preparation Examples 46-48, 55-65, and 73-76 were prepared from the compound of Preparation Example 33 and the appropriate amine using the method described in Preparation Example 34. These compounds have the general formula

And are listed in the table below.
Preparation Examples 49-54, 66-72, and 77-87 were prepared from the compound of Preparation Example 45 and the appropriate amine using the method described in Preparation Example 34. These compounds have the general formula

And are listed in the table below.

(Production Example 188)
Methyl {3-[(2R) -2-aminopropyl] phenyl} acetate

Methyl [3-((2R) -2-{[(1R) -1-phenyl-ethyl] -amino} -propyl) -phenyl] -acetate (Preparation Example 89) (13.65 g, 40.9 mmol) and ammonium formate ( A solution obtained by dissolving 12.9 g (204 mmol) in ethanol (200 ml) was heated to reflux in the presence of activated carbon-supported 20% palladium hydroxide (Pd (OH) _{2 /} C), 1.36 g). After 3 hours, the reaction mixture was cooled to room temperature, filtered through arbocel, and the filtrate was concentrated under reduced pressure. The residue was partitioned between dichloromethane (200ml) and 880 ammonia (100ml) and the organic phase separated. The aqueous phase was further extracted with dichloromethane (3 × 100 ml) and the combined organic extracts were washed with brine (100 ml), dried over sodium sulfate and concentrated in vacuo to give the title compound (8.48 g) as a pale yellow Obtained as an oil.
¹ H NMR (400MHz, CDCl ₃ ): δ = 7.90-7.87 (2H, m), 7.38-7.34 (2H, m), 3.90 (3H, s), 3.26-3.17 (1H, m), 2.78-2.73 ( 1H, dd), 2.64-2.59 (1H, dd), 1.14-1.12 (3H, d) ppm.
LRMS (electrospray): m / z [M + H] ⁺ 194.

(Production Example 89)
Methyl [3-((2R) -2-{[(1R) -1-phenyl-ethyl] -amino} -propyl) -phenyl] -acete
Salt

Methyl [3- (2-oxopropyl) phenyl] acetate (Preparation Example 90) (45.3 g, 236 mmol), (R) -α-methylbenzylamine (27.6 ml, 214 mmol), sodium triacetoxyborohydride ( A solution obtained by dissolving 68.1 g, 321 mmol) and acetic acid (14.7 ml, 257 mmol) in dichloromethane (1500 ml) was stirred at room temperature for 18 hours. The reaction mixture was quenched by adding saturated aqueous sodium bicarbonate (600 ml) and stirring was continued until bubbling ceased. The organic phase was separated and the aqueous phase was further extracted with dichloromethane (2 × 100 ml). The combined organic extracts were washed with brine (100 ml), dried over sodium sulfate, filtered through celite and concentrated under reduced pressure. The resulting oil was dissolved in methanol (200 ml), treated with 1M hydrogen chloride in methanol (300 ml) and concentrated under reduced pressure to give a 4: 1 mixture of diastereomers (mainly R, R). Obtained as an off-white hydrochloride salt. Recrystallization (diisopropyl ether / methanol) was performed twice to obtain the title compound (27.3 g) as a colorless crystalline solid.
¹ H NMR (400MHz, CD ₃ OD): δ = 7.92-7.90 (1H, d), 7.75 (1H, s), 7.55-7.49 (5H, m),
7.45-7.42 (1H, dd), 7.35-7.33 (1H, d), 4.68-4.63 (1H, q), 3.90 (3H, s), 3.43-3.38 (1H, dd), 3.25-3.19 (1H, m ), 2.71-2.65 (1H, dd), 1.71-1.69 (3H, d), 1.17-1.16, (3H, d) ppm.

(Production Example 90)
Methyl [3- (2-oxopropyl) phenyl] acetate

Tributyltin methoxide (80.3 ml, 279 mmol), methyl 3-bromobenzoate (53.5 g, 249 mmol), isopropenyl acetate (39.4 ml, 358 mmol), palladium (II) acetate (2.6 g, 11.6 mmol), and A mixture obtained by mixing tri-o-tolylphosphine (7.1 g, 23.2 mmol) in toluene (350 ml) was stirred at 100 ° C. for 18 hours under a nitrogen atmosphere. After cooling, the reaction mixture is 4M
Was treated with an aqueous potassium fluoride solution (560 ml) and stirred for 2 hours. The resulting mixture was diluted with additional toluene (200 ml), filtered through celite, and the filter pad was washed with ethyl acetate. The organic phase was separated, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with ethyl acetate: pentane (10:90 to 20:80, volume ratio) to give the title compound (45.3 g) as an orange Obtained as an oil.
¹ H NMR (400MHz, CDCl ₃ ): δ = 7.95-7.93 (1H, d), 7.87 (1H, s), 7.43-7.37 (2H, m),
3.91 (3H, s), 3.75 (2H, s), 2.18 (3H, s) ppm.
LRMS (electrospray): m / z [M + Na] + 215, [MH] - 191.

(Production Example 91)
3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy
Xyl) -ethylamino] -propyl} -benzoic acid methyl ester

The compound of Production Example 11 (7.10 g, 13.5 mmol) was added to a solution obtained by dissolving the compound of Production Example 88 (5.23 g, 27.0 mmol) in dichloromethane (50 ml), and the solvent was removed under reduced pressure. The reaction mixture was heated at 95 ° C. for 12 hours and cooled to room temperature. Diethyl ether (150 ml) was added, the reaction mixture was stirred for 1 hour, the resulting white precipitate was removed by filtration, and the solvent was removed by evaporation from the filtrate to give a yellow oil. The residue was diluted with dichloromethane: methanol: 880 ammonia (100: 0: 0
Purification by column chromatography on silica gel eluting with 95: 5: 0.5) gave the title compound (4.30 g) as a yellow oil.
¹ H NMR (400MHz, CD ₃ OD) δ -0.23 (3H, s), -0.06 (3H, s), 0.78 (9H, s), 1.06 (3H, d), 2.57 (1H, m), 2.66 ( 2H, m), 2.88 (2H, m), 3.83 (3H, s), 4.64 (1H, m), 4.85 (4H, s), 6.46 (2H, s), 6.49 (1H, m), 7.32 (12H , m), 7.78 (1H, s), 7.82 (1H, m).
LRMS: m / z APCI 640 [M + H ⁺ ].

(Production Example 92)
3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy
Xyl) -ethylamino] -propyl} -benzoic acid hydrochloride

A solution obtained by dissolving the compound of Production Example 91 (5.35 g, 8.37 mmol) in tetrahydrofuran (20 ml) was stirred, and 1M aqueous lithium hydroxide solution (18.4 ml, 18.4 mmol) was added in one portion. The reaction mixture was stirred for 12 hours and then heated at 40 ° C. for 12 hours. Additional 1M aqueous lithium hydroxide (36.8 ml, 36.8 mmol) and tetrahydrofuran (100 ml) were added in one portion, the reaction mixture was heated at 40 ° C. for 12 hours, the reaction mixture was cooled, and additional 1M aqueous lithium hydroxide (36.8 ml, 36.8 mmol) was added. The reaction mixture was heated at 60 ° C. for 5 hours, cooled to room temperature, tetrahydrofuran was removed under reduced pressure, and dioxane (50 ml) was added. The reaction mixture was heated at 60 ° C. for 1 hour, cooled to room temperature, and the solvent was removed under reduced pressure. The pH of the residue was adjusted to pH 1 with 1M aqueous hydrochloric acid, extracted with dichloromethane: methanol (97: 3; v / v; 3 × 150 ml), the combined organic extracts were washed with brine (30 ml), Dry over magnesium sulfate and remove the solvent under reduced pressure to give the title compound (5.00 g)
Was obtained as a yellow foam.
¹ H NMR (400MHz, CD ₃ OD) δ -0.13 (3H, s), 0.07 (3H, s), 0.86 (9H, s), 1.24 (3H, d), 2.83 (1H, m), 3.19 (1H , m), 3.30 (2H, m), 3.59 (1H, m), 5.05 (1H, m), 5.11 (4H, s), 6.64 (3H, m), 7.30 (10H, m), 7.47 (2H, m), 7.92 (1H, s), 7.97 (1H, m).
LRMS: m / z APCI 626 [M + H ⁺ ].

(Production Example 93)
3- {2- [2- (tert-Butyl-dimethyl-silanyloxy) -2- (3,5-dihydroxy-phenyl) -ethylamino] -propyl} -benzoic acid

The compound of Preparation 92 (4.97 g, 7.95 mmol) was dissolved in ethanol (300 ml), and ammonium formate (2.75 g, 60 mmol) and palladium hydroxide (500 mg) were added in one portion. The reaction mixture was heated to reflux for 1 hour then cooled to room temperature, filtered through arbocel and washed using methanol (500 ml). The filtrate was concentrated under reduced pressure to give the title compound as a white solid (3.60 g).
¹ H NMR (400MHz, CD ₃ OD) δ -0.06 (3H, s), 0.05 (3H, s), 0.86 (9H, s), 1.23 (3H, d), 2.83 (1H, m), 3.12 (2H , m), 3.25 (1H, m), 3.51 (1H, m), 4.90 (1H, m), 6.24 (1H, m), 6.35 (2H, s), 7.27 (2H, m), 7.83 (1H, m), 7.88 (1H, m).
LRMS: m / z APCI 446 [M + H ⁺ ].

  The compounds of Preparation Examples 100-104 and 115-124 were prepared from the compound of Preparation Example 33 and the appropriate amine using the method described in Preparation Example 34. These compounds have the general formula

And listed in the table below.
The compounds of Preparation Examples 96-99 were prepared from the compound of Preparation Example 45 and the appropriate amine using the method described in Preparation Example 34. These compounds have the general formula

And listed in the table below.
The compounds of Preparation Examples 94, 95, and 105-114 were prepared from the compound of Preparation Example 93 and the appropriate amine using the method described in Preparation Example 34. These compounds have the general formula

And listed in the table below.

(Production Example 125)
2- (4-Methoxy-2,3-dimethyl-phenyl) -ethylamine

A mixture of (4-methoxy-2,3-dimethyl-phenyl) -acetonitrile (200 mg, 1.14 mmol) and Raney® nickel (50 mg) in 2M methanolic ammonia (10 ml) was added to 60 psi of hydrogen. Stir at room temperature for 18 hours at gas pressure. TLC analysis showed that not all starting material was consumed, so additional Raney® nickel (50 mg) in 2M methanolic ammonia (10 ml) was added. The reaction mixture was stirred for an additional 18 hours at room temperature under 60 psi hydrogen gas pressure and filtered through arbocel. Concentrate the filtrate in vacuo and purify the residue by column chromatography on silica gel eluting with dichloromethane: methanol: 0.88 ammonia (100: 0: 0 to 90: 10: 1) to give the title compound as a light brown color. Solid (233mg
).
¹ H NMR (400MHz, CDCl ₃ ) δ: 6.96 (1H, d), 6.66 (1H, d), 3.80 (3H, s), 2.96-2.84 (2H, m), 2.81-2.73 (2H, m), 2.22 (3H, s), 2.17 (3H, s), 1.63 (2H, s) ppm LRMS APCI m / z 180 [M + H] ⁺ .

(Production Example 126)
2- (2,3-Dimethyl-phenyl) -ethylamine

2,3-Dimethylphenylacetonitrile (J. Org Chem, 51 (26), 5157-60; 1986) (190 mg, 1.31
Mmol) and Raney nickel (100 mg) in 2M methanolic ammonia (5 ml) were stirred at 50 psi hydrogen gas pressure for 4 days. The reaction mixture was filtered through arbocel and concentrated in vacuo to give the title compound as a solid (130 mg).
¹ H NMR (400 MHz, CDCl ₃ ) δ: 7.02-6.94 (3H, m), 2.26-2.13 (10H, m) ppm LRMS ESI m / z 150 [M + H] ⁺ .

(Production Example 127)
2- (2-Chloro-4-fluoro-phenyl) -ethylamine

To a solution of 2-chloro-4-fluorophenylacetonitrile (1.04 g, 6.15 mmol) and cobalt (II) chloride hexahydrate (2.18 g, 9.22 mmol) dissolved in methanol, sodium borohydride (1.73 g, 45.51 mmol) was added in small portions and the reaction mixture was stirred at room temperature for 3 hours. The resulting suspension was filtered through Celite®, concentrated in vacuo, and the residue was partitioned between 1M hydrochloric acid (40 ml) and dichloromethane (40 ml). The aqueous phase was separated, basified to pH 11 with 1M aqueous ammonia and extracted with dichloromethane (2 × 40 ml). The combined organic solutions were washed with brine (30 ml), dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 0.88 ammonia (100: 0: 0 to 98: 2: 0.2) to give the title compound as a yellow oil (350 mg).
¹ H NMR (400MHz, CDCl ₃ ) δ: 7.30 (1H, dd), 7.17 (1H, dd), 6.99 (1H, m), 2.86 (4H,
m) ppm
LRMS APCI m / z 174 [M + H] ⁺ .

(Production Example 128)
2- (5-Chloro-2-methoxy-phenyl) -ethylamine

Chlorotrimethylsilane (2 ml, 16 mmol) was added dropwise to lithium borohydride (2M in tetrahydrofuran, 4 ml, 8 mmol). 2-Methoxy-5-chlorophenylacetonitrile (312mg, 4
A solution obtained by dissolving (mmol) in tetrahydrofuran (2 ml) was added at 0 ° C., and the mixture was stirred for 24 hours while warming to room temperature. Dilute with methanol (20 ml) and concentrate under reduced pressure. The residue was dissolved in 20% potassium hydroxide solution (20 ml), extracted with dichloromethane (3 × 20 ml), the combined organic solutions were dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on an Isolute® SCX-2 cartridge eluting with methanol and then 1M ammonium in methanol to give an oily residue. This oil was triturated with diethyl ether to give the title compound (485 mg).
¹ H NMR (400MHz, CDCl ₃ ) δ: 7.11-7.00 (2H, m), 6.75-6.65 (1H, m) 3.72 (3H, s), 2.90-2.80 (2H, m), 2.70-2.60 (2H, m) ppm.

(Production Example 129)
2- (5-Chloro-2-hydroxy-phenyl) -ethylamine

The amine of Production Example 128 (66 mg, 0.36 mmol) was dissolved in 48% aqueous HBr and heated at 80 ° C. for 12 hours with stirring. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure to give a brown gum. This was dissolved in methanol (5 ml) and purified by ion exchange column to give the title compound as a brown gum (26 mg).
¹ H NMR (400MHz, CDCl ₃ ) δ: 2.70 (2H, t), 2.90 (2H, t), 6.70 (1H, d), 6.98 (1H, m), 7.02 (1H, s) ppm
LRMS APCI m / z 172 [M + H] ⁺ .

(Production Example 130)
2- (5-Fluoro-2-methyl-phenyl) -ethylamine

This compound was prepared using the method described in Preparation 128 and the appropriate nitrile.
¹ H NMR (400MHz, CDCl ₃ ) δ: 7.07 (1H, m), 6.83 (2H, m), 2.97 (2H, t), 2.78 (2H, m) 2.27 (3H, s) ppm
LRMS APCI m / z 154 [M + H] ⁺ .

(Production Example 131)
tert-Butyl (3-iodobenzyl) carbamate

A suspension obtained by mixing 3-iodobenzylamine hydrochloride (4.95 g, 18.4 mmol) in dichloromethane (100 ml) was mixed with triethylamine (3.1 ml, 22 mmol) and di-t-butyl dicarbonate (4.40 g, The resulting solution was stirred at room temperature for 1.5 hours under a nitrogen atmosphere. The reaction mixture was washed with 2M hydrochloric acid (30 ml) and water (30 ml), dried over sodium sulfate, and the solvent was removed under reduced pressure to give the title compound as a colorless solid (6.43 g).
¹ HNMR (400MHz, CDCl ₃ ) δ: 1.46 (s, 9H), 4.21-4.30 (m, 2H), 4.79-4.89 (bs, 1H), 7.06 (dd, 1H), 7.25 (d, 1H), 7.60 (d, 1H), 7.63 (s, 1H) ppm.
MS (electrospray) m / z 332 [MH] ^- , 356 [M + Na] ⁺ .

(Production Example 132)
tert-Butyl [(4'-hydroxybiphenyl-3-yl) methyl] carbamate

Preparation 131 iodide (0.75 g, 2.25 mmol), 4-hydroxyphenylboronic acid (0.62 g, 4.50 mmol), and 1,1′-bis (diphenylphosphino) ferrocenyl palladium (II) chloride (0.11) g, 0.14 mmol) in N, N-dimethylformamide (14 ml) was treated with 2M aqueous sodium carbonate solution (4 ml) and the resulting mixture was treated at 80 ° C. under nitrogen atmosphere at 16O 0 C. Heated for hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel eluting with ethyl acetate: pentane (1: 3) to give the title compound as a pale pink crystalline solid (0.73 g). Obtained.
¹ HNMR (400MHz, CDCl ₃ ) δ: 1.47 (s, 9H), 4.33-4.41 (m), 4.87-4.94 (bs, 1H), 6.89
(d, 2H), 7.21 (d, 1H), 7.37 (dd, 1H), 7.43-7.45 (m, 4H) ppm.
MS (electrospray) m / z 298 [MH] ^- , 322 [M + Na] ⁺ .

(Production Example 133)
3 '-(Aminomethyl) biphenyl-4-ol hydrochloride

The phenol from Preparation Example 132 (0.73 g, 2.43 mmol) was treated with 4M HCl in dioxane (6 ml, 24.3 mmol) and the resulting solution was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure to give the title compound as a colorless solid.
¹ HNMR (400MHz, CD ₃ OD) δ: 4.17 (s, 2H), 6.87 (d, 2H), 7.34 (d, 1H), 7.45-7.50 (m, 3H), 7.61 (d, 1H), 7.65 ( s, 1H) ppm.
MS (electrospray) m / z 198 [MH] ^- , 200 [M + H] ⁺ .

(Production Example 134)
2- (3-Chloro-2-hydroxy-phenyl) -ethylamine

  This compound was prepared according to the procedure described in DE1959898.

(Production Example 135)
Methyl-3-[(2R) -2-aminopropyl) phenyl] propanoate

Methyl- [3-((2R) -2-{[(1R) -1-phenylethyl] amino} propyl) phenyl] propionate hydrochloride (Preparation Example 136) was used to follow the procedure used in Preparation Example 22. Thus prepared to give the title compound as a brown oil.
¹ H NMR (400MHz, CD ₃ OD): δ = 7.21-7.17 (1H, t), 7.03-7.01 (3H, m), 3.61 (3H, s), 3.11-3.03 (1H, m), 2.91-2.87 (2H, t), 2.64-2.54 (4H, m), 1.07-1.05 (3H, d) ppm.
LRMS (electrospray): m / z [M + H] ⁺ 222.

(Production Example 136)
Methyl- [3-((2R) -2-{[(1R) -1-phenylethyl] amino} propyl) phenyl] propione
Salt

Prepared following the procedure used in Preparation 23 using methyl-3- [3- (2-oxopropyl) phenyl] propinate (Preparation Example 137) to give the title compound as a white crystalline solid.
¹ H NMR (400MHz, CD ₃ OD): δ = 7.54-7.47 (5H, m), 7.23-7.19 (1H, t), 7.12-7.10 (1H,
d), 6.92-6.91 (2H, d), 4.64-4.59 (1H, q), 3.61 (3H, s), 3.34-3.29 (1H, m), 3.20-3.12 (1H, m), 2.89-2.85 ( 2H, t), 2.62-2.56 (3H, m), 1.71-1.69 (3H, d), 1.18-1.16 (3H, d) ppm.
LRMS (electrospray): m / z [M + H] ⁺ 326.

(Production Example 137)
Methyl-3- [3- (2-oxopropyl) phenyl] propanoate

Suspension obtained by mixing methyl (2E) -3- [3- (2-oxopropyl) phenyl] acrylate (5.00 g, Preparation 138) and 10% palladium on carbon (500 mg) in ethanol (50 ml) The solution was stirred for 16 hours at room temperature under hydrogen atmosphere (60 psi). The catalyst was filtered off through arbocel, and the filtrate was concentrated under reduced pressure to give the title compound as a pale yellow oil. This oil was used without further purification.
¹ H NMR (400MHz, CD ₃ OD): δ = 7.27-7.23 (1H, q), 7.11-7.09 (1H, d), 7.05-7.04 (2H, d), 3.66 (5H, s), 2.96-2.92 (2H, t), 2.64-2.60 (2H, t), 2.14 (3H, s) ppm.
LRMS (electrospray): m / z [M + Na] + 243, [MH] - 219.

(Production Example 138)
Methyl (2E) -3- [3- (2-oxopropyl) phenyl] acrylate

3-bromophenylacetone (50.0 g, 235 mmol), methyl acrylate (40.4 g, 469 mmol), palladium (II) acetate (7.9 g, 35.2 mmol), tri-ortho-tolylphosphine (21.4 g, 70.4 mmol) A solution obtained by dissolving triethylamine (82 ml) in acetonitrile (900 ml) was heated to reflux for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The residue is pentane: ethyl acetate (change 90:10 to 70:30 by volume)
Purification by flash column chromatography eluting with gave the title compound as an orange oil (54.3 g).
¹ H NMR (400MHz, CD ₃ OD): δ = 7.66-7.62 (1H, d), 7.41-7.39 (1H, d), 7.34-7.31 (2H, t), 7.20-7.18 (1H, d), 6.43 -6.39 (1H, d), 3.77 (3H, s), 3.70 (2H, s), 2.15 (3H, s) ppm.
LRMS (electrospray): m / z [M + Na] + 241, [MH] - 217.

(Production Example 139)
3- (3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -propyl} -phenyl) -propionic acid methyl ester

The bromide of Preparation Example 11 (3.46 g, 6.56 mmol) and the amine of Preparation Example 135 (2.90 g, 13.1 mmol) were mixed in dichloromethane (50 ml), and the solvent was removed under reduced pressure. The resulting oil was heated at 90 ° C. for 12 hours, cooled to room temperature, the orange oil was stirred in ether (200 ml) for 5 minutes and the ether layer was carefully decanted. The remaining orange oil was stirred twice more with ether (2 × 200 ml), the ether layers combined and the solvent removed under reduced pressure. The resulting orange oil was purified by flash column chromatography eluting with dichloromethane: methanol: ammonia (100: 0: 0 then 96: 4: 0.4) to give the title compound as a golden oil (3.40 g ).
¹ H NMR (400MHz, CD ₃ OD) δ: -0.20 (3H, s), -0.05 (3H, s), 0.82 (9H, s), 1.03 (3H,
d), 2.52-2.65 (5H, m), 2.79-2.94 (4H, m), 3.60 (3H, s), 4.66 (1H, m), 5.04 (4H,
m), 6.49 (2H, s), 6.53 (1H, m), 6.89-6.96 (2H, m), 6.99 (1H, m), 7.15 (1H, m), 7.23-7.44 (10H, m); LRMS APCI m / z 668 [M + H] ⁺

(Production Example 140)
3- (3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -propyl} -phenyl) -propionate hydrochloride

A solution obtained by dissolving the ester of Production Example 139 (3.40 g, 5.10 mmol) in tetrahydrofuran (15 ml) was treated with lithium hydroxide (1M, 11.2 ml, 11.21 mmol). Dioxane (50 ml) and water (10 ml) were added and the resulting solution was stirred for 20 hours. Acidify the solution with hydrochloric acid (1N) to pH 1,
Extracted with dichloromethane (3 × 150 ml). The organic extract was washed with brine (50 ml) and dried over magnesium sulfate. Filtration and evaporation of the solvent gave a white foam (3.5 g, 91% yield).
¹ H NMR (400MHz, CD ₃ OD) δ: -0.13 (3H, s), 0.06 (3H, s), 0.86 (9H, s), 1.03 (3H, d), 2.58 (2H, t), 2.75 ( 1H, m), 2.88 (2H, t), 3.06 (1H, m), 3.23 (1H, m), 3.34 (1H, m), 3.55 (1H, m), 5.04-5.16 (5H, m), 6.66 (3H, m), 7.06 (1H, m), 7.12 (1H, s), 7.18 (1H, m), 7.23-7.47 (11H, m); LRMS APCI m / z 655 [M + H] ⁺

(Production Example 141)
3- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tylamino] propyl} phenyl) -propionic acid

3- (3- {2- [2- (3,5-Bis-benzyloxy-phenyl) -2- (tert-butyl-dimethyl-silanyloxy) -ethylamino] -propyl} -phenyl) -propionate hydrochloride Prepared according to the procedure used in Preparation Example 13 using (Preparation Example 140) to give the title compound as a yellow solid.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.06 (3H, s), 0.08 (3H, s), 0.86 (9H, s), 1.22 (3H, d), 2.54 (2H, t), 2.74 ( 1H, m), 2.90 (2H, t), 3.15 (1H, m), 3.26 (1H, m), 3.45 (1H, m), 4.90 (1H, m), 6.26 (1H, m), 6.35 (2H , s), 7.02 (1H, m), 7.08 (1H, s), 7.16 (1H, m), 7.24 (1H, m); LRMS APCI m / z 474 [M + H] ⁺

(Production Example 142)
3- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tylamino] propyl} phenyl) -N- (2-chlorobenzyl) propionamide

Prepared according to the procedure used in Preparation 34, using the compound of Preparation 141, 2-chlorobenzylamine and N, N-dimethylacetamide instead of N, N-dimethylformamide.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.15 (3H, s), 0.01 (3H, s), 0.84 (9H, s), 1.03 (3H, d), 2.47-2.58 (3H, m), 2.60-2.70 (2H, m), 2.80-2.95 (4H, m), 4.41 (2H, m), 4.59 (1H, m), 6.16 (1H, m), 6.24 (2H, s), 6.95 (2H, m), 7.02-7.08 (2H, m), 7.13-7.25 (3H, m), 7.36 (1H, m); LRMS APCI m / z 598 [M + H] ⁺

(Production Example 143)
3- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tilamino] propyl} phenyl) -N- (2,6-dichlorobenzyl) propionamide

Prepared according to the procedure used in preparation example 34 using the compound of preparation example 141, 2,6-dichlorobenzylamine and N, N-dimethylacetamide instead of N, N-dimethylformamide.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.15 (3H, s), 0.00 (3H, s), 0.85 (9H, s), 1.03 (3H, d), 2.44-2.57 (3H, m), 2.60-2.68 (2H, m), 2.80-2.90 (4H, m), 4.55-4.65 (3H, m), 6.16 (1H, m), 6.24 (2H, s), 6.91 (1H, m), 6.94 ( 1H, m), 7.01 (1H, m), 7.12 (1H, m), 7.26 (1H, m), 7.37-7.41 (2H, m); LRMS APCI m / z 631 [M + H] ⁺

(Production Example 144)
3- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tilamino] propyl} phenyl) -1- (3,4-dihydro-1H-isoquinolin-2-yl) -propan-1-one

Prepared according to the procedure used in Preparation 34, using the compound of Preparation 141, 1,2,3,4-tetrahydroisoquinoline, and N, N-dimethylacetamide instead of N, N-dimethylformamide.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.15 (3H, s), -0.01 (3H, s), 0.85 (9H, s), 0.99 (3H,
m), 2.42-2.64 (3H, m), 2.68-2.96 (8H, m), 3.63-3.76 (2H, m), 4.55-4.67 (3H, m),
6.16 (1H, m), 6.23 (2H, s), 6.81-7.21 (8H, m); LRMS APCI m / z 590 [M + H] ⁺

(Production Example 145)
2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tilamino] propyl} phenyl) -N- (2-chloro-4-fluorobenzyl) acetamide

Prepared according to the procedure used in Preparation 142 using the acid from Preparation 33 and 2-chloro-4-fluorobenzylamine.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.02 (3H, d), 0.00 (3H, s), 0.84 (9H, s), 1.04 (3H, d), 2.54-2.70 (3H, m), 2.86-2.93 (2H, m), 3.53 (2H, s), 4.41 (1H, s), 4.46 (1H, s), 4.60-4.63 (1H, m), 6.14-6.15 (1H, m), 6.22 ( 2H, d), 6.97-7.50 (7H, m), 7.64-7.69 (1H, m); LRMS APCI m / z 601 [M + H] ⁺ .

(Production Example 146)
N- (4-Bromobenzyl) -2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-di-
Hydroxyphenyl) ethylamino] -2-methylpropyl} phenyl) acetamide

Prepared according to the procedure used in Preparation 34, using acid from Preparation 33 and 4-bromobenzylamine 2-chloro-4-fluorobenzylamine.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.23 (s, 3H), -0.04 (s, 3H), 0.82 (s, 9H), 1.07 (d,
6H), 2.63-2.77 (m, 3H), 2.84 (t, 1H), 3.56 (s, 2H), 4.31 (s, 2H), 4.57-4.63 (m,
1H), 6.18 (t, 1H), 6.36 (s, 2H), 7.08 (t, 2H), 7.12-7.18 (m, 3H), 7.21 (t, 1H),
7.42 (d, 2H) .; LRMS ESI m / z 643 [M + H] ⁺ .

(Production Example 147)
2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tylamino] -2-methylpropyl} phenyl) -N- (3,4-dimethylphenyl) acetamide

Prepared according to the procedure used in Preparation 34, using the acid from Preparation 33 and 3,4-dimethylaniline.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.17 (s, 3H), -0.03 (s, 3H), 0.81 (s, 9H), 1.07 (d, 6H), 2.22 (d, 6H), 2.61 -2.77 (m, 3H), 2.83 (t, 1H), 3.61 (s, 2H), 4.57-4.61 (m, 1H), 6.18 (s, 1H), 6.29 (s, 2H), 7.06 (t, 2H ), 7.18 (s, 1H), 7.21-7.25 (m, 3H), 7.31 (s, 1H); LRMS ESI m / z 643 [M + H] ⁺ .

(Production Example 148)
2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tylamino] propyl} phenyl) -N- (2,3-dimethylbenzyl) acetamide

Prepared according to the procedure used in Preparation 34, using N, N-dimethylacetamide in place of the acid from Preparation 45, 2,3-dimethylbenzylamine and N, N-dimethylformamide.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.17 (3H, s), -0.04 (3H, s), 0.80 (9H, s), 0.97 (3H,
d), 2.09 (3H, s), 2.21 (2.46-2.51 (1H, dd), 2.56-2.65 (2H, m), 2.76-2.84 (2H, m), 3.45 (2H, s), 4.32 (2H, s), 4.53 (1H, dd), 5.44 (2H, s), 6.09 (1H, t), 6.17 (1H, 1), 6.18 (1H, s), 6.93-7.17 (7H, m); LRMS APCI m / z 578 [M + H] ⁺ .

(Production Example 149)
2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tylamino] propyl} phenyl) -N- (4-fluorobenzyl) acetamide

Prepared according to the procedure used in Preparation 34, using N, N-dimethylacetamide in place of the acid from Preparation 45, 4-fluorobenzylamine and N, N-dimethylformamide.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.17 (3H, s), -0.04 (3H, s), 0.80 (9H, s), 0.98 (3H,
d), 2.47 (1H, dd), 2.55-2.64 (H, m), 2.77-2.84 (2H, m), 3.46 (2H, s), 4.28 (2H,
s), 4.53 (1H, dd), 6.09-6.11 (1H, m), 6.17 (1H, s), 6.18 (1H, s), 6.91-7.02 (4H, m), 7.05-7.08 (1H, m) , 7.13 (1H, t), 7.17-7.23 (2H, m); LRMS APCI m / z 567 [M + H] ⁺ .

(Production Example 150)
2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tilamino] propyl} phenyl) -1- (4-pyridin-2-yl-piperazin-1-yl) ethanone

Prepared according to the procedure used in Preparation 34, using N, N-dimethylacetamide in place of the acid from Preparation 45, 1-pyridin-2-ylpiperazine, and N, N-dimethylformamide.
¹ H NMR (400MHz, CD ₃ OD) δ: -0.12 (3H, s), 0.00 (3H, s), 0.80 (9H, s), 1.12 (3H, d), 2.66 (1H, dd), 2.88- 2.93 (2H, m), 3.04-3.10 (1H, m), 3.15 (1H, dd), 3.32-3.43 (4H, m), 3.60-3.66 (4H, m), 3.73-3.79 (2H, m), 4.81-4.85 (1H, m), 6.18 (1H, t), 6.25 (1H, s), 6.26 (1H, s), 6.60-6.63 (1H, m), 6.72 (1H, d), 7.04-7.07 ( 2H, m), 7.12 (1H, d), 7.23 (1H, t), 7.46 (1H, dt), 8.00 (1H, d); LRMS APCI m / z 606 [M + H] ⁺ .

(Production Example 151)
2- (3- {2- [2- (tert-butyldimethylsilanyloxy) -2- (3,5-dihydroxyphenyl) ester
Tylamino] -2-methylpropyl} phenyl) -N- (2-phenylpropyl) acetamide

The title compound was prepared from the compound of Preparation 33 and the appropriate amine using the method described for Preparation 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ -0.20 (3H, s), -0.07 (3H, s), 0.74 (9H, s), 1.02 (3H, d), 1.09 (3H, d), 2.62 ( 1H, dd), 2.79 (1H, dd), 2.88-2.97 (2H, m), 3.04 (1H, dd), 3.16-3.24 (1H, m), 3.27-3.88 (2H, m), 3.41 (2H, s), 4.74 (1H, dd), 6.19 (1H, t), 6.27 (1H, s), 6.28 (1H, s), 7.01-7.07 (2H, m), 7.13-7.27 (4H, m).
LRMS APCI m / z 578 [M + H ⁺ ].

(Example 1)
N-benzyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide

To the solution obtained by dissolving the acid of Preparation Example 9 (50 mg, 0.10 mmol) and benzylamine (14 mg, 0.13 mmol) in N, N-dimethylformamide (1 ml), O- (1H-benzotriazole-1- Yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate (50 mg, 0.13 mmol) in N, N-dimethylformamide (3 ml) was added and the reaction mixture was added. Stir for 12 hours. The solvent was removed under reduced pressure to give a crude residue. Purification by column chromatography on silica gel using dichloromethane: methanol: 0.88 ammonia (97.5: 2.5: 0.25-90: 10: 1) gave the desired product (17 mg, 37% yield).
¹ H NMR (400 MHz, CD ₃ OD) δ 1.02 (3H, s), 1.04 (3H, s), 2.84-2.64 (4H, m), 3.52 (2H, s), 4.35 (2H, s), 4.53 -4.57 (1H, q), 6.18 (1H, s), 6.33 (2H, s), 7.02-7.04 (2H, d), 7.12-7.28 (7H, m).
LRMS: m / z APCI ⁺ 449 [MH ⁺ ].

  (Examples 2 to 11)

To a solution obtained by dissolving the appropriate amine (HNR ^A R ^B ) (30 μmol) in N, N-dimethylformamide (100 μl), the acid from Preparation 9 (30 μmol) was added to N, N-dimethylformamide. A solution obtained by dissolving in (100 μl) was added and the reaction mixture was sealed and shaken. Obtained by dissolving O-benzotriazol-1-yl-N, N, N ', N'-tetramethyluronium hexafluorophosphate (11.38 mg, 30 μmol) in N, N-dimethylformamide (200 μl) The solution was added and the reaction mixture was sealed and shaken and left at room temperature for 4 days. HPLC using a Phenomenex Luna C18 column (150 x 10 mm, 10 μm) with a flow rate of 8 ml / min and detection at 225 nm using the following gradient system
The reaction mixture was directly purified by
A-0.05% diethylamine aqueous solution
B-acetonitrile

Each product was analyzed using a Phenomenex Luna C18 (30 × 4.6 mm, 5 μm) column at a flow rate of 2.5 ml / min, using the gradient described in the table below.
A-water: 5% (6.5 mM) ammonium acetate in acetonitrile (95: 5)
B-acetonitrile

  A is 3-amino-5-ethyl-1H-pyrazole prepared as described in WO03 / 048133.

(Example 12)
N- [2- (4-Chloro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydro
Xyl-ethylamino] -2-methyl-propyl} -benzamide

To a solution obtained by dissolving the compound of Production Example 15 (1.56 g, 2.61 mmol) in methanol (25 ml) and water (18 ml), ammonium fluoride (1.08 g, 29.2 mmol) was added once at room temperature with stirring. Added to. The reaction mixture was heated at 40 ° C. for 48 hours, cooled to room temperature, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (100: 0: 0 then 95: 5: 0.5) to give the title compound as a brown solid (885 mg).
¹ H NMR (400MHz, CD ₃ OD) δ 1.10 (3H, s), 1.16 (3H, s), 2.75 (6H, m), 3.62 (2H, m), 4.66 (1H, dd), 6.23 (1H, m), 6.40 (1H, s), 6.41 (1H, s), 7.33 (6H, m), 7.67 (2H, m).
LRMS: m / z APCI 484 [M + H ⁺ ].

(Example 13)
N-adamantan-1-yl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

To a solution obtained by dissolving the compound of Production Example 30 (160 mg, 0.27 mmol) in methanol (2 ml) and water (1 ml), ammonium fluoride (100 mg, 2.70 mmol) was added all at once at room temperature with stirring. It was. The reaction mixture was heated at 40 ° C. for 12 hours, cooled to room temperature, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (93: 7: 0.7) to give the title compound as a white foam (78 mg). ¹ H NMR (400MHz, CD ₃ OD) δ 1.07 (3H, d), 1.68 (6H, s), 2.01 (9H, m), 2.60 (4H, m), 2.91 (1H, m), 3.40 (2H, s), 4.50 (1H, m), 6.13 (1H, m), 6.23 (2H, s), 6.99 (1H, d), 7.08 (1H, s), 7.10 (1H, d), 7.18 (1H, t ).
LRMS: m / z electrospray 479 [M + H ⁺ ], 477 [MH] ^- .

(Example 14)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (3-fluoro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 36 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.11 (3H, s), 1.15 (3H, s), 2.74-2.82 (2H, m), 2.90-3.00 (4H, m), 3.62-3.66 (2H, m ), 4.61-4.66 (1H, m), 6.23-6.24 (1H, m), 6.39 (1H, s), 6.40 (1H, s), 6.94-6.98 (1H, m), 7.03-7.07 (1H, m ), 7.10-7.12 (1H, m), 7.29-7.43 (3H, m), 7.65-7.69 (2H, m).
LRMS: m / z APCI 467 [M + H ⁺ ].

(Example 15)
N- [2- (2-Chloro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydro
Xyl-ethylamino] -2-methyl-propyl} -benzamide

The title compound was prepared from the compound of Preparation 37 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.10 (3H, s), 1.15 (3H, s), 2.76-2.84 (2H, m), 2.88-2.96 (2H, m), 3.10-3.14 (2H, m ), 3.66-3.70 (2H, m), 4.61-4.64 (1H, m), 6.22-6.24 (1H, m), 6.39 (1H, s), 6.40 (1H, s), 7.21-7.28 (2H, m ), 7.35-7.42 (4H, m), 7.66-7.69 (2H, m).
LRMS: m / z APCI 483 [M + H ⁺ ].

(Example 16)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (2,3-dimethyl-phenyl) -ethyl] -Benzamide

The title compound was prepared from the compound of Preparation 38 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.14 (3H, s), 1.19 (3H, s), 2.30 (3H, s), 2.31 (3H, s), 2.80-3.02 (6H, m), 3.56- 3.59 (2H, m), 4.63-4.67 (1H, m), 6.24-6.25 (1H, m), 6.40 (1H, s), 6.41 (1H, s), 6.99-7.07 (3H, m), 7.38- 7.45 (2H, m), 7.68-7.72 (2H, m).
LRMS: m / z APCI 477 [M + H ⁺ ].

(Example 17)
N- [2- (2-Chloro-4-fluoro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl- Propyl} -benzamide

The title compound was prepared from the compound of Preparation 39 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.09 (3H, s), 1.15 (3H, s), 2.75-2.83 (2H, m), 2.88-2.96 (2H, m), 3.08-3.11 (2H, m ), 3.64-3.68 (2H, m), 4.61-4.64 (1H, m), 6.22-6.23 (1H, m), 6.39 (1H, s), 6.40 (1H, s), 7.01-7.06 (1H, m ), 7.21-7.24 (1H, m), 7.35-7.42 (3H, m), 7.65-7.68 (2H, m).
LRMS: m / z APCI 501 [M + H ⁺ ].

(Example 18)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (4-methoxy-2,3-dimethyl-phenyl) ) -Ethyl] -benzamide

The title compound was prepared from the compound of Preparation 40 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.12 (3H, s), 1.18 (3H, s), 2.16 (3H, s), 2.30 (3H, s), 2.77-3.00 (6H, m), 3.52- 3.56 (2H, m), 3.80 (3H, s), 4.62-4.65 (1H, m), 6.23-6.24 (1H, m), 6.40 (1H, s), 6.41 (1H, s), 6.72-6.74 ( 1H, d), 7.01-7.03 (1H, d), 7.37-7.44 (2H, m), 7.67 (1H, s), 7.70-7.72 (1H, m).
LRMS: m / z APCI 507 [M + H ⁺ ].

(Example 19)
N- (3,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide

The title compound was prepared from the compound of Preparation 34 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.02 (3H, s), 1.04 (3H, s), 2.74 (4H, m), 3.56 (2H, s), 4.32 (2H, s), 4.54 (1H, m), 6.17 (1H, s), 6.36 (2H, s), 7.03 (1H, d), 7.15 (3H, m), 7.22 (1H, t), 7.36 (1H, d), 7.43 (1H, d ).
LRMS: m / z electrospray 517 [M + H ⁺ ].

(Example 20)
N- (3,4-dichloro-benzyl) -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Tylamino] -2-methyl-propyl} -benzamide

The title compound was prepared from the compound of Preparation 41 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.16 (3H, s), 1.20 (3H, s), 2.83-3.01 (4H, m), 4.59 (2H, s), 4.64-4.67 (1H, m), 6.23 (1H, m), 6.38 (1H, s), 6.39 (1H, s), 7.31-7.34 (1H, m), 7.41-7.55 (4H, s), 7.76-7.80 (2H, s).
LRMS: m / z APCI 503 [M + H ⁺ ].

(Example 21)
N- (4-Chloro-benzyl) -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Amino] -2-methyl-propyl} -benzamide

The title compound was prepared from the compound of Preparation 42 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.10 (3H, s), 1.15 (3H, s), 2.76-2.82 (2H, m), 2.90-2.96 (2H, m), 4.59 (2H, s), 4.60-4.63 (1H, m), 6.23 (1H, m), 6.37 (1H, s), 6.38 (1H, s), 7.34-7.45 (6H, m), 7.74-7.77 (2H, m).
LRMS: m / z APCI 469 [M + H ⁺ ].

(Example 22)
N-adamantan-1-yl-3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Amino] -2-methyl-propyl} -benzamide

The title compound was prepared from the compound of Preparation 43 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.27 (3H, s), 1.28 (3H, s), 1.79-1.81 (6H, m), 2.14 (3H, m), 2.21-2.22 (6H, m), 2.95-3.09 (4H, m), 4.71-4.74 (1H, m), 6.26 (1H, m), 6.42 (1H, s), 6.42 (1H, s), 7.40-7.46 (2H, m), 7.65 ( 1H, s), 7.68-7.70 (1H, m).
LRMS: m / z APCI 480 [M + H ⁺ ].

(Example 23)
N- (4-Chloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 46 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.01 (3H, s), 1.04 (3H, s), 2.74 (4H, m), 3.53 (2H, s), 4.34 (2H, s), 4.54 (1H, m), 6.18 (1H, s), 6.34 (2H, s), 7.03 (1H, d), 7.11 (1H, s), 7.20 (6H, m).
LRMS: m / z electrospray 483 [M + H ⁺ ].

(Example 24)
N- (4-trifluoromethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl)- Acetamide

The title compound was prepared from the compound of Preparation 47 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.01 (3H, s), 1.03 (3H, s), 2.74 (4H, m), 3.53 (2H, s), 4.37 (2H, s), 4.54 (1H, m), 6.18 (1H, s), 6.34 (2H, s), 7.03 (1H, d), 7.20 (7H, m).
LRMS: m / z electrospray 533 [M + H ⁺ ].

(Example 25)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl) -phenyl) -N-pyridin-2-ylmethyl-acetamide

The title compound was prepared from the compound of Preparation 48 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.01 (3H, s), 1.03 (3H, s), 2.74 (4H, m), 3.59 (2H, s), 4.45 (2H, s), 4.54 (1H, m), 6.16 (1H, s), 6.35 (2H, s), 7.05 (1H, d), 7.20 (5H, m), 7.72 (1H, t), 8.42 (1H, d).
LRMS: m / z electrospray 450 [M + H ⁺ ].

(Example 26)
N- (3,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 49 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.01 (3H, d), 2.58 (1H, m), 2.64 (2H, m), 2.78 (1H, m), 2.90 (1H, m), 3.56 (2H, s), 4.37 (2H, s), 4.54 (1H, m), 6.18 (1H, s), 6.25 (2H, s), 7.03 (5H, m), 7.38 (2H, m).
LRMS: m / z electrospray 503 [M + H ⁺ ].

(Example 27)
N- (benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 50 using the method described in Example 12 and isolated as a brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.57 (1H, m), 2.68 (2H, m), 2.81 (1H, m), 2.90 (1H, m), 3.53 (2H, s), 4.35 (2H, s), 4.52 (1H, m), 6.16 (1H, m), 6.25 (2H, s), 7.01 (1H, m), 7.08 (1H, s), 7.13 (1H, m ), 7.20 (6H, m).
LRMS: m / z APCI 435 [ M + H +], 433 [MH -].

(Example 28)
N-cyclohexylmethyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Tylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 51 using the method described in Example 12 and isolated as a brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 0.88 (2H, m), 1.06 (3H, d), 1.18 (3H, m), 1.42 (1H, m),
1.68 (5H, m), 2.58 (1H, m), 2.70 (2H, m), 2.81 (1H, m), 2.92 (1H, m), 2.99 (2H,
d), 3.46 (2H, s), 4.53 (1H, m), 6.15 (1H, m), 6.25 (2H, s), 7.00 (1H, m), 7.08 (2H, m), 7.19 (1H, m ).
LRMS: m / z APCI 441 [ M + H +], 439 [MH -].

(Example 29)
1- (3,4-Dihydro-1H-isoquinolin-2-yl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl}- Phenyl) -ethanone

The title compound was prepared from the compound of Preparation 52 using the method described in Example 12 and isolated as a brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.00 (3H, m), 2.57 (7H, m), 3.70 (1H, m), 3.80 (3H, m), 4.50 (1H, m), 4.68 (2H, d), 6.16 (1H, m), 6.26 (2H, s), 7.01 (7H, m).
LRMS: m / z APCI 461 [ M + H +], 459 [MH -].

(Example 30)
N-benzyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino]-
Propyl} -phenyl) -N-methyl-acetamide

The title compound was prepared from the compound of Preparation 53 using the method described in Example 12 and isolated as a brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.62 (3H, m), 2.88 (5H, m), 3.78 (2H, m), 4.50 (1H, m), 4.58 (2H, m), 6.16 (1H, m), 6.26 (2H, s), 7.01 (2H, m), 7.07 (2H, m), 7.20 (5H, m).
LRMS: m / z APCI 449 [ M + H +], 447 [MH -].

(Example 31)
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-hydroxy-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 54 using the method described in Example 12 and isolated as a brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.56 (1H, m), 2.68 (2H, m), 2.81 (2H, m), 3.52 (2H, s), 4.34 (2H, s), 4.53 (1H, m), 6.16 (1H, m), 6.25 (2H, s), 6.76 (2H, m), 7.00 (1H, m), 7.08 (4H, m), 7.18 (1H, m ).
LRMS: m / z APCI 451 [ M + H +], 449 [MH -].

(Example 32)
N- (4-Cyano-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 55 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.13 (3H, s), 1.15 (3H, s), 2.85 (4H, m), 3.61 (2H, s), 4.47 (2H, s), 4.62 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.11 (1H, d), 7.21 (2H, s), 7.28 (1H, m), 7.42 (2H, d), 7.67 (2H, d ).
LRMS: m / z electrospray ^{474 [M + H +],} 472 [MH -].

(Example 33)
N- (2,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide

The title compound was prepared from the compound of Preparation 56 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.12 (3H, s), 1.13 (3H, s), 2.85 (4H, m), 3.60 (2H, s), 4.46 (2H, s), 4.62 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.11 (1H, d), 7.20 (2H, m), 7.28 (3H, m), 7.47 (1H, s).
LRMS: m / z electrospray ^{517 [M + H +],} 515 [MH -].

(Example 34)
N- (benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide

To a solution obtained by dissolving the compound of Production Example 57 (130 mg, 0.23 mmol) in methanol (4 ml),
Trihydrofluorinated triethylamine (42 μl, 0.25 mmol) was added in one portion at room temperature with stirring. The reaction mixture was stirred for 12 hours and then the pH was adjusted to pH 7 using trifluoroacetic acid. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel eluting with dichloromethane: methanol: 880 ammonia (95: 5: 0.5 then 90: 10: 1) to give the title compound as white Obtained as a foam (80 mg).
¹ H NMR (400MHz, CD ₃ OD) δ 1.09 (3H, s), 1.10 (3H, s), 2.79 (4H, m), 3.53 (2H, s), 4.37 (2H, s), 4.55 (1H, m), 6.18 (1H, t), 6.33 (2H, s), 7.04 (1H, d), 7.13 (1H, s), 7.16 (1H, d), 7.25 (6H, m).
LRMS: m / z electrospray 449 [M + H ⁺ ].

(Example 35)
N- (2-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Ruamino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 58 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, s), 1.08 (3H, s), 2.70 (3H, m), 2.83 (1H, m), 3.57 (2H, s), 4.43 (2H, s), 4.56 (1H, m), 6.18 (1H, s), 6.34 (2H, s), 7.04 (1H, d), 7.18 (6H, m), 7.17 (1H, d).
LRMS: m / z electrospray 483 [M + H ⁺ ].

Example 36
N- (3-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tylamino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 59 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, s), 1.08 (3H, s), 2.72 (4H, m), 3.53 (2H, s), 3.68 (3H, s), 4.33 (2H, s), 4.56 (1H, m), 6.18 (1H, m), 6.32 (2H, s), 6.78 (2H, m), 7.03 (1H, d), 7.18 (5H, m).
LRMS: m / z electrospray 479 [M + H ⁺ ].

(Example 37)
N- (cyclohexylmethyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 60 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 0.91 (2H, m), 1.06 (3H, s), 1.08 (3H, s), 1.18 (3H, m), 1.44 (1H, m), 1.70 (5H, m), 2.70 (3H, m), 2.84 (1H, m), 3.02 (2H, d), 3.46 (2H, s), 4.58 (1H, m), 6.17 (1H, t), 6.34 (2H, s ), 7.07 (1H, d), 7.17 (2H, d), 7.22
(1H, t).
LRMS: m / z APCI 455 [M + H ⁺ ].

(Example 38)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl) -phenyl) -N-phenethyl-acetamide

The title compound was prepared from the compound of Preparation 61 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.07 (3H, s), 1.08 (3H, s), 2.73 (6H, m), 3.42 (2H, m), 3.47 (2H, s), 4.55 (1H, m), 6.17 (1H, s), 6.33 (2H, s), 7.15 (8H, m).
LRMS: m / z electrospray ^{463 [M + H +],} 461 [MH -].

(Example 39)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (4-chlorophenethyl) -acetamide

The title compound was prepared from the compound of Preparation 62 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.07 (3H, s), 1.08 (3H, s), 2.73 (6H, m), 3.43 (2H, m), 3.42 (2H, s), 4.55 (1H, m), 6.17 (1H, s), 6.36 (2H, s), 7.08 (5H, m), 7.21 (3H, m).
LRMS: m / z electrospray 497 [M + H ⁺ ], 495 [MH ⁻ ].

(Example 40)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl) -phenyl) -N- (4-phenylphenethyl) -acetamide

The title compound was prepared from the compound of Preparation 63 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.73 (6H, m), 3.43 (4H, m), 4.55 (1H, m), 6.18 (1H, m), 6.33 (2H, s), 7.08 (3H, m), 7.21 (3H, m), 7.31 (1H, t), 7.42 (2H, m), 7.51 (2H, d), 7.56 (2H, d ).
LRMS: m / z electrospray 540 [M + H ⁺ ].

(Example 41)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (4'-hydroxy-biphenyl-3-ylmethyl) -acetamide

The title compound was prepared from the compound of Preparation 64 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.07 (3H, s), 1.08 (3H, s), 2.73 (2H, m), 2.85 (2H, m), 3.57 (2H, s), 4.42 (2H, s), 4.58 (1H, m), 6.19 (1H, m), 6.33 (2H, s), 6.83 (2H, d), 7.07 (1H, d), 7.13 (2H, d), 7.23 (2H, m ), 7.38 (5H, m).
LRMS: m / z electrospray ^{541 [M + H +],} 539 [MH -].

(Example 42)
N-cycloheptyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyla
Mino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 65 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.07 (3H, s), 1.08 (3H, s), 1.58 (10H, m), 1.86 (2H, m), 2.73 (4H, m), 3.44 (2H, s), 3.80 (1H, m), 4.58 (1H, m), 6.18 (1H, m), 6.32 (2H, s), 7.05 (1H, d), 7.15 (2H, d), 7.23 (1H, t ).
LRMS: m / z electrospray ^{455 [M + H +],} 453 [MH -].

(Example 43)
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-phenethyl-acetamide

The title compound was prepared from the compound of Preparation 66 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.78 (7H, m), 3.40 (4H, m), 4.52 (1H, m), 6.13 (1H, m), 6.24 (2H, s), 7.08 (9H, m).
LRMS: m / z APCI 447 [ MH -].

(Example 44)
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-methylsulfanyl-benzyl) -acetamide

Using the method described in Example 12, the title compound was prepared from the compound of Preparation 67 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.44 (3H, s), 2.56 (1H, m), 2.75 (4H, m), 3.53 (2H, s), 4.44 (2H, s), 4.52 (1H, m), 6.13 (1H, m), 6.24 (2H, s), 7.10 (8H, m).

(Example 45)
N- (2,6-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 68 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.54 (1H, m), 2.78 (5H, m), 3.48 (2H, s), 4.52 (1H, m), 4.66 (2H, s), 6.15 (1H, m), 6.25 (2H, s), 7.00 (1H, m), 7.08 (2H, m), 7.18 (1H, m), 7.27 (1H, m), 7.38 (2H, m ).
LRMS: m / z APCI 503 [M + H ⁺ ].

Example 46
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-indan-2-yl-acetamide

The title compound was prepared from the compound of Preparation 69 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.58 (1H, m), 2.78 (6H, m), 3.22 (2H, m), 3.45 (2H, s), 4.56 (2H, m), 6.15 (1H, m), 6.25 (2H, s), 7.00 (8H, m).
LRMS: m / z APCI 461 [M + H ⁺ ].

(Example 47)
N- (2-Chloro-6-fluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydride
Roxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 70 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.54 (1H, m), 2.71 (2H, m), 2.83 (2H, m),
3.48 (2H, s), 4.57 (3H, m), 6.15 (1H, s), 6.25 (2H, s), 7.27 (7H, m).
LRMS: m / z APCI 487 [ M + H +], 485 [MH -].

(Example 49)
N- (4-Chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Ruamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 72 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.58 (1H, m), 2.71 (2H, m), 2.83 (1H, m), 2.90 (1H, m), 3.48 (2H, s), 4.38 (2H, s), 4.57 (1H, m), 6.16 (1H, s), 6.25 (2H, s), 7.02 (1H, d), 7.09 (1H, s), 7.11 (1H, m ), 7.20 (3H, m), 7.28 (2H, m).
LRMS: m / z APCI 469 [ M + H +], 467 [MH -].

(Example 50)
N- (2,5-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide

The title compound was prepared from the compound of Preparation 73 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.12 (3H, s), 1.13 (3H, s), 2.85 (4H, m), 3.62 (2H, s), 4.46 (2H, s), 4.62 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.20 (6H, m), 7.39 (1H, d).
LRMS: m / z electrospray ^{517 [M + H +],} 515 [MH -].

(Example 51)
N- (3,5-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide

The title compound was prepared from the compound of Preparation 74 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.11 (3H, s), 1.13 (3H, s), 2.85 (4H, m), 3.59 (2H, s), 4.37 (2H, s), 4.62 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.01 (1H, m), 7.12 (1H, m), 7.17 (3H, m), 7.28 (1H, d), 7.32 (1H, m ).
LRMS: m / z electrospray ^{517 [M + H +],} 515 [MH -].

(Example 52)
N- (2,6-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide

The title compound was prepared from the compound of Preparation 75 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.10 (3H, s), 1.11 (3H, s), 2.82 (4H, m), 3.54 (2H, s), 4.60 (1H, m), 4.71 (2H, s), 6.22 (1H, m), 6.38 (2H, s), 7.07 (1H, m), 7.18 (2H, m), 7.26 (1H, m), 7.31 (1H, m), 7.43 (1H, s ), 7.45 (1H, m).
LRMS: m / z electrospray ^{520 [M + H +],} 518 [MH -].

(Example 53)
N-biphenyl-2-ylmethyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 76 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.14 (3H, s), 1.15 (3H, s), 2.82 (2H, m), 2.93 (2H, m), 3.52 (2H, s), 4.32 (2H, s), 4.62 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.11 (13H, m).
LRMS: m / z electrospray ^{527 [M + H +],} 525 [MH -].

Example 54
N- (2-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethyl
Ruamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 77 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.56 (1H, m), 2.80 (4H, m), 3.55 (2H, s), 4.45 (2H, s), 4.52 (1H, m), 6.14 (1H, m), 6.25 (2H, s), 7.19 (8H, m).
LRMS: m / z APCI 469 [M + H ⁺ ].

Example 55
N- (3-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 78 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.60 (5H, m), 3.51 (2H, s), 3.69 (3H, s), 4.32 (2H, s), 4.51 (1H, m), 6.15 (1H, m), 6.25 (2H, s), 6.75 (3H, m), 7.02 (1H, m), 7.21 (4H, m).
LRMS: m / z APCI 465 [M + H ⁺ ].

Example 56
N- (3-trifluoromethylbenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 79 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.57 (1H, m), 2.66 (2H, m), 2.80 (1H, m), 2.90 (1H, m), 3.55 (2H, s), 4.43 (2H, s), 4.51 (1H, m), 6.16 (1H, m), 6.25 (2H, s), 7.03 (1H, m), 7.07 (1H, s), 7.14 (1H, m ), 7.21 (1H, m), 7.47 (2H, m), 7.53
(2H, m).
LRMS: m / z APCI 503 [ M + H +], 501 [MH -].

(Example 57)
N- (3,4-Difluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 80 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.58 (1H, m), 2.66 (2H, m), 2.80 (1H, m), 2.90 (1H, m), 3.53 (2H, s), 4.30 (2H, s), 4.52 (1H, m), 6.16 (1H, m), 6.24 (2H, s), 7.01 (2H, m), 7.15 (5H, m).
LRMS: m / z APCI 471 [ M + H +], 469 [MH -].

(Example 58)
N- (2-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 81 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.57 (1H, m), 2.68 (2H, m), 2.80 (1H, m), 2.87 (1H, m), 3.53 (2H, s), 3.78 (3H, s), 4.35 (2H, s), 4.52 (1H, m), 6.16 (1H, m), 6.23 (2H, s), 6.84 (1H, m), 6.91 (1H, m ), 7.01 (1H, m), 7.07 (1H, s), 7.15
(2H, m), 7.21 (2H, m).
LRMS: m / z APCI 465 [ M + H +], 463 [MH -].

(Example 59)
N- (3,4-dimethylbenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 82 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, d), 2.19 (3H, s), 2.19 (3H, s), 2.57 (1H, m), 2.66 (2H, m), 2.78 (1H, m), 2.88 (1H, m), 3.49 (2H, s), 4.26 (2H, s), 4.49 (1H, m), 6.16 (1H, m), 6.24 (2H, s), 6.93 (1H, m ), 6.97 (1H, s), 7.01 (2H, m), 7.06
(1H, s), 7.13 (1H, m), 7.19 (1H, m).
LRMS: m / z APCI 463 [ M + H +], 461 [MH -].

(Example 60)
N- (3,4-Dimethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 83 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, d), 2.57 (1H, m), 2.66 (2H, m), 2.79 (1H, m), 2.88 (1H, m), 3.50 (2H, s), 3.72 (3H, s), 3.78 (3H, s), 4.28 (2H, s), 4.50 (1H, m), 6.16 (1H, m), 6.24 (2H, s), 6.78 (2H, m ), 6.85 (1H, m), 7.01 (1H, m), 7.07
(1H, s), 7.14 (1H, m), 7.19 (1H, m).
LRMS: m / z APCI 495 [ M + H +], 493 [MH -].

(Example 61)
N- (2-ethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-e
Tylamino] -propyl} -phenyl) -acetamide

The title compound was prepared from the compound of Preparation 84 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, d), 1.35 (3H, t), 2.57 (1H, m), 2.68 (2H, m), 2.80 (1H, m), 2.88 (1H, m), 3.53 (2H, s), 4.00 (2H, q), 4.36 (2H, s), 4.50 (1H, m), 6.15 (1H, m), 6.25 (2H, s), 6.83 (1H, m ), 6.88 (1H, m), 7.01 (1H, m), 7.07
(1H, s), 7.15 (2H, m), 7.19 (2H, m).
LRMS: m / z APCI 479 [ M + H +], 477 [MH -].

(Example 62)
N- [2- (2-Chloro-phenyl) -ethyl] -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -Acetamide

The title compound was prepared from the compound of Preparation 85 using the method described in Example 12 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.58 (1H, m), 2.67 (2H, m), 2.81 (1H, m), 2.88 (3H, m), 3.43 (4H, m), 4.53 (1H, m), 6.16 (1H, m), 6.24 (2H, s), 7.04 (3H, m), 7.20 (6H, m).
LRMS: m / z APCI 483 [ M + H +], 481 [MH -].

(Example 63)
4-{[2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetylamino] -methyl} -benzamide

The title compound was prepared from the compound of Preparation 86 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, d), 2.57 (1H, m), 2.68 (2H, m), 2.80 (1H, m), 2.87 (1H, m), 3.58 (2H, s), 4.38 (2H, s), 4.51 (1H, m), 6.17 (1H, m), 6.25 (2H, s), 7.01 (1H, d), 7.07 (2H, m), 7.20 (1H, m ), 7.29 (2H, d), 7.80 (2H, d).
LRMS: m / z APCI 478 [ M + H +], 476 [MH -].

(Example 64)
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-indan-1-yl-acetamide

Using the method described in Example 12, the title compound was prepared from the compound of Preparation 87 and isolated as a light brown foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 1.81 (1H, m), 2.46 (1H, m), 2.57 (1H, m), 2.72 (2H, m), 2.87 (4H, m), 3.52 (2H, m), 4.53 (1H, m), 5.36 (1H, m), 6.16 (1H, m), 6.25 (2H, s), 7.01 (1H, m), 7.14 (7H, m ).
LRMS: m / z APCI 461 [ M + H +], 459 [MH -].

Example 65
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (3-fluoro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 94 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.80 (7H, m), 3.59 (2H, m), 4.55 (1H, m), 6.15 (1H, m), 6.26 (2H, s), 7.01 (3H, m), 7.30 (3H, m), 7.58 (2H, m).
LRMS: m / z APCI 453 [M + H ⁺ ].

Example 66
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-chloro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 95 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.81 (5H, m), 3.07 (2H, t), 3.63 (2H, t), 4.53 (1H, m), 6.15 (1H, m), 6.26 (2H, s), 7.20 (6H, m), 7.55 (2H, m).
LRMS: m / z APCI 469 [M + H ⁺ ].

Example 67
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-naphthalen-1-ylmethyl-acetamide

The title compound was prepared from the compound of Preparation 96 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 0.98 (3H, d), 2.47 (1H, m), 2.54 (2H, m), 2.78 (2H, m), 3.54 (2H, s), 4.51 (1H, m), 4.80 (2H, s), 6.17 (1H, s), 6.25 (2H, s), 6.98 (2H, m), 7.07 (2H, m), 7.40 (4H, m), 7.78 (1H, d ), 7.84 (1H, d), 7.90 (1H, d).
LRMS: m / z APCI 485 [ M + H +], 483 [MH -].

Example 68
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-fluoro-5-trifluoromethyl-benzyl) -Acetamide

The title compound was prepared from the compound of Preparation 97 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.03 (3H, d), 2.47 (1H, m), 2.63 (2H, m), 2.78 (1H, m), 2.89 (1H, m), 3.54 (2H, s), 4.46 (2H, s), 4.58 (1H, m), 6.17 (1H, s), 6.22 (2H, s), 7.01 (1H, d), 7.08 (2H, m), 7.20 (2H, m ), 7.58 (2H, m).
LRMS: m / z APCI 521 [ M + H +], 519 [MH -].

(Example 69)
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (3-chlorobenzyl) -acetamide

The title compound was prepared from the compound of Preparation 98 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.03 (3H, d), 2.58 (1H, m), 2.63 (2H, m), 2.78 (1H, m), 2.85 (1H, m), 3.57 (2H, s), 4.38 (2H, s), 4.52 (1H, m), 6.17 (1H, s), 6.26 (2H, s), 7.01 (1H, d), 7.08 (1H, s), 7.20 (6H, m ).
LRMS: m / z APCI 469 [ M + H +], 467 [MH -].

Example 70
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (4-fluoro-3-trifluoromethyl-benzyl) -Acetamide

The title compound was prepared from the compound of Preparation 99 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.03 (3H, d), 2.58 (1H, m), 2.63 (2H, m), 2.78 (1H, m), 2.89 (1H, m), 3.52 (2H, s), 4.38 (2H, s), 4.52 (1H, m), 6.17 (1H, s), 6.26 (2H, s), 7.03 (1H, d), 7.08 (2H, m), 7.20 (2H, m ), 7.51 (2H, m).
LRMS: m / z APCI 521 [ M + H +], 519 [MH -].

Example 71
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-methylsulfanyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 100 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.11 (3H, s), 1.12 (3H, s), 2.48 (3H, s), 2.85 (4H, m), 3.59 (2H, s), 4.47 (2H, s), 4.61 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.07 (2H, m), 7.26 (6H, m).
LRMS: m / z electrospray ^{497 [M + H +],} 494 [MH -].

(Example 72)
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetylamino] -methyl}- Benzamide

The title compound was prepared from the compound of Preparation 101 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.11 (3H, s), 1.12 (3H, s), 2.85 (4H, m), 3.60 (2H, s), 4.46 (2H, s), 4.61 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.10 (1H, d), 7.22 (2H, m), 7.28 (1H, m), 7.34 (2H, d), 7.82 (2H, d ).
LRMS: m / z electrospray ^{493 [M + H +],} 491 [MH -].

(Example 73)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (4-sulfamoyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 102 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.12 (3H, s), 1.13 (3H, s), 2.85 (4H, m), 3.60 (2H, s), 4.47 (2H, s), 4.61 (1H, m), 6.23 (1H, m), 6.38 (2H, s), 7.10 (1H, d), 7.22 (2H, m), 7.28 (1H, m), 7.40 (2H, d), 7.84 (2H, d ).
LRMS: m / z electrospray ^{529 [M + H +],} 527 [MH -].

Example 74
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetylamino] -methyl}- Benzoic acid methyl ester

The title compound was prepared from the compound of Preparation 103 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.08 (3H, s), 1.10 (3H, s), 2.85 (4H, m), 3.60 (2H, s), 3.92 (3H, s), 4.47 (2H, s), 4.61 (1H, m), 6.22 (1H, m), 6.38 (2H, s), 7.09 (1H, d), 7.20 (2H, m), 7.28 (1H, m), 7.37 (2H, d ), 7.95 (2H, d).
LRMS: m / z electrospray ^{508 [M + H +],} 506 [MH -].

(Example 75)
N- (1-Benzyl-piperidin-4-yl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl}- Phenyl) -acetamide

The title compound was prepared from the compound of Preparation 104 using the method described in Example 12 and isolated as a white solid.
¹ H NMR (400MHz, CD ₃ OD) δ 1.12 (3H, s), 1.13 (3H, s), 1.55 (2H, m), 1.87 (2H, m), 2.15 (2H, m), 2.80 (6H, m), 3.50 (2H, s), 3.55 (2H, s), 3.68 (1H, m), 4.61 (1H, m), 6.22 (1H, m), 6.37 (2H, s), 7.08 (1H, d ), 7.18 (2H, m), 7.26 (2H, m), 7.35 (2H, s), 7.36 (2H, s).
LRMS: m / z electrospray ^{533 [M + H +],} 531 [MH -].

(Example 76)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2-phenethyl] -benzamide

The title compound was prepared from the compound of Preparation 105 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.62 (1H, m), 2.75 (1H, m), 2.80 (2H, m), 2.94 (3H, m), 3.58 (2H, t), 4.56 (1H, m), 6.16 (1H, m), 6.27 (2H, s), 7.18 (1H, m), 7.26 (6H, m), 7.57 (1H, s), 7.59 (1H, m ).
LRMS: m / z APCI 435 [ M + H +], 433 [MH -].

Example 77
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (5-fluoro-2-methyl-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 106 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.33 (3H, s), 2.62 (1H, m), 2.76 (1H, m), 2.80 (2H, m), 2.94 (3H, m), 3.58 (2H, t), 4.55 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 6.82 (1H, m), 6.93 (1H, m), 7.12 (1H, m ), 7.35 (2H, m), 7.57 (1H, s), 7.61
(1H, m).
LRMS: m / z APCI 467 [ M + H +], 465 [MH -].

(Example 78)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-trifluoromethyl-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 107 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.62 (1H, m), 2.75 (1H, m), 2.82 (2H, m), 2.98 (1H, m), 3.12 (2H, t), 3.62 (2H, t), 4.56 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 7.35 (3H, m), 7.50 (2H, m), 7.61 (3H, m ).
LRMS: m / z APCI 503 [ M + H +], 501 [MH -].

(Example 79)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- (2-naphthalen-1-yl-ethyl) -benzamide

Using the method described in Example 12, the title compound was prepared from the compound of Preparation 108 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.60 (1H, m), 2.75 (3H, m), 2.96 (1H, m), 3.40 (2H, t), 3.70 (2H, t), 4.57 (1H, m), 6.17 (1H, m), 6.28 (2H, s), 7.35 (5H, m), 7.48 (3H, m), 7.59 (1H, m), 7.75 (1H, m ), 7.84 (1H, m), 8.23 (1H, m).
LRMS: m / z APCI 485 [ M + H +], 483 [MH -].

Example 80
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2,4,5-trimethyl-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 109 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.17 (3H, s), 2.17 (6H, s), 2.27 (3H, s), 2.62 (1H, m), 2.75 (1H, m), 2.81 (4H, m), 2.98 (1H, m), 3.50 (2H, t), 4.55 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 6.88 (1H, s ), 6.91 (1H, s), 7.35 (2H, m), 7.38
(1H, s), 7.40 (1H, m).
LRMS: m / z APCI 477 [ M + H +], 475 [MH -].

Example 81
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2,3-dimethyl-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 110 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.26 (3H, s), 2.26 (3H, s), 2.62 (1H, m), 2.75 (1H, m), 2.81 (2H, m), 2.95 (3H, m), 3.54 (2H, t), 4.56 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 6.98 (3H, m), 7.35 (2H, m ), 7.38 (1H, s), 7.41 (1H, m).
LRMS: m / z APCI 463 [ M + H +], 461 [MH -].

(Example 82)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-hydroxy-3-chloro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 111 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.62 (1H, m), 2.75 (1H, m), 2.81 (2H, m), 2.95 (3H, m), 3.60 (2H, t), 4.56 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 6.74 (1H, m), 7.06 (1H, m), 7.17 (1H, m), 7.35 (2H, m ), 7.57 (1H, s), 7.60 (1H, m).
LRMS: m / z APCI 485 [ M + H +], 483 [MH -].

Example 83
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (4-chloro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 112 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.62 (1H, m), 2.75 (1H, m), 2.81 (2H, m), 2.95 (3H, m), 3.58 (2H, t), 4.56 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 7.30 (6H, m), 7.58 (2H, m).
LRMS: m / z APCI 469 [ M + H +], 467 [MH -].

(Example 84)
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-hydroxy-5-chloro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 113 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.06 (3H, d), 2.63 (1H, m), 2.77 (1H, m), 2.86 (4H, m), 3.00 (1H, m), 3.58 (2H, t), 4.57 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 6.78 (1H, m), 7.00 (1H, m), 7.09 (1H, m), 7.30 (2H, m ), 7.57 (1H, s), 7.59 (1H, m).
LRMS: m / z APCI 485 [ M + H +], 483 [MH -].

Example 85
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-chloro-4-fluoro-phenyl) -ethyl] -benzamide

The title compound was prepared from the compound of Preparation 114 using the method described in Example 12 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.05 (3H, d), 2.62 (1H, m), 2.75 (1H, m), 2.83 (2H, m), 3.00 (1H, m), 3.05 (2H, t), 3.62 (2H, t), 4.56 (1H, m), 6.17 (1H, m), 6.26 (2H, s), 6.99 (1H, m), 7.19 (1H, m), 7.35 (3H, m ), 7.60 (2H, m).
LRMS: m / z APCI 487 [ M + H +], 485 [MH -].

Example 86
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (2-methyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 115 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.22 (3H, s), 2.73 (3H, m), 2.83 (1H, m), 3.56 (2H, s), 4.37 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.04 (1H, d), 7.10 (6H, m), 7.21 (1H, t ).
LRMS: m / z electrospray ^{465 [M + H +],} 462 [MH -].

Example 87
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (3-methyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 116 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.23 (3H, s), 2.73 (3H, m), 2.83 (1H, m), 3.56 (2H, s), 4.31 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.04 (4H, m), 7.15 (3H, m), 7.21 (1H, t ).
LRMS: m / z electrospray ^{465 [M + H +],} 462 [MH -].

Example 88
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (4-methyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 117 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.27 (3H, s), 2.73 (3H, m), 2.83 (1H, m), 3.56 (2H, s), 4.28 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.04 (1H, d), 7.10 (5H, m), 7.17 (1H, d ), 7.22 (1H, m).
LRMS: m / z electrospray ^{465 [M + H +],} 462 [MH -].

Example 89
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (2-methoxy-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 118 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.68 (2H, t), 2.77 (1H, m), 2.83 (1H, m), 3.56 (2H, s), 3.79 (3H, s), 4.37 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.37 (2H, s), 6.82 (1H, m), 6.92 (1H, d ), 7.03 (1H, d), 7.12 (3H, m), 7.22
(2H, m).
LRMS: m / z electrospray ^{480 [M + H +],} 478 [MH -].

Example 90
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (4-methoxy-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 119 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.68 (3H, m), 2.83 (1H, m), 3.56 (2H, s), 3.77 (3H, s), 4.27 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 6.92 (2H, d), 7.04 (2H, d), 7.17 (4H, m ), 7.21 (1H, m).
LRMS: m / z electrospray 481 [M + H ⁺ ], 478 [MH ⁻ ].

Example 91
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (2,3-dimethyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 120 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.15 (3H, s), 2.24 (3H, s), 2.68 (3H, m), 2.83 (1H, m), 3.53 (2H, s), 4.37 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.02 (1H, d), 7.08 (3H, m ), 7.11 (1H, m), 7.17 (1H, d), 7.21
(1H, m).
LRMS: m / z electrospray ^{478 [M + H +],} 476 [MH -].

(Example 92)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (3,4-dimethyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 121 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.19 (3H, s), 2.19 (3H, s), 2.68 (3H, m), 2.83 (1H, m), 3.54 (2H, s), 4.27 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 6.96 (1H, d), 6.97 (1H, s ), 7.06 (2H, m), 7.11 (1H, m), 7.18
(1H, m), 7.21 (1H, m).
LRMS: m / z electrospray ^{477 [M + H +],} 475 [MH -].

(Example 93)
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (2-chloro-6-methyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 122 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.37 (3H, s), 2.68 (3H, m), 2.83 (1H, m), 3.47 (2H, s), 4.53 (2H, s), 4.55 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.04 (1H, d), 7.09 (1H, m), 7.18 (4H, m ), 7.21 (1H, m).
LRMS: m / z electrospray 497 [M + H ⁺ ].

Example 94
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl
(Lopyl} -phenyl) -N- (3-chloro-4-methyl-benzyl) -acetamide

The title compound was prepared from the compound of Preparation 123 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.04 (3H, s), 1.05 (3H, s), 2.31 (3H, s), 2.68 (3H, m), 2.83 (1H, m), 3.56 (2H, s), 4.28 (2H, s), 4.53 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.04 (1H, d), 7.11 (1H, s), 7.18 (1H, m ), 7.21 (4H, m).
LRMS: m / z electrospray 497 [M + H ⁺ ].

Example 95
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- [2- (6-methoxynaphthalen-2-yl) Ethyl] acetamide

The title compound was prepared from the compound of Preparation 124 using the method described in Example 34 and isolated as a white foam.
¹ H NMR (400MHz, CD ₃ OD) δ 1.07 (3H, s), 1.07 (3H, s), 2.63 (2H, m), 2.81 (2H, m), 3.44 (2H, s), 3.51 (2H, m), 3.64 (2H, s), 3.87 (3H, s), 4.58 (1H, m), 6.18 (1H, m), 6.36 (2H, s), 7.04 (6H, m), 7.24 (1H, d ), 7.47 (1H, s), 7.63 (2H, m).
LRMS: m / z electrospray 543 [M + H ⁺ ].

Example 96
N- (2-chlorobenzyl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethyl
Amino] propyl} phenyl) propionamide

Prepared according to the procedure described in example 12 using the compound of preparation example 142.
¹ H NMR (400MHz, CD ₃ OD) 1.04 (3H, d), 2.50-2.72 (3H, m), 2.65-2.75 (2H, m), 2.76-2.85 (1H, m), 2.86-2.95 (3H, m), 4.40 (2H, s), 4.53 (1H, m), 6.16 (1H, m), 6.26 (2H, s), 6.94-7.08 (4H, m), 7.13-7.24 (3H, m), 7.35 (1H, m); LRMS APCI m / z 483 [M + H] ⁺ .

Example 97
N- (2,6-dichlorobenzyl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxy ester
Tilamino] propyl} phenyl) propionamide

Prepared according to the procedure described in example 12 using the compound of preparation 143.
¹ H NMR (400MHz, CD ₃ OD) δ: 1.04 (3H, d), 2.42-2.58 (3H, m), 2.62-2.75 (2H, m), 2.76-2.95 (4H, m), 4.53 (1H, m), 4.62 (2H, s), 6.16 (1H, m), 6.25 (2H, s), 6.92 (1H, m), 6.96 (1H, s), 7.01 (1H, m), 7.13 (1H, t ), 7.26 (1H, t), 7.38 (2H, m); LRMS APCI m / z 517 [M + H] ⁺ .

(Example 98)
1- (3,4-dihydro-1H-isoquinolin-2-yl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) propane- 1-on

Prepared according to the procedure described in example 12 using the compound of preparation example 144.
¹ H NMR (400MHz, CD ₃ OD) δ: 1,03 (3H, d), 2.65-2.95 (11H, m), 3.62-3.75 (2H, m), 4.46-4.68 (3H, m), 6.16 ( 1H, m), 6.24 (2H, s), 6.84-7.19 (8H, m); LRMS APCI m / z 475 [M + H] ⁺ .

Example 99
N- (2-Chloro-4-fluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) acetamide

The title compound was prepared from the compound of Preparation 145 according to the procedure described in Example 34.
¹ H NMR (400MHz, CD ₃ OD) δ 1.00 (3H, d), 2.60-2.65 (1H, m), 2.64-2.68 (2H, m), 2.83-2.93 (1H, m), 3.48 (2H, s ), 4.86 (2H, s), 4.47-4.50 (1H, m), 6.11 (1H, s), 6.21 (2H, m), 6.99-7.83 (7H, m).
LRMS: m / z APCI 687 [M + H ⁺ ].

(Example 100)
N- (4-Bromobenzyl) -2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethyl
Amino] -2-methylpropyl} phenyl) acetamide

The title compound was prepared from the compound of Preparation 146 according to the procedure described in Example 34.
¹ H NMR (400MHz, CD ₃ OD) δ: 1.07 (d, 6H), 2.63-2.78 (m, 3H), 2.84 (t, 1H), 3.57 (s, 2H), 4.31 (s, 2H), 4.53 -4.57 (m, 1H), 6.18 (s, 1H), 6.37 (s, 2H), 7.05 (d, 1H), 7.16 (t, 4H), 7.22 (t, 1H), 7.42 (d, 2H); LRMS APCI m / z 529 [M + H] ⁺ .

(Example 101)
2- (3- {2- [2- (3,5-Dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- (3,4-dimethylphenyl) acetamide

The title compound was prepared from the compound of Preparation Example 147 according to the procedure described in Example 34.
¹ H NMR (400MHz, CD ₃ OD) δ: 1.05 (d, 6H), 2.22 (d, 6H), 2.66-2.78 (m, 3H), 2.83 (t, 1H), 3.62 (s, 2H), 4.56 -4.59 (m, 1H), 6.18 (s, 1H), 6.32 (s, 2H), 7.04 (t, 2H), 7.18-7.24 (m, 4H), 7.31 (s, 1H); LRMS APCI m / z 463 [M + H] ⁺ .

(Example 102)
2- (3- {2- [2- (3,5-Dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -N- (2,3-dimethylbenzyl) acetamide

The title compound was prepared from the compound of Preparation Example 148 according to the procedure described in Example 12.
¹ H NMR (400MHz, CD ₃ OD) δ: 0.99 (3H, s), 2.20 (3H, s), 2.48 (1H, dd), 2.61-2.67 (2H, m), 2.72 (1H, dd), 2.80 (1H, dt), 3.45 (2H, s), 4.31 (2H, s), 4.44 (1H, dd), 6.09 (1H, t), 6.19 (1H, s), 6.20 (1H, s), 6.92- 7.17 (7H, m); LRMS APCI m / z 462 [M + H] ⁺ .

(Example 103)
2- (3- {2- [2- (3,5-Dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -N- (4-fluorobenzyl) acetamide

The title compound was prepared from the compound of Preparation 149 according to the procedure described in Example 12.
¹ H NMR (400MHz, CD ₃ OD) δ: 0.99 (3H, d), 2.49 (1H, dd), 2.60-2.66 (2H, m), 2.74 (1H, dd), 2.82-2.89 (1H, m) , 3.46 (2H, s), 4.27 (2H, s), 4.46 (1H, dd), 6.12 (1H, t), 6.21 (1H, s), 6.22 (1H, s), 6.91-6.98 (3H, m ), 7.02-7.07 (2H, m), 7.03-7.21 (3H, m); LRMS APCI m / z 451 [M + H] ⁺ .

(Example 104)
2- (3- {2- [2- (3,5-Dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -1- (4-pyridin-2-ylpiberazin-1-yl) ethanone

The title compound was prepared from the compound of Preparation 150 according to the procedure described in Example 12.
¹ H NMR (400MHz, CD ₃ OD) δ: 1.05 (3H, d), 2.59 (1H, dd), 2.78-2.93 (3H, m), 3.08-3.15 (1H, m), 3.31 (2H, t) , 3.41 (2H, t), 3.59 (2H, t), 3.66 (2H, t), 3.77 (2H, s), 4.55 (1H, dd), 6.13 (1H, t), 6.25 (1H, s), 6.26 (1H, s), 6.62-6.65 (1H, m), 6.73 (1H, d), 7.02-7.11 (3H, m), 7.20 (1H, t), 7.48 (1H, dt), 8.01 (1H, bd); LRMS APCI m / z 491 [M + H] ⁺ .

(Example 105)
2- (3- {2- [2- (3,5-Dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- (2-phenylpropyl) acetamide

The title compound was prepared from the compound of Preparation 151 according to the procedure described in Example 12.
¹ H NMR (400MHz, CD ₃ OD) δ: 0.92 (3H, d), 1.06 (3H, d), 2.40 (1H, dd), 2.53-2.59 (2H, m), 2.66 (1H, dd), 2.74 -2.83 (2H, m), 3.14-3.24 (2H, m), 3.27 (2H, s), 4.38 (1H, dd), 6.02 (1H, t), 6.13 (1H, s), 6.13 (1H, s ), 6.83-6.90 (2H, m), 6.98-7.07
(4H, m), 7.08-7.13 92H, m); LRMS APCI m / z 463 [M + H] ⁺ .
The ability of a compound of formula (1) to act as a potent β2 agonist (and therefore mediate smooth muscle relaxation) measures the effect of β2 adrenergic receptor stimulation on the electric field stimulation contraction of guinea pig tracheal strips. Can be determined by.

Guinea pig trachea Male Dunkin-Hartley guinea pigs (475-525 g) are killed by CO ₂ asphyxiation and femoral artery exsanguination, and the trachea is isolated. Four preparations are obtained from each animal and an incision is immediately started under the larynx and a 2.5 cm long trachea is taken. The tracheal piece is opened by cutting the cartilage facing the tracheal muscle, and then the transverse section is cut at a width of 3-4 cartilage rings. The strip preparation thus obtained is suspended in 5 ml organ baths using a cotton thread tied through the upper and lower cartilage bands. 3 μM indomethacin (Sigma I7378), 10 μM guanethidine (Sigma G8520), and 10
In a modified Krebs Ringer's solution containing μM atenolol (Sigma A7655), leave the strips to stand for 20 minutes with no tension, equilibrate, heat at 37 ° C, and 95% O ₂ /5% CO ₂ . After processing, add 1 g of initial tension. The preparation is allowed to equilibrate for an additional 30-45 minutes, during which time the preparation is re-tensioned (up to 1 g) twice at 15 minute intervals. Changes in tension are recorded and monitored by standard isometric transducers coupled to a data acquisition system (Pfizer custom design). Following tensioning equilibration, the tissue is subjected to electric field stimulation using the following parameters: train for 10 seconds every 2 minutes, 0.1% continuously over the entire duration of the experiment. Pulse width in milliseconds, 10 Hz, and just-maximal voltage (25 volts). EFS of postganglionic and cholinergic nerves in the trachea results in monophasic contraction of smooth muscle and records the twitch height. By using a peristaltic pump system (pump flow rate 7.5 ml / min), the organ bath was constantly perfused with the Krebs Ringer solution (except when adding a β2 agonist according to the present invention) throughout the experiment, The pump is then stopped for the cumulative supply time to the bus, and the pump is started again after reaching maximum response at the washout time.

Experimental protocol for assessment of efficacy and efficacy After equilibration to electric field stimulation, the preparation is stopped at a single dose of 300 nM to ensure maximum response with respect to suppression of contractile EFS response. Prime isoprenaline (Sigma I5627) ('primed'). The isoprenaline is then washed out over 40 minutes. After priming and washout recovery, a standard curve for isoprenaline is generated for all tissues by adding boluses to the bath one after another, increasing the concentration by half log (isoprenarin curve 1). . The concentration range used is 1 ^e-9 to 1 ^e / 3 ^e-6 M. When the isoprenaline curve is finished, the preparation is washed again for 40 minutes before starting a second curve for isoprenaline (as an internal standard) or for the β2 agonist of the present invention. The response of β2 agonist is expressed as percent inhibition of EFS response. Data for β2 agonists are normalized by expressing the inhibition as a percentage of the maximum inhibition caused by isoprenaline in curve 1. EC ₅₀ values for β2 agonists of the present invention are:
It represents the concentration of the compound required to obtain a half maximal effect. The data for β2 agonists of the present invention are then expressed as relative potency for isoprenaline, defined by the ratio of (EC ₅₀ β2 agonist) / (EC ₅₀ isoprenaline).

Confirmation of β2-mediated Functional Activity The β2 agonist activity of the test compound is confirmed using the protocol described above. However, prior to generating a curve for the β2 agonist of the present invention, the preparation is preincubated with 300 nM ICI118551 (a selective β2 antagonist) for at least 45 minutes (as a result
In the case of β2-mediated effects, a right shift of the dose response curve of the test compound occurs).

According to another method, the agonist potency for the β2 receptor of the compound of formula (1) measures the concentration of the compound of the invention required to obtain a half-maximal effect (EC ₅₀ ) on the β2 receptor. Can also be determined.

Compound Preparation A 10 mM / 100% DMSO (dimethyl sulfoxide) stock of compound is diluted to the required top dose in 4% DMSO. This top dose is used to generate a 10-point semi-log dilution curve (all in 4% DMSO). Isoprenaline (Sigma, I-5627) is used as a standard in all experiments and as a control well in each plate. Data are displayed as% isoprenaline response.

CHO (Chinese hamster ovary) cells (Kobilka et al., PNAS 84: 46-50,1987, and Bouvier et al., Mol Pharmacol 33: 133-139,1988 CHOhβ2) that recombinantly express cell culture human β2 adrenergic receptors. 10% fetal calf serum (Sigma, F4135, lot 90K8404 Exp 09/04), 2 mM glutamine (Sigma, G7513), 500 μg / ml geneticin (Sigma, G7034), and 10 μg / ml puromycin (Sigma, P8833) ) Was added in Dulbecco's MEM / NUT MIX F12 (Gibco, 21331-020). Cells were seeded to obtain a cell confluency of about 90% for testing.

Assay Each 25 μl / well dose of compound was transferred into a cAMP-Flashplate® with 1% DMSO as the basal control and 100 nM isoprenaline as the maximum control. This was diluted 1: 2 by adding 25 μl / well PBS. Cells were trypsinized (0.25% Sigma, T4049), washed with PBS (Gibco, 14040-174), and resuspended in stimulation buffer (NEN, SMP004B) to give 1 × 10 ⁶ cells / ml CHOhβ2. Got. The compound was incubated with 50 μl / well of cells for 1 hour. The cells were then lysed by adding 100 μl / well of detection buffer containing 0.18 μCi / ml ¹²⁵ I-cAMP (NEN, NEX-130) and the plates were incubated for an additional 2 hours at room temperature. The amount of ¹²⁵ I-cAMP bound to the flash plate was quantified using a TopcountNXT (Packard) at normal counting efficiency in 1 minute. Dose-response data were expressed as% isoprenaline activity and fitted using a 4-parameter sigmoid fit.

It has been found that the compounds of formula (1) according to the invention described in Examples 1 to 105 exhibit a β2 cAMP EC _{50 of} less than 30 nM.

Claims (17)

General formula (1)

[Where,
The (CH ₂ ) _n —C (═O) Q ¹ group is located at the meta or para position
R ¹ and R ² are independently selected from H and C ₁ -C ₄ alkyl;
n is 0, 1, or 2; and
Q ¹ is

A group selected from ^* -NR ⁸ -Q ² -A or ^* -NR ⁸ -Q ³
p is 1 or 2 and q is 1 or 2;
Q ² is a single bond or C ₁ -C ₄ alkylene optionally substituted with OH;
R ⁸ is H or C ₁ -C ₄ alkyl;
Q ³ is NR ⁹ R ¹⁰ , OR ⁹ , or C ₁ -C ₆ alkyl optionally substituted with phenoxy;
A is
A C ₃ -C ₁₀ cycloalkyl that may be bridged with one or more carbon atoms and optionally substituted with one hydroxy group,
One or two selected from O, N, or S, optionally substituted with one or two substituents selected from C ₁ -C ₄ alkyl, benzyl, and cyclopropylmethyl A 5- to 6-membered heterocyclic group which may be aromatic, containing a heteroatom, or quinolyl group, isoquinolyl group,

Or a group represented by

A group represented by
Selected from;
R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different and are H, C ₁ -C ₄ alkyl, OR ⁹ , SR ⁹ , SOR ⁹ , SO ₂ R ⁹ , halo, CN, Selected from CF ₃ , OCF ₃ , SO ₂ NR ⁹ R ¹⁰ , COOR ⁹ , CONR ⁹ R ¹⁰ , NR ⁹ R ¹⁰ , NHCOR ¹⁰ , and phenyl optionally substituted with OH;
R ⁹ and R ¹⁰ are the same or different and are selected from H or C ₁ -C ₄ alkyl;
R ¹¹ is selected from H or OH;
R ¹² and R ¹³ are identical or different, H, optionally substituted by OR ⁹ C ₁ -C ₄ ^{alkyl, OR 9, C (= O} ) NH 2, C (= O) CH 3, N (CH ₃ ) C (═O) CH ₃ , C (═O) OR ⁹ , phenyl optionally substituted with halogen, pyridyl optionally substituted with CN, and substituted with C ₁ -C ₄ alkyl Selected from optionally oxadiazolyl; and
^* Indicates the point of attachment to the carbonyl group, or, where appropriate, pharmaceutically acceptable salts and / or stereoisomers, geometric isomers, tautomers, solvates thereof. Or isotope- labeled compound . The (CH ₂ ) _n —C (═O) Q ¹ group is located in the meta or para position;
R ¹ and R ² are independently selected from H and C ₁ -C ₄ alkyl;
n is 0, 1, or 2;
Q ¹ is

And a group ^* —NR ⁸ —Q ² —A, wherein p is 1 or 2, Q ² is C ₁ -C ₄ alkylene, and R ⁸ is H or C ₁ — C ₄ alkyl and A is pyridyl, C ₃ -C ₁₀ cycloalkyl, tetrahydropyranyl, piperidinyl, tetrahydro, optionally bridged by 1, 2, 3, or 4 carbon atoms Thiopyranyl,

Or a group represented by

A group represented by
R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different, and H, C ₁ -C ₄ alkyl, OR ⁹ , SR ⁹ , SOR ⁹ , SO ₂ R ⁹ , halo, CN, Selected from CF ₃ , OCF ₃ , SO ₂ NR ⁹ R ¹⁰ , COOR ⁹ , CONR ⁹ R ¹⁰ , NR ⁹ R ¹⁰ , NHCOR ¹⁰ , and phenyl optionally substituted with OH;
R ⁹ and R ¹⁰ are the same or different and are selected from H or C ₁ -C ₄ alkyl; and
^* Indicates the point of attachment to the carbonyl group;
The compound of general formula (1) according to claim 1 or, where appropriate, its pharmaceutically acceptable salt and / or its stereoisomer, geometric isomer , tautomer, solvent Japanese or isotopically labeled compounds . Q ¹ is a group ^* -NH-Q ² -A, wherein A is cyclohexyl or adamantyl.
The compound according to 1 or 2. The compound according to claim 1 or 2, wherein A is naphthyl optionally substituted with OR ⁹ . Q ¹ is a group ^* -NH-Q ² -A wherein A is

(Wherein R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are the same or different, and H, C ₁ -C ₄ alkyl, OR ⁹ , SR ⁹ , halo, CN, CF ₃ , OCF ₃ , SO ₂ NR ⁹ R ¹⁰ , COOR ⁹ , CONR ⁹ R ¹⁰ , NR ⁹ R ¹⁰ , NHCOR ¹⁰ , and phenyl optionally substituted with OH, provided that at least two of R ^{3 to} R ⁷ are H 3. The compound according to claim 2, wherein R ⁹ and R ¹⁰ are the same or different and are selected from H or C ₁ -C ₄ alkyl. Q ² is -CH ₂ -,-(CH ₂ ) ₂ -,-(CH ₂ ) _3- , -CH (CH ₃ )-, -CH ₂ CH (CH ₃ )-, or C (CH ₃ ) ₂ 6. The compound according to any one of claims 1 to 5, which is-. Q ¹ is

Or

The compound according to claim 1, wherein R ³ , R ⁴ , R ⁵ , and R ⁶ are H. The compound according to any one of claims 1 to 7, wherein R ¹ is H or CH ₃ and R ² is CH ₃ .   9. The compound according to any one of claims 1 to 8, wherein n is 0 or 1. The following formula:

The compound as described in any one of Claims 1-9 represented by these. _{(CH 2) n -C (=} O) Q 1 group is located at the meta position, the compound according to any one of claims 1 to 10. N-benzyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
N-cyclopropyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1R, 2S) -2- (hydroxy Methyl) cyclohexyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-morpholin-4-ylpropyl) acetamide ;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (pyridin-2-ylmethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-morpholin-4-ylethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-isopropylacetamide;
N- (4-chlorobenzyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [2- (dimethylamino) ethyl] acetamide;
N- [2- (diethylamino) ethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3- (dimethylamino) propyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-pentylacetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-pyrrolidin-1-ylethyl) acetamide;
N- (2,4-dichlorobenzyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
N- (3,4-dichlorobenzyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-methoxybenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-hydroxyethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-propylacetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-methoxypropyl) acetamide;
N-cyclobutyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1R) -1- (1-naphthyl) ) Ethyl] acetamide;
N-2,3-dihydro-1H-inden-1-yl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) Phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [2- (1-methylpyrrolidine-2- Yl) ethyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-fluorobenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-phenylbutyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-methoxybenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-ethoxypropyl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3,4,5-trimethoxybenzyl) Acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [4- (trifluoromethyl) benzyl] acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [2- (trifluoromethyl) benzyl] acetamide ;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3,5-dimethoxybenzyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-phenoxyethyl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -2-hydroxy-1- Methylethyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1- (hydroxymethyl) -2-methylpropyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S, 2S) -1- (hydroxy Methyl) -2-methylbutyl] acetamide;
N-[(1R) -benzyl-2-hydroxyethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl ] Acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1R) -1- (hydroxymethyl) Propyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1- (hydroxymethyl) -2,2-dimethylpropyl] acetamide;
N-[(1S) -2-cyclohexyl-1- (hydroxymethyl) ethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2 -Methylpropyl) phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S, 2R) -2-hydroxy- 2,3-dihydro-1H-inden-1-yl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-propoxyethyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4-hydroxycyclohexyl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-propoxypropyl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-ethyl-N- (2-hydroxyethyl) acetamide ;
1-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetyl} piperidine-4-carboxamide;
5- {2-[(2- {3- [2- (4-acetylpiperazin-1-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino] -1-hydroxyethyl} benzene- 1,3-diol;
5- {2-[(2- {3- [2- (3,4-Dihydroisoquinolin-2 (1H) -yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
N-benzyl-2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-methylacetamide;
5- (1-hydroxy-2-{[2- (3- {2- [4- (2-hydroxyethyl) piperazin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino } Ethyl) benzene-1,3-diol;
5- (2-{[2- (3- {2- [4- (4-chlorophenyl) -4-hydroxypiperidin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino} -1-hydroxyethyl) benzene-1,3-diol;
5- {2-[(1,1-dimethyl-2- {3- [2- (4-methylpiperazin-1-yl) -2-oxoethyl] phenyl} ethyl) amino] -1-hydroxyethyl} benzene- 1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-methyl-N- (2-phenylethyl) acetamide ;
5- {2-[(1,1-dimethyl-2- {3- [2-oxo-2- (4-pyridin-2-ylpiperazin-1-yl) ethyl] phenyl} ethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3- (dimethylamino) propyl] -N -Methylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-hydroxyethyl) -N-propylacetamide ;
N- [2- (diethylamino) ethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- Methylacetamide;
5- {2-[(1,1-dimethyl-2- {3- [2- (4-methyl-1,4-diazepan-1-yl) -2-oxoethyl] phenyl} ethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
5- [2-({1,1-dimethyl-2- [3- (2-morpholin-4-yl-2-oxoethyl) phenyl] ethyl}
Amino) -1-hydroxyethyl] benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-methyl-N-[(1S) -1- Phenylethyl] acetamide;
5- [2-({1,1-dimethyl-2- [3- (2-oxo-2-piperidin-1-ylethyl) phenyl] ethyl}
Amino) -1-hydroxyethyl] benzene-1,3-diol;
5- (1-hydroxy-2-{[2- (3- {2-[(3R) -3-hydroxypyrrolidin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino} Ethyl) benzene-1,3-diol;
5- (1-hydroxy-2-{[2- (3- {2-[(3R) -3-hydroxypiperidin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino} Ethyl) benzene-1,3-diol;
5- {2-[(2- {3- [2- (4-acetyl-1,4-diazepin-1-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino] -1- Hydroxyethyl} benzene-1,3-diol;
5- (1-hydroxy-2-{[2- (3- {2- [4- (hydroxymethyl) piperidin-1-yl] -2-oxoethyl} phenyl) -1,1-dimethylethyl] amino} ethyl ) Benzene-1,3-diol;
N- (1-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetyl} pyrrolidin-3-yl) -N -Methylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-methoxyethyl) -N-propylmethyl Acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-ethyl-N- (2-methoxyethyl) acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3- (dimethylamino) -2,2 -Dimethylpropyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- [3-fluoro-5- (trifluoromethyl ) Benzyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1- (hydroxymethyl) -3-methylbutyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -2-hydroxy-1- Phenylethyl] acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N, N-diethylacetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-1H-pyrazol-5-ylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (5-methyl-1H-pyrazole-3- Yl) acetamide;
N- (cyclohexylmethyl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide;
4-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetyl} piperazine-1-carboxylate;
N- (5-chloropyridin-2-yl) -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (6-methylpyridin-2-yl) acetamide ;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-methylpyridin-2-yl) acetamide ;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-isoquinolin-1-ylacetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (4,6-dimethylpyridin-2-yl Acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (2-methoxybenzyl) acetamide;
N-[(1S) -1-benzyl-2-hydroxyethyl] -2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl ) Phenyl] acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (1-ethyl-1H-pyrazole-5- Yl) acetamide;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (1,3-dimethyl-1H-pyrazole- 5-yl) acetamide;
2- [3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N- (3-fluorobenzyl) acetamide;
1-{[3- (2-{[2- (3,5-dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] acetyl} -L-prolinamide;
5- {2-[(2- {3- [2- (5-Amino-3-tert-butyl-1H-pyrazol-1-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino ] -1-hydroxyethyl} benzene-1,3-diol;
2- [3- (2-{[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino} -2-methylpropyl) phenyl] -N-[(1S) -1-phenylethyl] acetamide ;
5- {2-[(2- {3- [2- (1,4-Dioxa-8-azaspiro [4.5] dec-8-yl) -2-oxoethyl] phenyl} -1,1-dimethylethyl) amino ] -1-hydroxyethyl} benzene-1,3-diol;
N- [2- (4-Chloro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -benzamide ;
N-adamantan-1-yl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (3-fluoro-phenyl) -ethyl] -benzamide ;
N- [2- (2-Chloro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -benzamide ;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (2,3-dimethyl-phenyl) -ethyl] -Benzamide;
N- [2- (2-Chloro-4-fluoro-phenyl) -ethyl] -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl- Propyl} -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -N- [2- (4-methoxy-2,3-dimethyl-phenyl) ) -Ethyl] -benzamide;
N- (3,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (3,4-dichloro-benzyl) -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -benzamide;
N- (4-chloro-benzyl) -3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -benzamide;
N-adamantan-1-yl-3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -benzamide;
N- (4-Chloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide ;
N- (4-trifluoromethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl)- Acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N-pyridin-2-ylmethyl-acetamide;
N- (3,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N-cyclohexylmethyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
1- (3,4-Dihydro-1H-isoquinolin-2-yl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl}- Phenyl) -ethanone;
N-benzyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino]-
Propyl} -phenyl) -N-methyl-acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-hydroxy-benzyl) -acetamide;
N- (4-Cyano-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide ;
N- (2,4-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (2-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (3-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (cyclohexylmethyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N-phenethyl-acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (4-chlorophenethyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (4-phenylphenethyl) -acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (4'-hydroxy-biphenyl-3 -Ylmethyl) -acetamide;
N-cycloheptyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-phenethyl-acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-methylsulfanyl-benzyl) -acetamide;
N- (2,6-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-indan-2-yl-acetamide;
N- (2-chloro-6-fluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (4-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (2,5-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (3,5-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N- (2,6-dichloro-benzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -Acetamide;
N-biphenyl-2-ylmethyl-2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetamide;
N- (2-chlorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (3-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (3-trifluoromethylbenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (3,4-difluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (2-methoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
N- (3,4-dimethylbenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-
Ethylamino] -propyl} -phenyl) -acetamide;
N- (3,4-dimethoxybenzyl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetamide;
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -acetylamino] -methyl} -benzamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-indan-1-yl-acetamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (3-fluoro-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-chloro-phenyl) -ethyl] -benzamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N-naphthalen-1-ylmethyl-acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (2-fluoro-5-trifluoromethyl-benzyl) -Acetamide;
2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (3-chlorobenzyl) -acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -phenyl) -N- (4-fluoro-3-trifluoromethyl-benzyl) -Acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (2-methylsulfanyl-benzyl)- Acetamide;
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetylamino] -methyl}- Benzamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (4-sulfamoyl-benzyl) -acetamide ;
4-{[2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -acetylamino] -methyl}- Benzoic acid methyl ester;
N- (1-Benzyl-piperidin-4-yl) -2- (3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl}- Phenyl) -acetamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2-phenethyl] -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (5-fluoro-2-methyl-phenyl) -ethyl] -benzamide ;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-trifluoromethyl-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- (2-naphthalen-1-yl-ethyl) -benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2,4,5-trimethyl-phenyl) -ethyl] benzamide;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2,3-dimethyl-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-hydroxy-3-chloro-phenyl) -ethyl] -benzamide ;
3- {2- [2- (3,5-dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (4-chloro-phenyl) -ethyl] -benzamide;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-hydroxy-5-chloro-phenyl) -ethyl] -benzamide ;
3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -propyl} -N- [2- (2-chloro-4-fluoro-phenyl) -ethyl] -benzamide ;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (2-methyl-benzyl) -acetamide ;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (3-methyl-benzyl) -acetamide ;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (4-methyl-benzyl) -acetamide ;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (2-methoxy-benzyl) -acetamide ;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (4-methoxy-benzyl) -acetamide ;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (2,3-dimethyl-benzyl) -Acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (3,4-dimethyl-benzyl) -Acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (2-chloro-6-methyl- (Benzyl) -acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- (3-chloro-4-methyl- (Benzyl) -acetamide;
2- (3- {2- [2- (3,5-Dihydroxy-phenyl) -2-hydroxy-ethylamino] -2-methyl-propyl} -phenyl) -N- [2- (6-methoxy-naphthalene) -2-yl) -ethyl] -acetamide;
N- (2-chlorobenzyl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) propionamide;
N- (2,6-dichlorobenzyl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) propionamide;
1- (3,4-Dihydro-1H-isoquinolin-2-yl) -3- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) propane- 1-on;
N- (2-chloro-4-fluorobenzyl) -2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) acetamide;
N- (4-bromobenzyl) -2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- (3,4-dimethylphenyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -N- (2,3-dimethylbenzyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -N- (4-fluorobenzyl) acetamide;
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] propyl} phenyl) -1- (4-pyridin-2-ylpiperazin-1-yl) ethanone; and
2- (3- {2- [2- (3,5-dihydroxyphenyl) -2-hydroxyethylamino] -2-methylpropyl} phenyl) -N- (2-phenylpropyl) acetamide;
2. The compound of claim 1, wherein the compound is selected from the group consisting of:   A pharmaceutical composition comprising at least an effective amount of the compound of formula (1) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or derivative thereof.   13. A compound of formula (1) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt, derivative or composition thereof for use as a medicament. Asthma of any type, of any etiology, or of any pathogen, especially atopic asthma, non-atopic asthma, allergic asthma, IgE-mediated atopic bronchial asthma, bronchial asthma, essential asthma, true asthma, pathophysiology Intrinsic asthma caused by mechanical disorders, extrinsic asthma caused by environmental factors, asthma of unknown cause, non-atopic asthma, bronchial asthma, emphysema asthma, exercise-induced asthma, allergen-induced asthma, cold-induced asthma, Asthma selected from the group consisting of occupational asthma, bacterial infection, fungal infection, protozoal infection, or infectious asthma caused by viral infection, non-allergic asthma, early asthma, childhood wheezing syndrome, and bronchiolytis ;
Chronic or acute bronchoconstriction, chronic bronchitis, peripheral airway obstruction, and emphysema;
• Obstructive or inflammatory airway disease of any type, of any etiology, or of any pathogen, especially chronic eosinophilic pneumonia; chronic obstructive pulmonary disease (COPD); associated with chronic bronchitis, emphysema, or COPD COPD including unrelated dyspnea; COPD characterized by irreversible and progressive airway obstruction; adult respiratory distress syndrome (ARDS); worsening airway hyperresponsiveness as a result of other medications; and pulmonary hypertension Airway disease associated with; obstructive or inflammatory airway disease selected from the group consisting of;
Bronchitis of any type, of any etiology or of any pathogen, especially
Acute bronchitis, acute laryngeal tracheobronchitis, arachidic bronchitis, catarrhal bronchitis, croup bronchitis, dry bronchitis, infectious asthmatic bronchitis, wet cough bronchitis, staphylococcal or streptococcal bronchitis Bronchitis selected from the group consisting of inflammation and alveolar bronchitis;
Acute lung injury;
Bronchiectasis of any type, of any etiology or of any pathogenicity, in particular columnar bronchiectasis, microcystic bronchiectasis, spindle bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, Bronchiectasis selected from the group consisting of dry bronchiectasis and follicular bronchiectasis;
Use of a compound of formula (1) according to any one of claims 1 to 12 or a medicament thereof in the manufacture of a medicament for treating a disease, disorder and disease selected from the group consisting of Use of acceptable salts, solvates, or compositions. Asthma of any type, of any etiology, or of any pathogen, especially atopic asthma, non-atopic asthma, allergic asthma, IgE-mediated atopic bronchial asthma, bronchial asthma, essential asthma, true asthma, pathophysiology Intrinsic asthma caused by mechanical disorders, extrinsic asthma caused by environmental factors, asthma of unknown cause, non-atopic asthma, bronchial asthma, emphysema asthma, exercise-induced asthma, allergen-induced asthma, cold-induced asthma, Asthma selected from the group consisting of occupational asthma, bacterial infection, fungal infection, protozoal infection, or infectious asthma caused by viral infection, non-allergic asthma, early asthma, childhood wheezing syndrome, and bronchiolytis ;
Chronic or acute bronchoconstriction, chronic bronchitis, peripheral airway obstruction, and emphysema;
• Obstructive or inflammatory airway disease of any type, of any etiology, or of any pathogen, especially chronic eosinophilic pneumonia; chronic obstructive pulmonary disease (COPD); associated with chronic bronchitis, emphysema, or COPD COPD including unrelated dyspnea; COPD characterized by irreversible and progressive airway obstruction; adult respiratory distress syndrome (ARDS); worsening airway hyperresponsiveness as a result of other medications; and pulmonary hypertension Airway disease associated with; obstructive or inflammatory airway disease selected from the group consisting of;
Bronchitis of any type, of any etiology, or of any pathogen, in particular acute bronchitis, acute laryngotracheobronchitis, arachidic bronchitis, catarrhal bronchitis, croup bronchitis, dry bronchitis, infectious asthma Bronchitis selected from the group consisting of traumatic bronchitis, wet cough bronchitis, staphylococcal or streptococcal bronchitis, and alveolar bronchitis;
Acute lung injury;
Bronchiectasis of any type, of any etiology or of any pathogenicity, in particular columnar bronchiectasis, microcystic bronchiectasis, spindle bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, Bronchiectasis selected from the group consisting of dry bronchiectasis and follicular bronchiectasis;
A compound of formula (1) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or solvate thereof, for the treatment of diseases, disorders and diseases selected from the group consisting of A pharmaceutical composition comprising a product. A compound according to any one of claims 1 to 15;
(a) a 5-lipoxygenase (5-LO) inhibitor, or a protein (FLAP) antagonist that activates 5-lipoxygenase,
_{(b) LTB 4, LTC 4} , LTD 4, and leukotriene antagonists, including antagonists of LTE ₄ (LTRA),
(c) histamine receptor antagonists including H1 and H3 antagonists,
(d) α ₁ -adrenergic receptor agonist and α ₂ -adrenergic receptor agonist, which are vasoconstrictive sympathomimetic agents for use as a decongestant,
(e) a muscarinic M3 receptor antagonist or anticholinergic agent,
(f) PDE inhibitors, such as PDE3 inhibitors, PDE4 inhibitors, and PDE5 inhibitors,
(g) Theophylline,
(h) sodium cromoglycate,
(i) COX inhibitors (NSAIDs), including non-selective COX-1 inhibitors, non-selective COX-2 inhibitors, selective COX-1 inhibitors, and selective COX-2 inhibitors,
(j) oral glucocorticosteroids and inhaled glucocorticosteroids such as DAGR (dissociated agonist of the corticoid receptor),
(k) a monoclonal antibody active against endogenous inflammatory entities,
(l) an anti-tumor necrosis factor (anti-TNF-α) drug,
(m) adhesion molecule inhibitors including VLA-4 antagonists,
(n) a kinin B ₁ receptor antagonist and a kinin B ₂ receptor antagonist,
(o) immunosuppressants,
(p) an inhibitor of matrix metalloprotease (MMP),
(q) tachykinin NK ₁ receptor antagonist, tachykinin NK ₂ receptor antagonist, and tachykinin NK ₃ receptor antagonist,
(r) an elastase inhibitor,
(s) an adenosine A2a receptor agonist,
(t) an inhibitor of urokinase,
(u) a compound acting on a dopamine receptor, such as a D2 agonist,
(v) a modulator of the NFκβ pathway, such as an IKK inhibitor,
(w) a modulator of a cytokine signaling pathway, such as a p38 MAP kinase inhibitor, a syk kinase inhibitor, or a JAK kinase inhibitor,
(x) a drug that can be classified as a mucolytic or antitussive, and
(y) Combination with other therapeutic agents selected from antibiotics.